<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunol Res</journal-id><journal-id journal-id-type="iso-abbrev">J Immunol Res</journal-id><journal-id journal-id-type="pmc-domain-id">2403</journal-id><journal-id journal-id-type="pmc-domain">jimmres</journal-id><journal-id journal-id-type="publisher-id">jir</journal-id><journal-title-group><journal-title>Journal of Immunology Research</journal-title></journal-title-group><issn pub-type="ppub">2314-8861</issn><issn pub-type="epub">2314-7156</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11221958</article-id><article-id pub-id-type="pmcid-ver">PMC11221958.1</article-id><article-id pub-id-type="pmcaid">11221958</article-id><article-id pub-id-type="pmcaiid">11221958</article-id><article-id pub-id-type="pmid">38962577</article-id><article-id pub-id-type="doi">10.1155/2024/4312908</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Advances in Bacterial Lysate Immunotherapy for Infectious Diseases and Cancer</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2294-1314</contrib-id><name name-style="western"><surname>Rahman</surname><given-names initials="MM">Md. Mijanur</given-names></name><email>mijanur.rahman@griffithuni.edu.au</email><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="I2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9218-457X</contrib-id><name name-style="western"><surname>Grice</surname><given-names initials="ID">I. Darren</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="I3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9638-8091</contrib-id><name name-style="western"><surname>Ulett</surname><given-names initials="GC">Glen C.</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="I2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wei</surname><given-names initials="MQ">Ming Q.</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="I2" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>
<institution content-type="edu">School of Pharmacy and Medical Sciences</institution>
<institution content-type="edu">Griffith University</institution>, Gold Coast 4222, QLD, Australia</aff><aff id="I2">
<sup>2</sup>
<institution content-type="edu">Menzies Health Institute Queensland</institution>
<institution content-type="edu">Griffith University</institution>, Gold Coast 4222, QLD, Australia</aff><aff id="I3">
<sup>3</sup>
<institution content-type="edu">Institute for Glycomics</institution>
<institution content-type="edu">Griffith University</institution>, Gold Coast 4222, QLD, Australia</aff><author-notes><fn fn-type="other"><p>Academic Editor: Lele Zhu</p></fn></author-notes><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>12</day><month>6</month><year>2024</year></pub-date><volume>2024</volume><issue-id pub-id-type="pmc-issue-id">453123</issue-id><elocation-id>4312908</elocation-id><history><date date-type="received"><day>2</day><month>1</month><year>2024</year></date><date date-type="rev-recd"><day>22</day><month>4</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>4</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>06</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>03</day><month>07</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-30 19:25:56.990"><day>30</day><month>11</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024 Md. Mijanur Rahman et al.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="JIR2024-4312908.pdf"/><abstract><p>Antigenic cell fragments, pathogen-associated molecular patterns, and other immunostimulants in bacterial lysates or extracts may induce local and systemic immune responses in specific and nonspecific paradigms. Based on current knowledge, this review aimed to determine whether bacterial lysate has comparable functions in infectious diseases and cancer treatment. In infectious diseases, including respiratory and urinary tract infections, immune system activation by bacterial lysate can identify and combat pathogens. Commercially available bacterial lysates, including OM-85, Ismigen, Lantigen B, and LW 50020, were effective in children and adults in treating respiratory tract infections, chronic obstructive pulmonary disease, rhinitis, and rhinosinusitis with varying degrees of success. Moreover, OM-89, Uromune, Urovac, Urivac, and ExPEC4V showed therapeutic benefits in controlling urinary tract infections in adults, especially women. Bacterial lysate-based therapeutics are safe, well-tolerated, and have few side effects, making them a good alternative for infectious disease management. Furthermore, a nonspecific immunomodulation by bacterial lysates may stimulate innate immunity, benefiting cancer treatment. &#8220;Coley's vaccine&#8221; has been used to treat sarcomas, carcinomas, lymphomas, melanomas, and myelomas with varying outcomes. Later, several similar bacterial lysate-based therapeutics have been developed to treat cancers, including bladder cancer, non-small cell lung cancer, and myeloma; among them, BCG for in situ bladder cancer is well-known. Proinflammatory cytokines, including IL-1, IL-6, IL-12, and TNF-<italic toggle="yes">&#945;</italic>, may activate bacterial antigen-specific adaptive responses that could restore tumor antigen recognition and response by tumor-specific type 1 helper cells and cytotoxic T cells; therefore, bacterial lysates are worth investigating as a vaccination adjuvants or add-on therapies for several cancers.</p></abstract><funding-group><award-group><funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dx.doi.org/10.13039/501100001791">Griffith University</funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Bacterial lysates (BLs) or extract-based preparations comprising antigen-rich cell fragments, pathogen-associated molecular patterns (PAMPs), and several other immunostimulants stimulate the immune system to recognize and combat infections [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>]. It has been claimed that such preparations induce local and systemic immunomodulation, but clinical trials have found conflicting results. BLs are widely used therapeutically, though their immune system effects are only partially known [<xref rid="B6" ref-type="bibr">6</xref>]. Polyvalent mechanical bacterial lysates (PMBLs) and polyvalent chemical bacterial lysates (PCBLs) are two types of BLs used in clinical settings [<xref rid="B7" ref-type="bibr">7</xref>]. Patients with recurring respiratory tract infections (RTIs) and children with otitis media or nasopharyngitis benefit more from PMBLs than PCBLs [<xref rid="B8" ref-type="bibr">8</xref>]. This may be because PMBLs contain comparatively less damaged and more chemically pure bacterial antigens than PCBLs, increasing immunogenicity [<xref rid="B9" ref-type="bibr">9</xref>].</p><p>Since the 1950s, BLs have been used to reduce the incidence of recurrent respiratory tract infections (RRTIs) in children and adults [<xref rid="B7" ref-type="bibr">7</xref>]. Some commercially marketed BLs are beneficial in treating RTIs, chronic obstructive pulmonary disease (COPD), rhinitis, rhinosinusitis, and urinary tract infections (UTIs). In pediatric RTIs, BLs lowered the incidence rate (OM-85, Luivac, and Ismigen), shortened the duration (OM-85 and Luivac), decreased the frequency of acute episodes (Lantigen B), and reduced the need for antibiotics (OM-85 and Luivac). Luivac lowered the incidence and duration of RTIs in adults, limited the need for antibiotics, and decreased the bacterial count in colonized individuals [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>]. Moreover, BLs lowered the severity (Ismigen) and frequency (OM-85, Ismigen) of exacerbations and the number of days with fever and hospitalization (Ismigen) in adults with COPD [<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>]. In pediatric rhinosinusitis, OM-85 lowered the incidence of rhinosinusitis attacks, and Ismigen decreased the intensity of allergic rhinitis (AR) symptoms. Additionally, OM-85 reduced the incidence of RTIs and antibiotic usage in HIV&#8201;+&#8201;individuals. In adult UTIs, OM-89 (Uro-Vaxom) reduced the frequency of recurrences and lowered the incidence of bacteriuria, dysuria, and leukocyturia. In pediatric UTIs, Urivac proved effective in generating relapse-free progression of recurrent UTIs [<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>].</p><p>A meta-analysis of 19 studies comparing BLs treatments to a control group found a 24% improvement in allergy symptoms and also improved asthma symptoms by 22% and rhinitis symptoms by 300% more than the control group [<xref rid="B18" ref-type="bibr">18</xref>]. In a noninterventional prospective cohort study of 57 children with repeated otitis media (middle ear infections) or pharyngotonsillitis episodes in Spain, a 3-month treatment with bacterial immunostimulant combinations made from bacterial lysates (either polyvalent-specific vaccines (made from the lysate of <italic toggle="yes">Streptococcus pneumoniae</italic>, <italic toggle="yes">Haemophilus influenzae</italic>, <italic toggle="yes">Streptococcus pyogenes</italic>, and <italic toggle="yes">Moraxella catarrhalis</italic>) or auto-vaccines) reduced the frequency, severity, and consequences of acute episodes after 6 months [<xref rid="B19" ref-type="bibr">19</xref>]. Another meta-analysis of five trials found that using BLs (PCBLs: OM-85; PMBLs: Ismigen, MV130, and MV310) reduced wheeze episodes and asthma exacerbations [<xref rid="B20" ref-type="bibr">20</xref>]. Moreover, the BLs group demonstrated improving AR symptoms three times faster than the control group in a meta-analysis of three studies [<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>].</p><p>Furthermore, a systematic review and meta-analysis revealed that BLs such as Uro-Vaxom&#174;, Urovac&#174;, and ExPEC4V reduced UTI recurrence compared to placebo. Uro-Vaxom reduced UTI recurrence the most among the BLs, with a greater benefit at 3 months compared to 6 months after therapy. Urovac treatment also indicated a decrease in the recurrence of UTIs [<xref rid="B24" ref-type="bibr">24</xref>].</p><p>William Coley developed &#8220;Coley toxins&#8221; in 1891, a heat-killed mix of <italic toggle="yes">S. pyogenes</italic> and <italic toggle="yes">Serratia marcescens</italic>. Patients with sarcomas, carcinomas, lymphomas, melanomas, and myelomas treated with them with varying degrees of success [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>]. Multiple months (precisely 4 months) of treatment with &#8220;Coley toxins&#8221; led to complete tumor remission in an inoperable sarcoma case [<xref rid="B27" ref-type="bibr">27</xref>]. The 5-year survival rate for inoperable carcinomas was 34%&#8211;73% and for sarcomas 13%&#8211;79%, depending on the tumor subtype. Coley's therapy (preparation methods of the &#8220;Coley toxins&#8221; were inconsistent) results were ambiguous, unreplicable, and unpredictable; consequently, new radiation therapy replaced it in the early twentieth century. As immunology progressed, &#8220;Coley toxins&#8221; were found to stimulate and regulate the immune system in a multilevel manner&#8212;this increased interest in the medicinal potentials of Coley's approach [<xref rid="B28" ref-type="bibr">28</xref>]. Later, several bacterial lysate- or extract-based immunotherapies were developed, including intravesical bacillus Calmette&#8211;Gu&#233;rin (BCG) for in situ bladder carcinoma [<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>], heat-killed <italic toggle="yes">Mycobacterium indicus pranii</italic> for invasive bladder cancer and non-small cell lung cancers (NSCLC) [<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>], and heat-killed whole-cell <italic toggle="yes">Mycobacterium obuense</italic> for melanoma patients [<xref rid="B34" ref-type="bibr">34</xref>].</p></sec><sec id="sec2"><title>2. How Does Bacterial Lysate-Based Immunotherapy Work in General?</title><p>Numerous research data now exist showing that BLs function as immunomodulators capable of eliciting antibodies against pathogens and producing immunoregulatory responses in mucosal tissues [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>]. Notably, they may interact with diverse cells&#8212;such as monocytes or macrophages (M<italic toggle="yes">&#966;</italic>), dendritic cells (DCs), or epithelial cells&#8212;through the engagement of surface Toll-like receptors (TLRs) with bacterial wall components, such as proteoglycans or lipopolysaccharides (LPS). These interactions drive the development of monocytes into M<italic toggle="yes">&#966;</italic> and activate immature DCs, producing specific chemokines and cytokines [<xref rid="B6" ref-type="bibr">6</xref>].</p><p>Activation of both nonspecific and specific immunological pathways is required for bacterial lysates to exert their immune impact. Activation of nonspecific mechanisms (innate immune system) involves signal transmission by TLRs (TLR-2/TLR-6, TLR-9, and TLR-7/TLR-8), an increase in chemotaxis as well as cytotoxic and phage activity of phagocytes (M<italic toggle="yes">&#966;</italic>, DCs, and neutrophils), an increase in the activity of natural killer (NK) cells (CCL2, 3), activation of DCs along with a proliferation in their antigen presentation ability and increased migration into the respiratory tract, activation of specific mechanisms (acquired immune system) is marked by an increased concentration of immunoglobulins (Ig) A and IgG antibodies, increased T-cell activity and the ability to activate other specific mechanisms (activation of T and B cells), activation of B cells (CCL2, CCL3, CCL20, CCL22, BAFF, IL-6, and APRIL), and increased activity of CD4+ CD25+ Foxp3+ regulatory T cells [<xref rid="B39" ref-type="bibr">39</xref>].</p></sec><sec id="sec3"><title>3. Successful Immunotherapeutic Bacterial Lysates for Infectious Diseases</title><sec id="sec3.1"><title>3.1. OM-85</title><p>OM-85 (Broncho-Vaxom&#174;, Broncho-Munal&#174;, Ommunal&#174;, Paxoral&#174;, and Vaxoral&#174;) is an over-the-counter oral preparation of lyophilized bacterial lysates of eight common respiratory pathogens (<italic toggle="yes">H. influenzae</italic>, <italic toggle="yes">Diplococcus pneumoniae</italic>, <italic toggle="yes">Klebsiella pneumoniae</italic>, <italic toggle="yes">Klebsiella ozaenae</italic>, <italic toggle="yes">Staphylococcus aureus</italic>, <italic toggle="yes">S. pyogenes</italic>, <italic toggle="yes">Streptococcus viridans</italic>, and <italic toggle="yes">Neisseria catarrhalis</italic>). OM-85 has been used for several decades in different countries (excluding the USA as OM-85 or similar products are not yet approved by the FDA) in both adults and children to treat and prevent recurrent respiratory infections, including COPD, asthma, and rhinosinusitis [<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B40" ref-type="bibr">40</xref>]. However, in a review in 2019, the European Medicines Agency recommended the use of BLs only for the prevention of RRTIs except for pneumonia, and they also stated that there are no adequate data to support that the BLs are effective in treating existing respiratory infections or preventing pneumonia [<xref rid="B41" ref-type="bibr">41</xref>]. OM-85 was shown to have immunomodulatory [<xref rid="B36" ref-type="bibr">36</xref>] and antiviral [<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>] properties and is widely used to prevent recurrent upper respiratory infections in adults and children [<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>], with an excellent safety profile [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B44" ref-type="bibr">44</xref>]. In addition, OM-85 decreased the frequency and duration of wheezing episodes in preschool children with acute respiratory infections [<xref rid="B46" ref-type="bibr">46</xref>]. It slowed the onset of severe lower respiratory diseases in infants at risk [<xref rid="B47" ref-type="bibr">47</xref>]. Because wheezing-inducing lower respiratory tract infections are common precursors of childhood asthma [<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B49" ref-type="bibr">49</xref>], an NIH-sponsored trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02148796">NCT02148796</ext-link>) is currently testing whether OM-85 given to high-risk, 6&#8211;18 months infants for 10 days, monthly, for 2 consecutive years can prevent or delay the development of wheezing or asthma-like symptoms during a 3-year observation period off therapy in these young children [<xref rid="B50" ref-type="bibr">50</xref>].</p><p>OM-85 also reduced RTIs and exacerbations in patients with allergic rhinitis, asthma, or COPD [<xref rid="B51" ref-type="bibr">51</xref>]. After treatment with OM-85, RTIs decreased by 45% (38/69, <italic toggle="yes">p</italic>&#8201; &lt; 0.05). OM-85 with standard optimized care reduced medical exacerbations by 36%. In addition, OM-85 increased serum and secretory IgA levels. Its safety profile was also acceptable, with only minor gastrointestinal (nausea, vomiting, and stomach discomfort) and dermatologic (rash and urticarial) side effects in clinical studies [<xref rid="B17" ref-type="bibr">17</xref>].</p><p>In Ukraine, OM-85 was tested for clinical and immunological efficacy in children with RTIs. Acute RTIs were found in 108 children aged 1&#8211;3 years: 57 received conventional treatment, and 51 got OM-85 at 3.5&#8201;mg daily. Overall weakness decreased by 0.99 days, cough by 1.45 days, and catarrhal manifestations 1.23 days earlier in the OM-85-treated group (<italic toggle="yes">p</italic>&#8201; &lt; 0.05). OM-85 therapy supplementations also normalized phagocytic levels, CD3+, CD4+, and CD21+ cell concentrations along with IgA and IgM levels [<xref rid="B52" ref-type="bibr">52</xref>].</p><p>Esposito et al. [<xref rid="B53" ref-type="bibr">53</xref>] conducted a prospective, randomized, single-blind study to compare the immune response, efficacy, and safety of conventional inactivated influenza vaccines IIV (Fluarix, GlaxoSmithKlineBiologicals, Rixensart, Belgium) in 68 children with RRTIs who were vaccinated with (<italic toggle="yes">n</italic>&#8201;=&#8201;33) or without (<italic toggle="yes">n</italic>&#8201;=&#8201;35) OM-85. Respiratory morbidity significantly decreased in children treated with OM-85 (<italic toggle="yes">p</italic>&#8201; &lt; 0.05), positively impacting RRTI incidence. The two groups had similar adverse effects. These findings show that OM-85 does not affect children's influenza vaccine immunological response. However, OM-85 before and during the IIV vaccine reduces respiratory morbidity and is well-tolerated and safe [<xref rid="B53" ref-type="bibr">53</xref>]. A meta-analysis of OM-85 in pediatric RRTIs found that it reduced respiratory infection frequency (mean difference, MD&#8201;=&#8201;&#8722;2.22 days, 95% CI (&#8722;2.75, &#8722;1.90)) and wheezing duration (MD&#8201;=&#8201;&#8722;3.37 days, 96% CI (&#8722;4.52, &#8722;2.22)) [<xref rid="B54" ref-type="bibr">54</xref>]. Two other meta-analyses found that OM-85 prevented respiratory infection in children but did not address wheezing or allergic illness [<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>]. Another meta-analysis of 53 trials revealed that OM-85 reduced respiratory infections in children with RRTIs [<xref rid="B13" ref-type="bibr">13</xref>]. Moreover, OM-85, coupled with standard asthma medication, may prevent RRTIs and decline asthma attack intensity in children. Sixty asthmatic children were placed into two groups: OM-85 (orally) (24 children, 15 boys, and 9 girls aged 5&#8211;14 years) or conventional inhaled corticosteroid (ICS) (36 children, 23 boys, and 13 girls aged 5&#8211;15 years). Both groups had considerably fewer asthma episodes after treatment. After OM-85 treatment, peripheral blood NKT and CD4+ NKT cells increased and had higher levels of IFN-<italic toggle="yes">&#947;</italic>, IL-4, and IL-10, whereas IL-4 levels were lower than the ICS group [<xref rid="B57" ref-type="bibr">57</xref>].</p><p>Clinical investigations also showed that OM-85 reduces acute COPD exacerbations, antibiotic prescriptions, and symptoms. A randomized, double-blind, placebo-controlled clinical study by Tang et al. [<xref rid="B58" ref-type="bibr">58</xref>] examined the efficacy and safety of OM-85 in Chinese adults with COPD or chronic bronchitis. OM-85 significantly reduced the proportion of COPD patients with recurrent acute exacerbations (defined as two or more exacerbations) compared to placebo during the 12-week treatment period, and these benefits were maintained during the 10-week follow-up. The results support earlier studies of OM-85 in Asian and Caucasian populations, showing that it protects against chronic bronchitis and COPD exacerbations [<xref rid="B58" ref-type="bibr">58</xref>]. A meta-analysis of 13 RCTs found that OM-85 significantly reduced COPD exacerbations (<italic toggle="yes">p</italic>&#8201; &lt; 0.01; weighted mean difference (WMD)&#8201;=&#8201;&#8722;0.86; 95% CI (&#8722;1.38, &#8722;0.34)) and antibiotic treatment days (<italic toggle="yes">p</italic>&#8201; &lt; 0.01; WMD&#8201;=&#8201;&#8722;9.49; 95% CI (&#8722;11.93, &#8722;7.05)). The negative cost-effectiveness ratio also favors OM-85 therapy [<xref rid="B59" ref-type="bibr">59</xref>].</p><p>According to a double-blind RCT [<xref rid="B60" ref-type="bibr">60</xref>], oral OM-85 has outstanding and sustained efficacy in treating AR symptoms and may be an alternate treatment for persistent AR. OM-85 therapy elevated IFN-<italic toggle="yes">&#947;</italic> and reduced IL-4 and IL-13 in nasal lavage. Reduced scores for overall nasal symptoms, itching, rhinorrhea, and sneezing (<italic toggle="yes">p</italic>&#8201; &lt; 0.05) were also found. Eosinophils in nasal smears decreased following OM-85 therapy. The OM-85-induced improvements lasted 4 to 8 weeks. In chronic rhinosinusitis (CRS), OM-85 reduced the number of episodes and days with antibiotics per month in children and provided long-term prevention [<xref rid="B22" ref-type="bibr">22</xref>]. The European Position Paper on rhinosinusitis and nasal polyps supports OM-85 for CRS therapy in adults with level 1b evidence [<xref rid="B61" ref-type="bibr">61</xref>].</p><p>For AD, a study found that OM-85 reduced recurring episodes by 20% compared to placebo. Oral delivery of OM-85 to children with established AD substantially reduced and delayed new flares (hazard ratio (HR) of recurrent new flares&#8201;=&#8201;0.80; 95% CI (&#8722;0.29, 1.63)). OM-85 and placebo had similar and excellent tolerance with no severe adverse effects [<xref rid="B62" ref-type="bibr">62</xref>]. In contrast, a randomized placebo-controlled study of 606 neonates found no difference in AD prevalence between the bacterial lysate and placebo groups. However, early bacterial lysate feeding may prevent AD in babies with a single atopic family background [<xref rid="B54" ref-type="bibr">54</xref>].</p><p>Bacterial antigen therapy for allergic illness is still debated. BL therapy may lessen asthma attack length, coughing, and wheezing compared to the control group [<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B63" ref-type="bibr">63</xref>], while other studies have shown no significant difference in allergy episodes between treated and placebo groups [<xref rid="B64" ref-type="bibr">64</xref>]. Interestingly, Pivniouk et al. [<xref rid="B65" ref-type="bibr">65</xref>] found that providing OM-85 to the airway compartment protects against experimental allergic asthma by activating several immune pathways, and this protection needed a cumulative dosage 27- to 46-fold lower than the oral route. Intranasal OM-85 may be more effective because it directly accesses airway mucosal networks when asthma first develops. Cardinal cellular and molecular asthma characteristics were assessed in mice, sensitized and challenged with ovalbumin or <italic toggle="yes">Alternaria</italic>, and given OM-85 intranasally. In all animals, airway OM-85 controlled allergic asthma by targeting the airway epithelium/IL-33/ILC2 axis, lung allergen-induced type 2 responses, and DCs whose Myd88/Trif-dependent tolerogenic reprogramming was enough to prevent asthma. Allergies are often accompanied by an immune system imbalance toward type 2 T helper (Th2) and away from type 1 T helper (Th1) cell response [<xref rid="B18" ref-type="bibr">18</xref>]. Several studies [<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B68" ref-type="bibr">68</xref>] found that OM-85 could switch the immunological response from Th1/Th2 to Th1.</p><p>According to an <italic toggle="yes">in vitro</italic> study of Pivniouk et al. [<xref rid="B69" ref-type="bibr">69</xref>], OM-85 can lower ACE2 expression in human airway cell lines and primary cells. By downregulating SARS-CoV-2 receptor expression, OM-85 suppresses epithelial cell infection <italic toggle="yes">in vitro</italic>. After going through proper clinical trials, OM-85 might be utilized as a preventative medication alongside vaccinations and other future medicines to stop COVID-19 (<xref rid="tab1" ref-type="table">Table 1</xref>).</p><sec id="sec3.1.1"><title>3.1.1. Mode of Action of OM-85</title><p>PAMPs like OM-85 mature mucosal DCs in gut-associated immunological tissue (Peyer's patches through M cells), activating innate and adaptive immune responses. Downstream events include activation of monocytes, NK cells, M<italic toggle="yes">&#966;</italic>, and T cells such as Th1 cells, regulatory T (Treg) cells, and cytotoxic CD8+ cells; epithelial and mucosa antimicrobial peptide expression; polymorphic neutrophil recruitment to the lung; B-cell and antiviral Th1-related cytokine production; and B-cell maturation (leading to increased serum and airway immunoglobulins). OM-85 also supports immune system development in children by downregulating Th2 and activating Treg cells to restore Th1/Th2 imbalances [<xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B91" ref-type="bibr">91</xref>].</p><p>Tang et al. [<xref rid="B58" ref-type="bibr">58</xref>] suggested OM-85 may stimulate lung macrophage phagocytic activity, DC function, and respiratory tract secretory IgA (sIgA) production. Sinonasal immunity studies have shown that bitter taste receptors (T2R) enhance ciliary beat frequency (CBF) and other local immune defenses such as nitric oxide (NO) release and antibacterial chemical production. Air&#8211;liquid interfaces (ALIs) were pretreated with nitric oxide synthase (NOS) or T2R signal transduction inhibitors to test whether topical bacterial lysate works by a comparable mechanism. A study discovered that blocking OM-85-induced CBF and NO generation revealed that the observed effects are NO-dependent, transient receptor potential cation channel subfamily M member 5 (TRPM5)-dependent, and phospholipase C isoform <italic toggle="yes">&#946;</italic>2 (PLC<italic toggle="yes">&#946;</italic>2)-dependent, indicating T2R activation. This shows that topical OM-85 may directly activate T2R and the immune system in response to the bacterial antigens in the lysate, unlike oral treatment [<xref rid="B17" ref-type="bibr">17</xref>].</p><p>Some evidence showed that OM-85 stimulates TLRs. Host pattern recognition receptors (PRRs), most notably TLRs, recognize conserved PAMPs for innate immunological signaling [<xref rid="B92" ref-type="bibr">92</xref>]. Without myeloid differentiation, primary response 88 (MyD88) protein, OM-85 could not establish influenza immunity in mice. However, treating with TLR2/6 and TLR9 ligands simultaneously protects against pathogenic gram-positive and gram-negative bacteria [<xref rid="B92" ref-type="bibr">92</xref>]. This protective effect in isolated lung epithelial cells was accompanied by fast pathogen death in the lungs. Other findings indicate that OM-85 may trigger TLR4 and TLR2 [<xref rid="B93" ref-type="bibr">93</xref>]. It also boosts Treg cell growth and Th1 cell responsiveness [<xref rid="B94" ref-type="bibr">94</xref>]. <italic toggle="yes">In vitro</italic>, OM-85 preferentially activated nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and mitogen-activated protein kinase (MAPK) in human monocyte-derived DCs from COPD patients [<xref rid="B95" ref-type="bibr">95</xref>]. DCs and peripheral blood mononuclear cells (PBMC) significantly upregulated chemokines (CXCL8, CXCL6, CCL3, CCL20, and CCL22) and B-cell-activating cytokines (IL-6, BAFF, and IL-10). In asthma and COPD, OM-85 remarkably reduced rhinovirus-induced cell death and virus multiplication in human bronchial epithelial cells [<xref rid="B43" ref-type="bibr">43</xref>]. OM-85 appreciably boosted virus-interacting proteins C1q-R and <italic toggle="yes">&#946;</italic>-defensin expression, relevant for antigen presentation and phagocytosis while reducing rhinovirus-induced intracellular adhesion molecule 1 (ICAM-1) expression [<xref rid="B96" ref-type="bibr">96</xref>].</p><p>Polyclonal B-cell activation by OM-85 increased serum IgG and bronchoalveolar lavage IgA and IgG. The binding and neutralization of influenza virus by IgA protects against associated bacterial infections. These findings imply that OM-85 induces polyclonal mucosal antibody responses and increases adaptive CD8+ T-cell responses. OM-85 protected mice against nebulized influenza viral infection by increasing IL-6 and tumor necrosis factor <italic toggle="yes">&#945;</italic> (TNF-<italic toggle="yes">&#945;</italic>) expression in bronchoalveolar lavage fluid compared to fatal influenza infection [<xref rid="B97" ref-type="bibr">97</xref>]. Boosted inflammation decreased virus titers and host mortality [<xref rid="B98" ref-type="bibr">98</xref>].</p><p>Furthermore, OM-85 oral treatment for 10 days in BALB/c mice increased influenza virus immune response, reduced viral load, and susceptibility to <italic toggle="yes">S. pneumoniae</italic> secondary infections [<xref rid="B42" ref-type="bibr">42</xref>]. The maturation of DCs and B cells was nonspecific, with increased surface expression of antigen presentation molecules (MHC II, CD86, and CD40) and decreased inducible T-cell costimulator ligand (ICOSL). ICOSL&#8211;ICOS interactions cause allergic Th2 response, whereas OM-85 protects against it. The balanced release of cytokines and anti-inflammatory activity factors by OM-85 creates an &#8220;early warning&#8221; state that protects against infectious pathogens and controls inflammation. The three activation routes were rebalancing Th1/Th2, activating B cells via a T-cell-independent mechanism, releasing chemokines, and activating polymorphonuclear leukocytes [<xref rid="B96" ref-type="bibr">96</xref>] (<xref rid="fig1" ref-type="fig">Figure 1</xref>).</p></sec></sec><sec id="sec3.2"><title>3.2. Ismigen</title><p>Ismigen, a PMBLs immunomodulator, contains <italic toggle="yes">S. aureus</italic>, <italic toggle="yes">S. pyogenes</italic>, <italic toggle="yes">S. viridans</italic>, <italic toggle="yes">S. pneumoniae</italic> (six different serotypes: TY I/EQII, TY2/EQ22, TY3/EQ 14, TY5/EQ 15, TY8/EQ23, and TY47/EQ24), <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">K. ozaenae</italic>, <italic toggle="yes">H. influenzae</italic> serotype B, and <italic toggle="yes">M. catharralis</italic> [<xref rid="B72" ref-type="bibr">72</xref>]. Mechanical lysis yields ismigen, which has benefits over chemical lysates as immunomodulators. With mechanical lysis, corpuscular antigens are better retained, allowing for a long-term immune response. Mechanical lysates were significantly more effective than chemical lysates in treating lower RTIs with Imigen/Respibron&#174; [<xref rid="B99" ref-type="bibr">99</xref>].</p><p>In grass pollen-sensitive children, sublingual Ismigen reduced seasonal AR symptoms [<xref rid="B15" ref-type="bibr">15</xref>]. Ismigen may impair Th2 cell response by affecting mucosal immunity. In a study, the Ismigen-administered group showed a significant decrease in total nasal symptom (<italic toggle="yes">p</italic>=0.001), total ocular symptom (<italic toggle="yes">p</italic>=0.04), and visual analog scale scores for nasal and eye symptoms (<italic toggle="yes">p</italic> &lt; 0.001 and <italic toggle="yes">p</italic> &lt; 0.001, respectively), as well as an increase in peak nasal inspiratory flow (<italic toggle="yes">p</italic>=0.04) compared to the placebo group. The placebo group had a statistically significant rise in allergen-specific IgE concentrations, whereas the Ismigen group did not [<xref rid="B15" ref-type="bibr">15</xref>]. However, a double-blind, placebo-controlled randomized trial of 80 children between 5 and 17 years showed that around one of the two children with seasonal AR has been found with nasal carrier of <italic toggle="yes">S. aureus</italic>. The nasal colonization of <italic toggle="yes">S. aureus</italic> has not been affected by the sublingual treatment of Ismigen, and thus, Ismigen was not recommended to remove <italic toggle="yes">S. aureus</italic> from the nasal carrier [<xref rid="B70" ref-type="bibr">70</xref>]. In another trial, Ismigen reduced AR symptom severity in 61.5% of patients [<xref rid="B21" ref-type="bibr">21</xref>].</p><p>A double-blind, randomized, placebo-controlled study found that Ismigen medication significantly reduced exacerbation frequency (215 vs. 248 instances), length (10.6 vs. 15.8 days), antibiotic usage (&#8722;270 doses), and hospitalization time (275 vs. 590 days) in moderate-to-very severe COPD for study vs. control. Two groups of 178 adults were randomized to receive Ismigen (first 10 days each month for 3 months) or a placebo. After therapy, patients were monitored for 9 months. Selected clinical outcomes were considerably lower in the lysate group than in the placebo group. Even in severe COPD patients with comorbidities, Ismigen prophylaxis reduces acute exacerbation episode frequency, intensity, and duration [<xref rid="B14" ref-type="bibr">14</xref>].</p><p>Hans et al. [<xref rid="B72" ref-type="bibr">72</xref>] found that Ismigen selectively inhibits the most prevalent respiratory pathogens (<italic toggle="yes">S. aureus</italic>, <italic toggle="yes">S. pyogenes</italic>, <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">H. influenzae</italic>, and <italic toggle="yes">M. catarrhalis</italic>), restoring the oropharynx's eubiotic colonization profile 1&#8211;2 months after therapy.</p><p>A meta-analysis of 15 randomized clinical trials in 2,557 individuals found that PMBLs reduce respiratory tract infection recurrence in children and adults (relative risk: &#8722;0.513, 95% CI (&#8722;0.722, &#8722;0.303), <italic toggle="yes">p</italic> &#8804; 0.001) [<xref rid="B8" ref-type="bibr">8</xref>]. Prospective open research examined whether a PMBL treatment (drug name not stated in the abstract) might induce an efficient and well-targeted immune response and improve clinical outcomes. Twenty-five of 27 clinically responding individuals had increased salivary PMBLs antigen-specific antibodies. The link between PMBL-specific immunoglobulin titers and clinical findings was significant for IgG and IgA but not IgM. Only patients with clinical improvement showed Th1 switch, whereas three responders and four nonresponders showed Th0. One clinically responding patient had weak Th2 polarization. Samples from responder patients showed opsonization of live microorganisms [<xref rid="B35" ref-type="bibr">35</xref>]. In addition, Avdeev et al. [<xref rid="B100" ref-type="bibr">100</xref>] found that mechanical bacterial lysate (MBL) may prevent severe COPD exacerbations. Frequent COPD exacerbations were studied in 60 individuals (groups C and D according to the GOLD classification) and blindly assigned into two groups. After 6 months, the MBL group showed statistically significant improvements in respiratory function, exacerbation frequency, emergency medical service use, basic therapy adjustments, and hospitalization. MBL therapy was safe and had little side effects. On the contrary, a phase IV, randomized, controlled, double-blind, multicenter Advanced Immunological Approach in COPD Exacerbation (AIACE) trial included 142 adult patients in the placebo group and 146 in the treatment group failed to meet its primary endpoint&#8212;a reduction in exacerbations of COPD [<xref rid="B73" ref-type="bibr">73</xref>]. In 49 children (21 received Ismigen and 28 received a placebo) with allergic asthma and dust mite allergy, a double-blind, placebo-controlled, multicenter, randomized trial conducted in Poland revealed that Ismigen may have a preventative impact on episodes of asthma exacerbation connected to infections as well as those unrelated to them [<xref rid="B71" ref-type="bibr">71</xref>] (<xref rid="tab1" ref-type="table">Table 1</xref>).</p></sec><sec id="sec3.3"><title>3.3. Lantigen B</title><p>Lantigen B is a chemically lysed preparation of six respiratory tract bacteria (<italic toggle="yes">S. aureus</italic>, <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">S. pneumoniae</italic>, <italic toggle="yes">S. pyogenes</italic>, <italic toggle="yes">M. catarrhalis</italic>, and <italic toggle="yes">H. influenzae</italic>). Since its development in the 1960s, Lantigen B has been experimentally used to reduce winter RTIs [<xref rid="B11" ref-type="bibr">11</xref>].</p><p>A double-blind, placebo-controlled, multicenter clinical study found that Lantigen B reduced infectious episodes in recurrent RTIs. The placebo group had a mean of 1.43 (95% CI (1.01, 1.86)) episodes throughout the 8-month trial, whereas the Lantigen B-treated group had 0.86 (95% CI (0.54, 1.19)). The treated group used antibiotics for 1.24 days compared to 2.83 in the placebo group [<xref rid="B64" ref-type="bibr">64</xref>].</p><p>More recently, a therapeutic dosage of Lantigen B was found to alter the primary SARS-CoV-2 receptor in oropharyngeal cells and lower viral production <italic toggle="yes">in vitro</italic>. This action may work synergistically with vaccination and treatment to reduce the number of potentially infected cells and, thus, lower SARS-CoV-2 infection [<xref rid="B11" ref-type="bibr">11</xref>] (<xref rid="tab1" ref-type="table">Table 1</xref>).</p></sec><sec id="sec3.4"><title>3.4. LW 50020 (Luivac)</title><p>LW 50020 (Luivac) is a chemically lysed preparation, an oral immunomodulator containing the antigens of seven RTI-causing bacteria (<italic toggle="yes">S. aureus</italic>, <italic toggle="yes">Streptococcus mitis</italic>, <italic toggle="yes">S. pyogenes</italic>, <italic toggle="yes">S. pneumoniae</italic>, <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">M. catarrhalis</italic>, and <italic toggle="yes">H. influenzae</italic>), and induces specific and nonspecific immune responses in mucosa-associated lymphoid tissue [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B75" ref-type="bibr">75</xref>]. Several controlled clinical investigations showed that LW 50020 lowers RTIs in children and adults [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B101" ref-type="bibr">101</xref>, <xref rid="B102" ref-type="bibr">102</xref>].</p><p>A multicenter, open study in 14 countries in Europe, Latin America, and Asia enrolled 4,965 individuals with recurrent RTIs. They found that LW 50020 is safe and effectively reduces the incidence, severity, duration, and socioeconomic consequences of ubiquitous RTIs. Compared to the first trial period (first course of LW 50020 and drug-free interval), in the second trial period (second course and follow-up) with RTIs, antibiotic and symptomatic treatments and school or work absences decreased by at least 50%. Excellent or very good tolerability and acceptance were reported by 99% of the research participants [<xref rid="B75" ref-type="bibr">75</xref>].</p><p>Recurrent RTIs have been treated with oral LW 50020 in a prospective, placebo-controlled, randomized, double-blind trial. The trial found that bacterial lysate-receiving patients had a much lower clinical severity score than placebo patients. No primary medication adverse effects were reported [<xref rid="B12" ref-type="bibr">12</xref>].</p><p>An open-label, noncomparative Thai trial found that oral LW50020 was safe and effective in protecting patients from RTIs with or without risk factors. Other clinical benefits were reduced infection severity, duration, treatment expense, and school or work absences. After the research, RTIs per month were 63.5% lower than in the 12 months before. Tolerability and acceptability were excellent and acceptable in 96.8% of patients [<xref rid="B74" ref-type="bibr">74</xref>] (<xref rid="tab1" ref-type="table">Table 1</xref>).</p></sec><sec id="sec3.5"><title>3.5. Polyvaccinium Mite</title><p>Intranasal polyvaccinium mite (a PCBL consisting of <italic toggle="yes">S. aureus</italic>, <italic toggle="yes">Staphylococcus epidermidis</italic>, <italic toggle="yes">Streptococcus salivarius</italic>, <italic toggle="yes">S. pneumoniae</italic>, <italic toggle="yes">S. pyogenes</italic>, <italic toggle="yes">Escherichia coli</italic>, <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">H. influenzae</italic>, <italic toggle="yes">Corynebacterium pseudodiphtheriticum</italic>, and <italic toggle="yes">M. catarrhalis</italic>) added to standard antiallergy treatment during grass pollen season does not improve the process AR in children but significantly increased peak nasal inspiratory flow (<italic toggle="yes">p</italic>=0.01) and decreased nasal symptoms on the visual analog scale (<italic toggle="yes">p</italic>=0.03) compared to placebo [<xref rid="B76" ref-type="bibr">76</xref>] (<xref rid="tab1" ref-type="table">Table 1</xref>).</p></sec><sec id="sec3.6"><title>3.6. OM-89 (Uro-Vaxom)</title><p>OM-89 (Uro-Vaxom) contains bacterial extracts from 18 uropathogenic <italic toggle="yes">E. coli</italic> strains. The European Association of Urology (EAU) recommends this immune-prophylaxis medication for women with recurrent uncomplicated UTIs [<xref rid="B103" ref-type="bibr">103</xref>]. It stimulates innate and adaptive immunological responses by stimulating DCs and Treg cells, promoting cellular migration to the urothelial mucosa [<xref rid="B104" ref-type="bibr">104</xref>].</p><p>A 2005 global, randomized, double-blinded, placebo-controlled study found that OM-89 significantly reduced UTIs. There were 453 individuals treated, 231 with OM-89, and 222 received a placebo. The OM-89 treatment substantially reduced postbaseline UTI rates by 34% compared to the placebo group (0.84 vs. 1.28; <italic toggle="yes">p</italic>&#8201; &lt; 0.003) [<xref rid="B78" ref-type="bibr">78</xref>]. Moreover, 62 women with recurrent UTIs in weeks 16&#8211;28 of pregnancy received one OM-89 capsule daily until delivery in an open-label, multicenter pilot study. Only 19.4% of women had UTIs throughout the trial, compared to 52.5% in the 6 months before. Urinary tract infections were considerably decreased following OM-89 prophylaxis (<italic toggle="yes">p</italic>=0.001). In addition, dysuria improved, and antibiotic use reduced. Only two patients had minor adverse effects (nausea and heartburn), and all newborns were healthy [<xref rid="B79" ref-type="bibr">79</xref>]. In a 6-month, double-blind cross-over trial of 70 paraplegic individuals, OM-89 drastically reduced UTI recurrence compared to placebo [<xref rid="B82" ref-type="bibr">82</xref>]. Rugendorff [<xref rid="B81" ref-type="bibr">81</xref>] found excellent tolerability and a statistically significant reduction in reinfection in lower UTI patients. A randomized, double-blind experiment found a substantial decrease in UTI recurrences (<italic toggle="yes">p</italic>&#8201; &lt; 0.0005) in the OM-89 group compared to the placebo group, and 67.2% of patients had no repeats (<italic toggle="yes">p</italic>&#8201; &lt; 0.0005). The incidence of bacteriuria, dysuria, and leukocyturia decreased considerably. No adverse effects were reported with OM-89 in the trial [<xref rid="B80" ref-type="bibr">80</xref>]. Moreover, Tammen and Frey [<xref rid="B83" ref-type="bibr">83</xref>] found that treating UTIs with OM-89 considerably decreased recurrences throughout the trial period compared to the pretrial period (<italic toggle="yes">p</italic>&#8201; &lt; 0.001). The product was well tolerated: 4.4% of 521 patients reported adverse symptoms, and just two discontinued therapy (0.4%).</p><p>Another randomized double-blinded placebo-controlled trial of 451 patients found no meaningful difference in UTI reduction; however, the study's UTI rates were low, which may have impacted the findings [<xref rid="B105" ref-type="bibr">105</xref>]. A retrospective medical record assessment [<xref rid="B77" ref-type="bibr">77</xref>] found that OM-89 was beneficial for treating recurrent cystitis in women with uncontrolled diabetes (<xref rid="tab1" ref-type="table">Table 1</xref>).</p></sec><sec id="sec3.7"><title>3.7. Uromune&#174;</title><p>The sublingual vaccination, Uromune&#174;, a mucosal immunostimulant, contains equal amounts of inactivated whole bacteria <italic toggle="yes">E. coli</italic>, <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">Proteus vulgaris</italic>, and <italic toggle="yes">Enterococcus faecalis</italic> [<xref rid="B84" ref-type="bibr">84</xref>]. A retrospective cohort analysis of 669 women's medical records by [<xref rid="B85" ref-type="bibr">85</xref>] found that Uromune&#174; decreased the risk of recurrent UTIs by 90.28% (87.18%&#8211;93.38%) with no adverse effects and lowered antibiotic use. In a multicenter observational trial of 319 women treated with Uromune&#174;, it was found that it significantly reduced recurrent UTIs (<italic toggle="yes">p</italic> &lt; 0.0001) [<xref rid="B86" ref-type="bibr">86</xref>]. A UK prospective trial of 77 women indicated that 78% of women who took sublingual Uromune&#174; daily for 3 months did not have another UTIs in the following 12 months [<xref rid="B84" ref-type="bibr">84</xref>] (<xref rid="tab1" ref-type="table">Table 1</xref>).</p></sec><sec id="sec3.8"><title>3.8. Urovac</title><p>Urovac, a whole-cell vaccine, contains heat-killed bacteria from 10 human uropathogenic strains, including six <italic toggle="yes">E. coli</italic> strains and one strain each of <italic toggle="yes">Proteus mirabilis</italic>, <italic toggle="yes">Proteus morganii</italic>, <italic toggle="yes">E. faecalis</italic>, and <italic toggle="yes">K. pneumoniae</italic> in equal proportions. A double-blind, placebo-controlled, phase II clinical study found that women who received six vaccination doses were infection-free longer than those who had placebo or primary immunizations. A total of 55% of women with six vaccinations did not have UTIs, but 89% of placebo-treated women did. The women experienced no severe side effects [<xref rid="B88" ref-type="bibr">88</xref>]. A randomized, double-blind, placebo-controlled clinical trial [<xref rid="B87" ref-type="bibr">87</xref>] showed that multivalent vaginal mucosal vaccination reduced <italic toggle="yes">E. coli</italic> urinary tract infections. The data implied that sexually active women aged 20&#8211;50 may benefit most from the immunization. Another trial by Uehling et al. [<xref rid="B89" ref-type="bibr">89</xref>] found that Urovac delayed recurrent UTI reinfection by 8 weeks compared to the placebo. The mean time to reinfection was delayed from 8.7 weeks for placebo-treated women to 13 weeks for vaccine-treated women, with variable immunological responses in serum, urine, and vaginal fluid. There were no significant side effects (<xref rid="tab1" ref-type="table">Table 1</xref>).</p></sec><sec id="sec3.9"><title>3.9. Urivac</title><p>A prospective, open, multicentered, parallel-group randomized CRUTIL study found that a preventative single dose of urinary antiseptic at bedtime and the hexavalent vaccine Urivac (lysates of <italic toggle="yes">Propionibacterium acnes</italic>, <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">Pseudomonas aeruginosa</italic>, <italic toggle="yes">E. faecalis</italic>, <italic toggle="yes">E. coli</italic>, and <italic toggle="yes">P. mirabilis</italic>) was most effective in preventing recurrent UTIs. The research included 83 recurrent UTI-afflicted children aged 3&#8211;15 years. Three groups of children were randomized: 22 received lysate Urivac treatment, 28 received another BLs Uro-Vaxom therapy, and 33 received standard therapy. The first group (Urivac) ended the trial with 87% (19) relapse-free patients. Uro-Vaxom-treated children had 72% (20) relapse-free patients (OR&#8201;=&#8201;2.5; <italic toggle="yes">p</italic> &gt; 0.05, the minimum value of predicted event&#8722;4.84), and 17 children at 1-year follow-up. Only 13 children (40%) without nighttime urine antiseptic and BLs had no recurrence (<italic toggle="yes">p</italic> &#8804; 0.05, OR&#8201;=&#8201;0.26 with the hexavalent vaccination group) [<xref rid="B16" ref-type="bibr">16</xref>] (<xref rid="tab1" ref-type="table">Table 1</xref>).</p></sec><sec id="sec3.10"><title>3.10. ExPEC4V</title><p>The ExPEC4V candidate vaccine had four bioconjugates with the O-antigens of the four extraintestinal pathogenic <italic toggle="yes">E. coli</italic> serotypes: O1A, O2, O6A, and O25B. A phase I, first-in-human, staggered, randomized, placebo-controlled single-blind trial in 13 Swiss medical centers found that ExPEC4V vaccination reduced UTIs and evoked robust, lasting, and functional immune responses [<xref rid="B90" ref-type="bibr">90</xref>] (<xref rid="tab1" ref-type="table">Table 1</xref>).</p></sec><sec id="sec3.11"><title>3.11. <italic toggle="yes">E. coli</italic> and <italic toggle="yes">E. faecalis</italic> Lysates</title><p>A randomized, double-blind, placebo-controlled clinical trial in Germany with 606 newborns showed that prophylactic treatment with sterile BLs of <italic toggle="yes">E. coli</italic> and <italic toggle="yes">E. faecalis</italic> in infants with single heredity for atopy for 26 weeks in the 1st year of life is cost-effective at 3 and 6 years because it reduced prevalence [<xref rid="B106" ref-type="bibr">106</xref>]. However, oral BLs of heat-killed <italic toggle="yes">E. coli</italic> and <italic toggle="yes">E. faecalis</italic> administered in the first 7 months of infancy did not affect AD, asthma, and AR at school age [<xref rid="B107" ref-type="bibr">107</xref>].</p></sec><sec id="sec3.12"><title>3.12. <italic toggle="yes">Helicobacter pylori</italic> Lysates</title><p>The systemic immune response to <italic toggle="yes">H. pylori</italic> cell sonicates was studied in children with symptomatic gastroduodenal illness by Czinn et al. [<xref rid="B108" ref-type="bibr">108</xref>]. Patients with positive cultures had considerably greater serum IgA antibody levels to <italic toggle="yes">H. pylori</italic> cell sonicates than controls. Serum IgM antibody levels were not substantially higher in <italic toggle="yes">H. pylori</italic> patients [<xref rid="B108" ref-type="bibr">108</xref>]. In another study, <italic toggle="yes">H. pylori</italic>-infected C57BL/6 mice were subsequently inoculated with <italic toggle="yes">H. pylori</italic> lysate either orally with cholera toxin or intraperitoneally with alum using vaccination techniques previously shown prophylactic protection. Oral vaccination raised blood IgG&#8201;+&#8201;M and gastric IgA antibodies against <italic toggle="yes">H. pylori</italic> antigen and Th1-specific mucosal CD4+ T-cell proliferation. Parenteral vaccination dramatically increased <italic toggle="yes">H. pylori</italic>-specific serum antibody titers but did not boost mucosal antibody or cellular immune responses compared to control infected animals. Thus, <italic toggle="yes">H. pylori</italic>-specific mucosal immune responses with a Th1 profile may give therapeutic protection [<xref rid="B109" ref-type="bibr">109</xref>].</p></sec><sec id="sec3.13"><title>3.13. Autologous Bacterial Lysates (ABL)</title><p>Autologous bacterial lysates (ABL) are made by inactivating the isolated bacteria from the infected site by heat and homogenizing them in a solution to promote IgG and IgM production and T-cell activation [<xref rid="B110" ref-type="bibr">110</xref>]. Ahumada-Cota et al. [<xref rid="B111" ref-type="bibr">111</xref>] examined the effects and composition of an ABL for treating and preventing recurrent UTIs in adults. Remission occurs in 70% of patients within 3 months of treatment, and the infection is controlled for 6&#8211;12 months. LC-MS examination of patients' sera reveals cytosolic proteins, fimbriae, outer membrane proteins, and LPS in ABL fractions. The ABL treated and controlled recurrent UTIs in adults, and its composition suggests that <italic toggle="yes">E. coli</italic> surface components might be exploited to build a polyvalent protective vaccination. Unlike standard antimicrobials, ABL therapy eliminates symptoms and infection for up to 4 months. These products are biological medicines that exhibit the immunogenic components of the microbe without synthetic chemical substances through a natural and normal physiological pathway to generate an active protective immunization and cure challenging illnesses. Here, the mucosal immune system is essential because it is constantly exposed to many antigens, which activates a controlled immunological response at the local and systemic levels [<xref rid="B104" ref-type="bibr">104</xref>]. The efficacy of ABL was evaluated in a prospective study including 12 children with complicated UTI; five (42%) of the participants received ABL for 3 months and demonstrated ongoing improvement. After an initial negative phase, three patients (25%) had persistent UTI, whereas four patients (33%) never responded. These observations support the development of a polyvalent immunogen to treat and prevent recurring UTI [<xref rid="B112" ref-type="bibr">112</xref>]. Furthermore, oral ABL also stimulated bladder mucosa in the study of Ahumada-Cota et al. [<xref rid="B111" ref-type="bibr">111</xref>].</p></sec></sec><sec id="sec4"><title>4. Potential Bacterial Lysates <italic toggle="yes">In Vitro</italic> and Preclinical Stage</title><sec id="sec4.1"><title>4.1. A PMBLs of 13 Bacterial Strains</title><p>Sidoti Migliore et al. [<xref rid="B113" ref-type="bibr">113</xref>] examined the molecular mechanisms of bronchial epithelial cells' innate response in the presence of PMBLs containing 13 inactivated bacterial strains of common upper and lower respiratory pathogens (<italic toggle="yes">S. aureus</italic>, <italic toggle="yes">S. viridans</italic>, <italic toggle="yes">S. pyogenes</italic>, <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">K. ozaenae</italic>, <italic toggle="yes">H. influenzae</italic>, <italic toggle="yes">M. catarrhalis</italic>, and <italic toggle="yes">S. pneumoniae</italic>). The PMBLs increased the expression of cellular adhesion molecules such as ICAM-1, E-cadherin, and amphiregulin, a growth factor that promotes human bronchial epithelial cell proliferation. Interestingly, the PMBLs induced human bronchial epithelial cells to produce <italic toggle="yes">&#946;</italic>-defensin-2, a potent antimicrobial peptide, resulting in direct antimicrobial action. PMBL-stimulated human bronchial epithelial cells also signal innate lymphoid cells to produce more IL-22 by innate lymphoid cells through IL-23, which may help epithelial cells release antimicrobial peptides. These findings suggest that PMBLs may improve airway epithelial cell antibacterial activity and mucosal barrier integrity [<xref rid="B113" ref-type="bibr">113</xref>].</p></sec><sec id="sec4.2"><title>4.2. <italic toggle="yes">Mycobacterium tuberculosis</italic> Lysates</title><p>
<italic toggle="yes">M. tuberculosis</italic> (MTB)-specific antigen &#8220;early secreted antigenic target six kDa&#8221; (ESAT-6) or MTB lysate stimulated mitofusin 2 (MFN2) interaction with &#8220;nucleotide-binding domain, leucine-rich&#8211;containing family, pyrin domain&#8211;containing-3&#8221; (NLRP3) inflammasomes, resulting in inflammasome assembly and IL-1b release [<xref rid="B114" ref-type="bibr">114</xref>]. Further, Hirsch et al. [<xref rid="B115" ref-type="bibr">115</xref>] employed a crude French-press preparation of virulent MTB H37Rv with all bacterial components. MTB leads to &#8220;induced&#8221; Treg (iTreg) growth, which relies on mononuclear phagocytes expressing &#8220;transforming growth factor-beta&#8221; (TGF<italic toggle="yes">&#946;</italic>) and &#8220;indoleamine 2,3-dioxygenase&#8221; (IDO). In this human <italic toggle="yes">in vitro</italic> model, MTB H37RvL generated CD4&#8201;+&#8201;CD25hi&#8201;+&#8201;Foxp3+ T-regs with elevated TGF<italic toggle="yes">&#946;</italic> expression and suppressed T-cell responses. Moreover, Crespo et al. [<xref rid="B116" ref-type="bibr">116</xref>] investigated whether <italic toggle="yes">in vitro</italic> MTB or <italic toggle="yes">Mycobacterium leprae</italic> lysate exposure affects <italic toggle="yes">Porphyromonas gingivalis</italic> immune responses and proposed a novel experimental immunology-paleopathology interaction. Human peripheral blood mononuclear cells (PBMC) treated with <italic toggle="yes">M. leprae</italic> or MTB lysates on day 1 show an inflammatory shift (increased TNF-<italic toggle="yes">&#945;</italic> and IFN-<italic toggle="yes">&#947;</italic>) when exposed to the oral pathogen <italic toggle="yes">P. gingivalis</italic> on day 2. MTB infection or exposure to its metabolites induces a milieu rich in proinflammatory/anti-inflammatory cytokines and strong microbial activation via antigenic and TLRs components.</p></sec><sec id="sec4.3"><title>4.3. <italic toggle="yes">H. influenzae</italic> Lysate</title><p>Aerosolized <italic toggle="yes">H. influenzae</italic> lysate protected mice against respiratory infections from several pathogenic gram-positive and gram-negative bacteria and fungi, including <italic toggle="yes">S. pneumoniae</italic>, <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">P. aeruginosa</italic>, <italic toggle="yes">Bacillus anthracis</italic>, and <italic toggle="yes">Aspergillus fumigatus</italic> [<xref rid="B98" ref-type="bibr">98</xref>].</p></sec><sec id="sec4.4"><title>4.4. <italic toggle="yes">S. aureus</italic> Lysates</title><p>Camussone et al. [<xref rid="B117" ref-type="bibr">117</xref>] found that immunizing heifers with <italic toggle="yes">S. aureus</italic> bacterin or lysate made with ISCOM Matrix produced specific IgG in whey compared to controls. Innate immune system stimulation helps evolve adaptive immune response. This research assessed innate and T-helper activation by measuring IL-4, IL-10, IL-12p-40, TNF-<italic toggle="yes">&#945;</italic>, and IFN-<italic toggle="yes">&#947;</italic> mRNA levels 24&#8201;hr after the second vaccination dosage. The vaccines increased the expression of IL-10, IL-12, and TNF-<italic toggle="yes">&#945;</italic>. Heifers immunized with a CP5 <italic toggle="yes">S. aureus</italic> bacterin formulated with ISCOM Matrix had greater relative expression levels of IL-10 and IL-12, 24&#8201;hr after a second vaccination dose than those vaccinated with Al (OH)<sub>3</sub> [<xref rid="B118" ref-type="bibr">118</xref>]. Both formulations showed increased activation of proinflammatory cytokines (IL-12 and TNF-<italic toggle="yes">&#945;</italic>) and regulatory cytokines (IL-10), with early induction more obvious following vaccination with <italic toggle="yes">S. aureus</italic> lysate [<xref rid="B117" ref-type="bibr">117</xref>].</p></sec><sec id="sec4.5"><title>4.5. Probiotic Bacterial Lysates</title><p>An inactive bacteriologic (IAB; proprietary lysate preparation of <italic toggle="yes">Lactobacillus bulgaricus</italic>, ReseT&#174;) and a probiotic (<italic toggle="yes">Lactobacillus rhamnosus</italic>, LGG) were tested on adult <italic toggle="yes">Drosophila</italic>. The inert lysate of <italic toggle="yes">L. bulgaricus</italic> activates a subset of conserved TLRs and &#8220;nucleotide-binding oligomerization domain-containing protein&#8221; (NOD) receptors in human cells <italic toggle="yes">in vitro</italic>. NF-<italic toggle="yes">&#954;&#946;</italic> signaling patterns in the brain and abdominal tissues were changed by short-term IAB and probiotic <italic toggle="yes">L. rhamnosus</italic> therapy [<xref rid="B119" ref-type="bibr">119</xref>].</p></sec></sec><sec id="sec5"><title>5. Bacterial Lysates or Extracts as an Immunotherapy for Cancer</title><p>Coley began treating his cancer patients with streptococcal live cultures and noticed that creating a fever was essential for tumor shrinkage; nevertheless, this method also resulted in several deaths. Consequently, Coley produced a variety of &#8220;antitumor vaccinations&#8221; by combining heat-inactivated <italic toggle="yes">S. pyogenes</italic> with <italic toggle="yes">S. marcescens</italic>, commonly known as &#8220;Coley toxins&#8221; or &#8220;Coley vaccines.&#8221; He could induce infection symptoms such as inflammation, chills, and fever without risking bacteremia [<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>].</p><sec id="sec5.1"><title>5.1. How Do BLs Combat Cancer?</title><p>&#8220;Coley toxins,&#8221; BCG, and heat-killed mycobacterial preparations may induce or modulate systemic immune activation to fight cancer. By nature, bacterial preparations stimulate innate and type 1 immunity. Most of their immune response comes from PAMPs, which interact with PRRs to activate NK, <italic toggle="yes">&#947;&#948;</italic> T, and myeloid cells. Myeloid cells include M<italic toggle="yes">&#966;</italic>, DCs, and granulocytes, which sit between innate and adaptive immunity. DC activation leads to adaptive immunity, favoring CD4+ Th1 responses and CD8+ cytotoxic cell activity. The most significant effect of bacterial preparations may be on DCs, which are necessary for adaptive immunity because they process and present antigens to CD4+ and CD8+ lymphocytes [<xref rid="B120" ref-type="bibr">120</xref>, <xref rid="B121" ref-type="bibr">121</xref>].</p><p>DCs fail to grow in malignancy and cannot generate type 1 responses. Hypoxia and increased synthesis of vascular endothelial growth factor (VEGF), macrophage colony-stimulating factor (M-CSF), IL-6, IDO, extracellular adenosine, and immunosuppressive cytokines, including IL-10 and TGF-<italic toggle="yes">&#946;</italic>, characterize the cancer site's immunosuppressive milieu. All the above causes affect DC functioning in cancer to various degrees. The immunological deficiency of DCs is seen in the circulation and lymph nodes, evident in impaired systemic immune activity [<xref rid="B122" ref-type="bibr">122</xref>, <xref rid="B123" ref-type="bibr">123</xref>]. Because bacterial products stimulate DCs, which preferentially promote Th1 development and cytotoxic immune responses, this impact may restore DC function by creating a cytokine milieu that counteracts tumor-induced immunosuppression [<xref rid="B34" ref-type="bibr">34</xref>].</p><p>&#8220;Coley toxins&#8221; and their recent changes may activate innate immunity, resulting in therapeutic advantages. IL-1, IL-6, IL-12, and TNF-<italic toggle="yes">&#945;</italic> may mediate this process by creating a cytokine milieu that triggers a bacterial antigen-specific adaptive response. The cytokine milieu promoting immunological activation may restore tumor-specific Th1 and cytotoxic T cells' ability to recognize and respond to tumor antigens [<xref rid="B124" ref-type="bibr">124</xref>, <xref rid="B125" ref-type="bibr">125</xref>].</p><p>In cancer immunology, activating and stimulating NK cells and M<italic toggle="yes">&#966;</italic> using bacterial products or PRRs agonists have indicated the ability to correct immunosuppressive tumor microenvironment inadequacies [<xref rid="B126" ref-type="bibr">126</xref>]. Classical activation of M<italic toggle="yes">&#966;</italic>, which is associated with high IL-12 and low IL-10, by bacterial products may offset the protumor effects of tumor-associated M<italic toggle="yes">&#966;</italic>, which has low IL-12 and elevated IL-10 [<xref rid="B127" ref-type="bibr">127</xref>, <xref rid="B128" ref-type="bibr">128</xref>]. IL-10 downregulates proinflammatory cytokines, including IL-1, IL-6, and TNF-<italic toggle="yes">&#945;</italic> effectively, although its actions are not only limited to these mediators. In fact, IL-10 also inhibits the synthesis of chemotactic substances like IL-8 and chemokines that may draw more leukocytes to the site of inflammation [<xref rid="B129" ref-type="bibr">129</xref>]. BCG, a nonspecific anticancer immune stimulant, causes a local inflammatory response in the bladder with infiltration of innate immune cells, including M<italic toggle="yes">&#966;</italic>, and lymphocytes, particularly CD4+ Th1 cells, increasing the effector/suppressor ratio [<xref rid="B124" ref-type="bibr">124</xref>, <xref rid="B125" ref-type="bibr">125</xref>]. Type 1 immunity arises from the ensuing cytokine environment, including IL-6, IL-8, IL-10, IL-12, TNF-<italic toggle="yes">&#945;</italic>, IFN-<italic toggle="yes">&#947;</italic>, granulocyte-macrophage colony-stimulating factor (GM-CSF), chemokines, and adhesion molecules [<xref rid="B130" ref-type="bibr">130</xref>, <xref rid="B131" ref-type="bibr">131</xref>].</p><p>After bacterial extract treatment, vascular, ulcerating, or fungal tumors may deteriorate quickly and slough. Tumors with diminished vascularity soften and shrink. After an intravenous injection, the skin may redden, tighten, and temporarily grow in size. Immunotherapy typically causes a temporary increase in tumor growth; hence, immune-related response criteria (irRC) were developed to revise response evaluation criteria in solid tumors (RECIST) [<xref rid="B132" ref-type="bibr">132</xref>, <xref rid="B133" ref-type="bibr">133</xref>]. A robust immune response may generate a massive inflow of immune cells into the tumor, making up to 40% of its volume. Tumors with more lymphocytes have better prognoses [<xref rid="B134" ref-type="bibr">134</xref>]. This influx may cause a temporary enlargement that is hard to distinguish from malignancy without a biopsy. The 12-week delay before continuing or stopping therapy is one of the main differences between RECIST and irRC. Ultimate immunotherapy responses to tumors may take up to 12 weeks. Bacterial fever specialists assess patient response based on pain reduction, blood indicator improvement, energy, mobility, and appetite. Softening indicates a response in palpable tumors [<xref rid="B135" ref-type="bibr">135</xref>] (<xref rid="fig2" ref-type="fig">Figure 2</xref>).</p></sec><sec id="sec5.2"><title>5.2. Anticancer Immune Response and PAMPs</title><p>Bacteria are immunogenic, and their highly conserved structures (such as PAMPs) could activate the innate immune system, resulting in a proinflammatory response against the tumors. PAMPs, also known as microbe-associated molecular patterns (MAMP), are one of the most effective tools to enhance tumor immune reactivity. PAMP structures are recognized by PRRs. The most significant PAMPs are bacterial DNA, which activate cGAS/STING signaling and can be detected in the cell cytoplasm; others, including unmethylated CpG motifs in bacterial DNA, activate the intracellular TLR9, lipoproteins activate TLR2, and newly generated bacterial proteins' N-formylmethionine (f-Met) stimulates f-Met receptors 1 and 2. Different bacteria have their own PAMPs that may cause inflammation in addition to these common ones [<xref rid="B136" ref-type="bibr">136</xref>].</p><p>In recent years, PAMP and PRR interactions have been intensively researched, indicating that they go beyond activating innate immune cells that defend against pathogens and engage in other processes, some of which are important to cancer treatment [<xref rid="B120" ref-type="bibr">120</xref>, <xref rid="B121" ref-type="bibr">121</xref>]. The well-analyzed PRRs are TLRs, which identify bacterial lipoproteins, RNA, and DNA. PRRs include TLR-1 through TLR-12, C-type-lectin receptors (Dectin-1 and Dectin-2), and intracellular PRRs (NOD1, NOD2, NALP3, ISD, RIG-1, and MDA5) are mainly located on and inside dedicated antigen-presenting cells such DCs and M<italic toggle="yes">&#966;</italic> [<xref rid="B135" ref-type="bibr">135</xref>].</p><p>DCs are activated when they encounter antigens and PAMPs at the same moment and then migrate to the regional draining lymph nodes where they could activate antigen-specific T and B cells; besides, PAMP-stimulated DCs may develop dose-dependent NK cell helper responses [<xref rid="B137" ref-type="bibr">137</xref>]. To activate DCs, neither antigen nor PAMPs is enough. However, antigen-presenting DCs without PAMPs or PRRLs generate T-cell tolerance to the corresponding antigens. Conversely, properly activated T cells through costimulatory DC signals such as CD80, CD86, ICOSL, CD137, and OX40, together with DC-generated cytokines, undergo clonal expansion. Depending on the pathogen, they develop into CD8+ cytotoxic T cells (CTLs) that destroy cancer cells or Th1 and Th2. Th1 cells cause B cells to make IgG antibodies; Th2 cells induce IgM and then IgA, IgE, and IgG (humoral reaction) [<xref rid="B138" ref-type="bibr">138</xref>].</p><p>BCG (<italic toggle="yes">in situ</italic> bladder carcinoma), a live attenuated strain of <italic toggle="yes">Mycobacterium bovis</italic> developed initially as a tuberculosis vaccine, and Imiquimod (basal cell carcinoma) are TLRs agonists that induce TLR2 and TLR4 [<xref rid="B139" ref-type="bibr">139</xref>, <xref rid="B140" ref-type="bibr">140</xref>] and TLR 7 [<xref rid="B141" ref-type="bibr">141</xref>] signaling, respectively. Both of these, and perhaps &#8220;Coley toxins&#8221; (considered as a PAMP mix), activate NF-<italic toggle="yes">&#954;</italic>B and transcription of proinflammatory cytokine genes such IFN-<italic toggle="yes">&#945;</italic>, TNF-<italic toggle="yes">&#945;</italic>, IL-6, and IL-12 through MYD88 [<xref rid="B142" ref-type="bibr">142</xref>, <xref rid="B143" ref-type="bibr">143</xref>]. Other receptors, such as mannose, complement, and lectin, also identify microbes. Although poorly described, these receptors may induce innate and adaptive immune responses against tumors. However, certain PRRs have been linked to tumor promotion in recent years [<xref rid="B128" ref-type="bibr">128</xref>, <xref rid="B144" ref-type="bibr">144</xref>].</p><p>When activated, several T-cell types express TLRs and may read PAMPs independently. This TLR expression is transitory and downregulated after a few days unless they receive continual PAMP stimulation [<xref rid="B138" ref-type="bibr">138</xref>]. In mice, B cells generating IgM, IgG1, and IgG2c express TLRs and respond to TLRs dependently, whereas IgE-producing B cells do not. In humans, similar outcomes have been discovered [<xref rid="B145" ref-type="bibr">145</xref>]. TLR expression on adaptive immune system cells may give additional checkpoints to detect infection [<xref rid="B146" ref-type="bibr">146</xref>]. These findings show that PAMPs must be continuously provided to mimic a proliferative infection. Many cancer patients have tumor-specific T cells, proving that neoplastic cells are visible to the immune system. T cells in chronic diseases may experience exhaustion, characterized by programmed cell death protein 1 (PD-1) expression and cell cycle arrest, or anergy, characterized by decreased IL-2, IFN-<italic toggle="yes">&#947;</italic>, and TNF-<italic toggle="yes">&#945;</italic> expression [<xref rid="B147" ref-type="bibr">147</xref>]. Lack of costimulation by antigen-presenting cells (tumors do not generate PAMPs) or inhibitory stimulation by Treg cells or myeloid-derived suppressor cells (MDSC) in the tumor environment might induce anergy (tumor escape). Anergy and exhaustion may be reversed <italic toggle="yes">in vivo</italic> [<xref rid="B148" ref-type="bibr">148</xref>, <xref rid="B149" ref-type="bibr">149</xref>]. PAMPs mediate Treg suppression of naive T cells. PAMP-activated DCs may reactivate anergic or exhausted T cells in cancer patients, with distinct T-cell clones targeting pathogens and neoplastic cells. Repeated PAMP administration in cancer mice reduces MDSC levels [<xref rid="B150" ref-type="bibr">150</xref>], perhaps reducing tumor escape. Orange et al. [<xref rid="B135" ref-type="bibr">135</xref>] suggested using combined PAMPs (multiple bacterial products) for many weeks in patients with intact immunological function. They discovered early evidence supporting this idea in mice with cancer, single PAMPs caused tumor growth to decrease, and combined PAMPs cured it [<xref rid="B150" ref-type="bibr">150</xref>].</p></sec><sec id="sec5.3"><title>5.3. Clinical Effectiveness of Bacterial Lysates or Extracts against Cancer</title><p>Several whole-cell BLs or extract formulations for cancer therapy have been created and explored following on from &#8220;Coley toxins.&#8221; The concept is that &#8220;Coley toxins,&#8221; mixed bacterial vaccines, BCG, heat-killed whole cell mycobacterial preparations, and pneumococcal vaccine PCV-13 improve the patient's immune system and capacity to respond to tumor cells, restricting and preventing tumor development and spread. The most effective illustration of this concept is BCG. BCG is FDA-approved for intravenous immunotherapy of <italic toggle="yes">in situ</italic> bladder cancer [<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>]. Also, BCG is the preferred therapy for nonmuscle invasive bladder cancer because, despite its toxicity, it reduces recurrence in high-risk patients better than mitomycin C. Though sometimes used to treat melanoma, BCG has been tested in other malignancies with minimal effectiveness [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B151" ref-type="bibr">151</xref>]. Intralesional BCG improves survival in late-stage melanoma patients with cutaneous metastases [<xref rid="B152" ref-type="bibr">152</xref>]. Recently, BCG has been studied in renal and prostate cancer [<xref rid="B30" ref-type="bibr">30</xref>]; however, sepsis danger has restricted further development. Heat-killed formulations with comparable immunological properties but more excellent safety is considered an alternative.</p><p>Cadila Pharmaceuticals Ltd.'s heat-killed <italic toggle="yes">M. indicus pranii</italic> vaccine, FDA-approved for leprosy, has shown promising results in invasive bladder cancer, NSCLC, and advanced solid tumors refractory to standard treatments [<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>]. This product is being evaluated in superficial transitional cell carcinomas of the bladder (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00694798">NCT00694798</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00694915">NCT00694915</ext-link>), stage III&#8211;IV melanoma (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00675727">NCT00675727</ext-link>), hormone-refractory metastatic prostate cancer in combination with Docetaxel (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00525408">NCT00525408</ext-link>), and NSCLC in combination with Paclitaxel&#8201;+&#8201;Cisplatin (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00680940">NCT00680940</ext-link>).</p><p>Another saprophytic nonpathogenic <italic toggle="yes">Mycobacterium</italic> studied for cancer therapy is <italic toggle="yes">Mycobacterium vaccae</italic> [<xref rid="B153" ref-type="bibr">153</xref>, <xref rid="B154" ref-type="bibr">154</xref>]. Its favorable safety profile, immunomodulatory activities [<xref rid="B154" ref-type="bibr">154</xref>, <xref rid="B155" ref-type="bibr">155</xref>, <xref rid="B156" ref-type="bibr">156</xref>], and promising patient benefits encouraged Immodulon Therapeutics Ltd. to create a comparable product based on heat-killed whole-cell <italic toggle="yes">M. obuense</italic>. This preparation (IMM-101) demonstrated safety in a phase I clinical study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01308762">NCT01308762</ext-link>) in stage III/IV melanoma patients [<xref rid="B157" ref-type="bibr">157</xref>]. A total of 10 of 18 patients survived after almost 3 years, and seven were undergoing therapy (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01559818">NCT01559818</ext-link>) as of September 2013 [<xref rid="B34" ref-type="bibr">34</xref>].</p><p>Over 30 years and hundreds of applications, Coley recorded six treatment-related deaths in his department and three from colleagues. All nine patients had incurable late-stage tumors; thus, he suspected bacterial extracts caused them. Two intravenous-injected patients died from embolism; three received an excessive initial dose, one dose that was straight into the tumor; three died from renal failure, apparently caused by tumor lysis syndrome; one received a second injection with a high fever. Thus, six of nine fatalities were avoidable. Modern therapeutic settings might successfully have treated the three supposed tumor lysis syndrome patients [<xref rid="B135" ref-type="bibr">135</xref>].</p></sec></sec><sec id="sec6"><title>6. What Distinguishes Tumor Lysate from BLs in the Battle against Cancer?</title><p>In the context of cancer immunotherapy, BLs are generally acknowledged to be nonspecific immunostimulants, but tumor cell lysate (TCL) has the potential to function as a more targeted specific immunostimulant. A diverse array of target antigens is included in TCL, a combination of proteins generated by the induced lysis of tumor cells [<xref rid="B158" ref-type="bibr">158</xref>]. In addition, knowledge of important tumor-associated antigens (TAAs) and targets, including possibly undiscovered TAAs, is not a prerequisite for the TCL method of immunization [<xref rid="B159" ref-type="bibr">159</xref>, <xref rid="B160" ref-type="bibr">160</xref>]. TCL is an attractive vaccination candidate due to its simplicity of production and storage, absence of host-specific constraints, and unnecessity of prior knowledge about particular TAAs [<xref rid="B161" ref-type="bibr">161</xref>]. However, it should be noted that TCL also comprises naturally present immunosuppressants in cancer cells, including hyaluronan, which is recognized for its ability to induce tolerogenic maturation of DCs and M<italic toggle="yes">&#966;</italic> rather than immunogenic maturation [<xref rid="B162" ref-type="bibr">162</xref>]. TCL is hypothesized to include agents that induce the death of immune cells, including Fas ligand and TGF<italic toggle="yes">&#946;</italic> [<xref rid="B163" ref-type="bibr">163</xref>]. On the other hand, well-chosen immunostimulatory adjuvants, which are often used to stimulate DC maturation, may counterbalance the adverse effects of immunosuppressive components found in TCL [<xref rid="B164" ref-type="bibr">164</xref>].</p><p>Through dying, stressed, or damaged cells, several endogenous factors are translocated to the cell membrane or discharged into the extracellular environment. These signals can stimulate the immune system and commence procedures for repairing and modifying damaged tissues [<xref rid="B165" ref-type="bibr">165</xref>]. They are also known as damage-associated molecular patterns (DAMPs) and may serve as danger signals or adjuvants for immune cells, or they may be crucial components of homeostatic systems [<xref rid="B166" ref-type="bibr">166</xref>]. In the extracellular matrix of healthy tissues, DAMPs are typically nonexistent or present in extremely low concentrations. Via PRRs on their surfaces, they can interact with nearly all variants of immune cells, including DCs. TLRs, a class of membrane-spanning proteins that identify structurally conserved self- and pathogen-related chemicals, are the principal mediators of this connection [<xref rid="B167" ref-type="bibr">167</xref>]. There are 10 documented distinct TLRs in humans, each of which recognizes unique DAMPs [<xref rid="B168" ref-type="bibr">168</xref>] and PAMPs [<xref rid="B169" ref-type="bibr">169</xref>]. A crucial component of the innate immune response, these receptors facilitate the contact between immune cells and pathogens [<xref rid="B170" ref-type="bibr">170</xref>]. Induction and modulation of efficient adaptive immune responses against infections and malignancies are also significantly influenced by the signals transmitted by various TLRs [<xref rid="B171" ref-type="bibr">171</xref>, <xref rid="B172" ref-type="bibr">172</xref>, <xref rid="B173" ref-type="bibr">173</xref>, <xref rid="B174" ref-type="bibr">174</xref>]. Besides, DAMP sensing has been attributed to several PRRs including receptors belonging to the family of C-type lectins, such as Mincle and CLEC9a [<xref rid="B175" ref-type="bibr">175</xref>], and cytosolic PRRs such as AIM, DAI, MDA-5, NLRP3, and RIG-I [<xref rid="B166" ref-type="bibr">166</xref>, <xref rid="B176" ref-type="bibr">176</xref>].</p><p>Lysates of tumor cells are superior vehicles for delivering a vast array of antigens coupled to MHC class I/II molecules, stimulating a more comprehensive immune response [<xref rid="B166" ref-type="bibr">166</xref>, <xref rid="B177" ref-type="bibr">177</xref>]. As indicated by the development of specific CTLs against tumor antigens and a substantial decrease in tumor size in mice models, research studies using DCs pulsed with tumor lysates have yielded noteworthy outcomes in stimulating robust immune responses [<xref rid="B178" ref-type="bibr">178</xref>, <xref rid="B179" ref-type="bibr">179</xref>, <xref rid="B180" ref-type="bibr">180</xref>, <xref rid="B181" ref-type="bibr">181</xref>, <xref rid="B182" ref-type="bibr">182</xref>]. Additionally, promising results have been shown in mice and humans from several trials using DCs loaded with autologous, allogeneic, and partial autologous tumor lysates [<xref rid="B183" ref-type="bibr">183</xref>, <xref rid="B184" ref-type="bibr">184</xref>, <xref rid="B185" ref-type="bibr">185</xref>, <xref rid="B186" ref-type="bibr">186</xref>]. Furthermore, in several clinical trials investigating the use of allogeneic lysates derived from diverse human tumor cell lines to treat cancer, favorable outcomes have been seen [<xref rid="B187" ref-type="bibr">187</xref>, <xref rid="B188" ref-type="bibr">188</xref>, <xref rid="B189" ref-type="bibr">189</xref>, <xref rid="B190" ref-type="bibr">190</xref>]. Nevertheless, immunoregulatory cytokines such as IL-10 and TGF<italic toggle="yes">&#946;</italic> may be secreted by some cancer cells during cell culture, therefore producing a more tolerogenic phenotype on DCs, a possible obstacle rather than an advantage [<xref rid="B166" ref-type="bibr">166</xref>]. Several studies indicated that DC process signals from peripheral physiological or pathological microenvironments via their PRRs. The functional capacities acquired by DCs vary depending on the kind, quantity, and combinations of these stimuli [<xref rid="B191" ref-type="bibr">191</xref>, <xref rid="B192" ref-type="bibr">192</xref>].</p><p>The use of patient-specific tumor cells to generate a tailored whole-tumor lysate (WTL) cancer vaccine would provide an extensive repertoire of known and unidentified antigenic T-cell epitopes, which are essential for eliciting a comprehensive immune response [<xref rid="B193" ref-type="bibr">193</xref>, <xref rid="B194" ref-type="bibr">194</xref>]. These polyclonal CD8+ and CD4+ antitumor T-cell responses raised against tumor neoantigens and/or TAAs would be beneficial in reducing tumor escape variants through the loss of single or multiple antigens in the tumor cell [<xref rid="B195" ref-type="bibr">195</xref>, <xref rid="B196" ref-type="bibr">196</xref>, <xref rid="B197" ref-type="bibr">197</xref>]. The cognate assistance that CD4+ T helper cells provide to CD8+ T cells may also stimulate long-term immunological memory against the tumor. Additionally, whole-tumor vaccinations elicited a greater objective response (8.1%) in patients than specified tumor antigen-based vaccines (3.6%), according to a meta-analysis of about 1,800 patients from different cancer clinical trials [<xref rid="B198" ref-type="bibr">198</xref>]. The combination of heat shock-treated tumor cell lysates and <italic toggle="yes">Concholepas concholepas</italic> hemocyanin as an adjuvant in the therapeutic vaccine TRIMELVax effectively inhibits the growth of aggressive and weakly immunogenic B16F10 melanoma tumors in mice, extending their survival even in the absence of an immune checkpoint inhibitor [<xref rid="B199" ref-type="bibr">199</xref>]. For WTL preparation, the patient's tumor might be collected during debulking surgery. Malignancies such as glioblastomas, ovarian, breast, and lung carcinomas might potentially benefit from WTL treatment due to the ability to collect enough quantities of tumor material [<xref rid="B200" ref-type="bibr">200</xref>]. Allogeneic tumor cell lines that express shared TAAs may be used as a substitute when autologous tumor materials are scarce. The allogeneic melanoma tumor cell lysate Melacine (Corixa Corp.) has shown some anticancer properties when paired with the adjuvant DETOX (purified mycobacterial cell wall skeleton and monophosphoryl lipid A) [<xref rid="B193" ref-type="bibr">193</xref>, <xref rid="B201" ref-type="bibr">201</xref>].</p></sec><sec id="sec7"><title>7. Future Insights</title><p>As fundamental science, technology, and clinical research advance and bacterial lysates progressively establish themselves as an innovative weapon in combating cancer and other infectious diseases, the use of BLs in these areas will probably expand. Ongoing investigations may likely reveal more mechanisms by which bacterial lysate immunotherapy operates, including how bacterial constituents control immune responses in the context of cancer and infectious diseases. This will accelerate the development of more focused medicines. Engineering bacterial lysates to improve their immunogenicity, safety, and specificity via the development of designer bacterial strains or the modification of existing strains to produce lysates with tailored therapeutic qualities might be of scientific interest [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B91" ref-type="bibr">91</xref>].</p><p>Potential future developments in genomics and immune profiling technologies might facilitate the identification of blood-based immune signals that can be used to predict a patient's response to bacterial lysate immunotherapy under individualized treatment regimens. Subsequent investigations may concentrate on ascertaining if bacterial lysates may be used to create a tumor microenvironment that is more conducive to antitumor immune responses [<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B192" ref-type="bibr">192</xref>, <xref rid="B202" ref-type="bibr">202</xref>].</p><p>Further research may investigate other combination techniques that combine bacterial lysate immunotherapy with checkpoint inhibitors, chemotherapy, or targeted treatments. Combinatorial medicines are expected to boost treatment efficacies, circumvent resistance mechanisms, and enhance anticancer or anti-infection immune responses. Therapeutic studies will be required in the future to confirm the safety, effectiveness, and clinical value of bacterial lysate immunotherapy in diverse patient populations [<xref rid="B193" ref-type="bibr">193</xref>, <xref rid="B203" ref-type="bibr">203</xref>].</p></sec><sec id="sec8"><title>8. Conclusions</title><p>A strong interplay between specific (acquired) and nonspecific (natural, innate) immune mechanisms plays a crucial role in protecting against infectious agents. A nonspecific response actively supports specific response mechanisms. This enables effective protection of our body against infections, both at the stage when pathogens reach the body and after their penetration into tissues. Stimulating microbial antigens such as bacterial lysates (BLs) or extracts activates specific immunity mechanisms: humoral and cell-mediated responses and nonspecific immunity. Specific antibodies or immunoglobulins of various classes are involved in the humoral response to protect from recurrent infections. BLs have been found effective in children and adults in treating respiratory tract infections, chronic obstructive pulmonary diseases, rhinitis, rhinosinusitis, and urinary tract infections. The World Health Organization and the Centers for Disease Control have declared antibiotic resistance as one of the most significant risks to humanity in our lifetime. There is a pressing need to utilize new antibiotic-free therapies (such as BLs) in preventing UTI recurrences. Correspondingly, BL-based nonspecific immune stimulants could help the immune system detect and fight against cancers such as sarcomas, carcinomas, lymphomas, melanomas, myelomas, bladder cancer, and non-small cell lung cancer. The late stage of cancer that is sensitive to conventional therapies becomes resistant later. Biological therapies such as BLs or extracts-based preparations are helpful to fight tumor cells in addition to traditional therapies because they are characterized by less toxicity and specific targeting of tumor cells. There is an urgent need for high-quality, large-sample-size studies on the clinical efficacy and mechanisms of action of BLs with various bacterial antigen compositions, methods of preparation, and routes of administration to determine their potential for treating infectious diseases and cancer as well.</p></sec></body><back><ack><title>Acknowledgments</title><p>All authors acknowledge Griffith University's School of Pharmacy and Medical Sciences and library for their assistance with resources. Md. Mijanur Rahman, the primary author, also acknowledges the GUPRS and GUIPRS scholarships he is receiving from Griffith University to pursue doctoral studies. Open access publishing facilitated by Griffith University, as part of the Wiley - Griffith University agreement via the Council of Australian University Librarians.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>AD:</term><def><p>Atopic dermatitis</p></def></def-item><def-item><term>ALIs:</term><def><p>Air&#8211;liquid interfaces</p></def></def-item><def-item><term>APRIL:</term><def><p>A proliferation-inducing ligand</p></def></def-item><def-item><term>AR:</term><def><p>Allergic rhinitis</p></def></def-item><def-item><term>BAFF:</term><def><p>B-cell-activating factor belonging to the tumor necrosis factor (TNF) family</p></def></def-item><def-item><term>BCG:</term><def><p>Bacillus Calmette&#8211; Gu&#233;rin</p></def></def-item><def-item><term>BLs:</term><def><p>Bacterial lysates</p></def></def-item><def-item><term>CBF:</term><def><p>Ciliary beat frequency</p></def></def-item><def-item><term>CCL:</term><def><p>Chemokine (C-C motif) ligand</p></def></def-item><def-item><term>CD:</term><def><p>Cluster of differentiation</p></def></def-item><def-item><term>cGAS:</term><def><p>Cyclic GMP-AMP synthase</p></def></def-item><def-item><term>CI:</term><def><p>Confidence interval</p></def></def-item><def-item><term>COPD:</term><def><p>Chronic obstructive pulmonary disease</p></def></def-item><def-item><term>CpG:</term><def><p>Unmethylated cytosine&#8211;guanine dinucleotide</p></def></def-item><def-item><term>CRS:</term><def><p>Chronic rhinosinusitis</p></def></def-item><def-item><term>DAMPs:</term><def><p>Damage-associated molecular patterns</p></def></def-item><def-item><term>ESAT-6:</term><def><p>Early secreted antigenic target 6 kDa</p></def></def-item><def-item><term>f-Met:</term><def><p>N-formylmethionine</p></def></def-item><def-item><term>GM-CSF:</term><def><p>Granulocyte-macrophage colony-stimulating factor</p></def></def-item><def-item><term>HR:</term><def><p>Hazard ratio</p></def></def-item><def-item><term>IAB:</term><def><p>Inactive bacteriologic</p></def></def-item><def-item><term>ICAM-1:</term><def><p>Intracellular adhesion molecule 1</p></def></def-item><def-item><term>ICOSL:</term><def><p>Inducible T-cell costimulator ligand</p></def></def-item><def-item><term>ICS:</term><def><p>Inhaled corticosteroid</p></def></def-item><def-item><term>IDO:</term><def><p>Indoleamine 2,3-dioxygenase</p></def></def-item><def-item><term>IFN:</term><def><p>Interferons</p></def></def-item><def-item><term>Ig:</term><def><p>Immunoglobulins</p></def></def-item><def-item><term>IL:</term><def><p>Interleukins</p></def></def-item><def-item><term>irRC:</term><def><p>Immune-related response criteria</p></def></def-item><def-item><term>iTreg:</term><def><p>Induced regulatory T cells</p></def></def-item><def-item><term>MAMP:</term><def><p>Microbe-associated molecular patterns</p></def></def-item><def-item><term>MAPK:</term><def><p>Mitogen-activated protein kinase</p></def></def-item><def-item><term>M-CSF:</term><def><p>Macrophage colony-stimulating factor</p></def></def-item><def-item><term>MD:</term><def><p>Mean difference</p></def></def-item><def-item><term>MDSC:</term><def><p>Myeloid-derived suppressor cells</p></def></def-item><def-item><term>MFN2:</term><def><p>Mitofusin 2</p></def></def-item><def-item><term>mL:</term><def><p>Milliliter</p></def></def-item><def-item><term>Myd88:</term><def><p>Myeloid differentiation primary response 8</p></def></def-item><def-item><term>MyD88:</term><def><p>Myeloid differentiation primary response 88</p></def></def-item><def-item><term>M<italic toggle="yes">&#966;</italic>:</term><def><p>Macrophages</p></def></def-item><def-item><term>NALP3:</term><def><p>NACHT, leucine-rich region, and PYD domain&#8211;containing protein-3</p></def></def-item><def-item><term>NF-kB:</term><def><p>Nuclear factor kappa-light-chain-enhancer of activated B cells</p></def></def-item><def-item><term>NK:</term><def><p>Natural killer cells</p></def></def-item><def-item><term>NKT:</term><def><p>Natural killer T cells</p></def></def-item><def-item><term>NLRP3:</term><def><p>Nucleotide-binding domain, leucine-rich&#8211;containing family, pyrin domain&#8211;containing-3</p></def></def-item><def-item><term>NO:</term><def><p>Nitric oxide</p></def></def-item><def-item><term>NOD:</term><def><p>Nucleotide-binding oligomerization domain-containing protein</p></def></def-item><def-item><term>NOS:</term><def><p>Nitric oxide synthase</p></def></def-item><def-item><term>NSCLC:</term><def><p>Non-small cell lung cancers</p></def></def-item><def-item><term>PAMPs:</term><def><p>Pathogen-associated molecular patterns</p></def></def-item><def-item><term>PBMC:</term><def><p>Peripheral blood mononuclear cells</p></def></def-item><def-item><term>PCBLs:</term><def><p>Polyvalent chemical bacterial lysates</p></def></def-item><def-item><term>PD-1:</term><def><p>Programmed cell death protein 1</p></def></def-item><def-item><term>PLC<italic toggle="yes">&#946;</italic>2:</term><def><p>Phospholipase C isoform <italic toggle="yes">&#946;</italic>2</p></def></def-item><def-item><term>PMBLs:</term><def><p>Polyvalent mechanical bacterial lysates</p></def></def-item><def-item><term>PRRs:</term><def><p>Pattern recognition receptors</p></def></def-item><def-item><term>RECIST:</term><def><p>Response evaluation criteria in solid tumors</p></def></def-item><def-item><term>RR:</term><def><p>Risk ratio</p></def></def-item><def-item><term>RRTIs:</term><def><p>Recurrent respiratory tract infections</p></def></def-item><def-item><term>RTIs:</term><def><p>Respiratory tract infections</p></def></def-item><def-item><term>SARS-CoV-2:</term><def><p>Severe acute respiratory syndrome coronavirus 2</p></def></def-item><def-item><term>sIgA:</term><def><p>Secretory IgA</p></def></def-item><def-item><term>STING:</term><def><p>Stimulator of interferon genes</p></def></def-item><def-item><term>T2R:</term><def><p>Bitter taste receptors</p></def></def-item><def-item><term>TAAs:</term><def><p>Tumor-associated antigens</p></def></def-item><def-item><term>TCL:</term><def><p>Tumor cell lysate</p></def></def-item><def-item><term>TGF<italic toggle="yes">&#946;</italic>:</term><def><p>Transforming growth factor-beta</p></def></def-item><def-item><term>Th1:</term><def><p>Type 1 T helper cells</p></def></def-item><def-item><term>Th2:</term><def><p>Type 2 T helper cells</p></def></def-item><def-item><term>TLRs:</term><def><p>Toll-like receptors</p></def></def-item><def-item><term>TNF-<italic toggle="yes">&#945;</italic>:</term><def><p>Tumor necrosis factor <italic toggle="yes">&#945;</italic></p></def></def-item><def-item><term>Treg:</term><def><p>Regulatory T cells</p></def></def-item><def-item><term>Trif:</term><def><p>TIR (Toll/interleukin-1 receptor) domain-containing adaptor protein inducing interferon <italic toggle="yes">&#946;</italic></p></def></def-item><def-item><term>TRPM5:</term><def><p>Transient receptor potential cation channel subfamily M member 5</p></def></def-item><def-item><term>UTIs:</term><def><p>Urinary tract infections</p></def></def-item><def-item><term>VEGF:</term><def><p>Vascular endothelial growth factor</p></def></def-item><def-item><term>WTL:</term><def><p>Whole-tumor lysate</p></def></def-item><def-item><term>WMD:</term><def><p>Weighted mean difference.</p></def></def-item></def-list></glossary><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that they have no conflicts of interest.</p></sec><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crews</surname><given-names>D. W.</given-names></name><name name-style="western"><surname>Dombroski</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>King</surname><given-names>M. R.</given-names></name></person-group><article-title>Prophylactic cancer vaccines engineered to elicit specific adaptive immune response</article-title><source><italic toggle="yes">Frontiers in Oncology</italic></source><year>2021</year><volume>11</volume><pub-id pub-id-type="doi">10.3389/fonc.2021.626463</pub-id><pub-id pub-id-type="publisher-id">626463</pub-id><pub-id pub-id-type="pmcid">PMC8044825</pub-id><pub-id pub-id-type="pmid">33869008</pub-id></element-citation></ref><ref id="B2" content-type="article"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghasemian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-marzoqi</surname><given-names>A.-H.</given-names></name><name name-style="western"><surname>Al-abodi</surname><given-names>H. R.</given-names></name><etal/></person-group><article-title>Bacterial l -asparaginases for cancer therapy: current knowledge and future perspectives</article-title><source><italic toggle="yes">Journal of Cellular Physiology</italic></source><year>2019</year><volume>234</volume><issue>11</issue><fpage>19271</fpage><lpage>19279</lpage><pub-id pub-id-type="doi">10.1002/jcp.28563</pub-id><pub-id pub-id-type="other">2-s2.0-85069739046</pub-id><pub-id pub-id-type="pmid">30993718</pub-id></element-citation></ref><ref id="B3" content-type="article"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>R.</given-names></name></person-group><article-title>Immunological mechanisms of vaccination</article-title><source><italic toggle="yes">Nature Immunology</italic></source><year>2011</year><volume>12</volume><issue>6</issue><fpage>509</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/ni.2039</pub-id><pub-id pub-id-type="other">2-s2.0-79956079190</pub-id><pub-id pub-id-type="pmid">21739679</pub-id><pub-id pub-id-type="pmcid">PMC3253344</pub-id></element-citation></ref><ref id="B4" content-type="article"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gogoi</surname><given-names>H.</given-names></name></person-group><article-title>Bacterial immunotherapy: is it a weapon in our arsenal in the fight against cancer?</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2023</year><volume>14</volume><pub-id pub-id-type="doi">10.3389/fimmu.2023.1277677</pub-id><pub-id pub-id-type="publisher-id">1277677</pub-id><pub-id pub-id-type="pmcid">PMC10711065</pub-id><pub-id pub-id-type="pmid">38090593</pub-id></element-citation></ref><ref id="B5" content-type="article"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></name></person-group><article-title>Current status and future directions of bacteria-based immunotherapy</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2022</year><volume>13</volume><pub-id pub-id-type="doi">10.3389/fimmu.2022.911783</pub-id><pub-id pub-id-type="publisher-id">911783</pub-id><pub-id pub-id-type="pmcid">PMC9226492</pub-id><pub-id pub-id-type="pmid">35757741</pub-id></element-citation></ref><ref id="B6" content-type="article"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su&#225;rez</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ferrara</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rial</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dee</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chabalgoity</surname><given-names>J. A.</given-names></name></person-group><article-title>Bacterial lysates as immunotherapies for respiratory infections: methods of preparation</article-title><source><italic toggle="yes">Frontiers in Bioengineering and Biotechnology</italic></source><year>2020</year><volume>8</volume><pub-id pub-id-type="doi">10.3389/fbioe.2020.00545</pub-id><pub-id pub-id-type="publisher-id">545</pub-id><pub-id pub-id-type="pmcid">PMC7289947</pub-id><pub-id pub-id-type="pmid">32582669</pub-id></element-citation></ref><ref id="B7" content-type="article"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janeczek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kaczy&#324;ska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Emeryk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cingi</surname><given-names>C.</given-names></name></person-group><article-title>Perspectives for the use of bacterial lysates for the treatment of allergic rhinitis: a systematic review</article-title><source><italic toggle="yes">Journal of Asthma and Allergy</italic></source><year>2022</year><volume>15</volume><fpage>839</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.2147/JAA.S360828</pub-id><pub-id pub-id-type="pmid">35769192</pub-id><pub-id pub-id-type="pmcid">PMC9236485</pub-id></element-citation></ref><ref id="B8" content-type="article"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cazzola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Anapurapu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Page</surname><given-names>C. P.</given-names></name></person-group><article-title>Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: a meta-analysis</article-title><source><italic toggle="yes">Pulmonary Pharmacology &amp; Therapeutics</italic></source><year>2012</year><volume>25</volume><issue>1</issue><fpage>62</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.pupt.2011.11.002</pub-id><pub-id pub-id-type="other">2-s2.0-84856808082</pub-id><pub-id pub-id-type="pmid">22155205</pub-id></element-citation></ref><ref id="B9" content-type="article"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>La Mantia</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nicolozi</surname><given-names>F.</given-names></name></person-group><article-title>Immunoprophylaxis of recurring bacterial infections of respiratory tracts in pediatric age: clinical experience through a new immune stimulating vaccine</article-title><source><italic toggle="yes">GIMMOC</italic></source><year>2007</year><volume>9</volume><fpage>1</fpage><lpage>8</lpage></element-citation></ref><ref id="B10" content-type="article"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Efficacy and safety of OM-85 in paediatric recurrent respiratory tract infections which could have a possible protective effect on COVID-19 pandemic: a meta-analysis</article-title><source><italic toggle="yes">International Journal of Clinical Practice</italic></source><year>2021</year><volume>75</volume><issue>5</issue><pub-id pub-id-type="doi">10.1111/ijcp.13981</pub-id><pub-id pub-id-type="publisher-id">e13981</pub-id><pub-id pub-id-type="pmcid">PMC7883224</pub-id><pub-id pub-id-type="pmid">33405321</pub-id></element-citation></ref><ref id="B11" content-type="article"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pizzimenti</surname><given-names>C.</given-names></name><name name-style="western"><surname>D&#8217;Agostino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pirrello</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ruiba</surname><given-names>A.</given-names></name><name name-style="western"><surname>Melioli</surname><given-names>G.</given-names></name></person-group><article-title>The SARS-CoV-2 cellular receptor ACE2 is expressed in oropharyngeal cells and is modulated in vitro by the bacterial lysate lantigen B</article-title><source><italic toggle="yes">Archives of Clinical and Biomedical Research</italic></source><year>2023</year><volume>7</volume><fpage>13</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.26502/acbr</pub-id></element-citation></ref><ref id="B12" content-type="article"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rutishauser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pitzke</surname><given-names>P.</given-names></name><name name-style="western"><surname>Grevers</surname><given-names>G.</given-names></name><name name-style="western"><surname>van Aubel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Elsasser</surname><given-names>U.</given-names></name><name name-style="western"><surname>K&#228;mmereit</surname><given-names>A.</given-names></name></person-group><article-title>Use of a polyvalent bacterial lysate in patients with recurrent respiratory tract infections: results of a prospective, placebo-controlled, randomized, double-blind study</article-title><source><italic toggle="yes">Advances in Therapy</italic></source><year>1998</year><volume>15</volume><issue>6</issue><fpage>330</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">10351117</pub-id></element-citation></ref><ref id="B13" content-type="article"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>K.</given-names></name></person-group><article-title>Broncho-Vaxom in pediatric recurrent respiratory tract infections: a systematic review and meta-analysis</article-title><source><italic toggle="yes">International Immunopharmacology</italic></source><year>2018</year><volume>54</volume><fpage>198</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2017.10.032</pub-id><pub-id pub-id-type="other">2-s2.0-85034087196</pub-id><pub-id pub-id-type="pmid">29154122</pub-id></element-citation></ref><ref id="B14" content-type="article"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cazzola</surname><given-names>M.</given-names></name></person-group><article-title>A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD: a double-blind, randomized, placebo-controlled trial</article-title><source><italic toggle="yes">Trends in Medicine</italic></source><year>2006</year><volume>6</volume><issue>3</issue><fpage>199</fpage><lpage>207</lpage></element-citation></ref><ref id="B15" content-type="article"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janeczek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Emeryk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rachel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Duma</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>&#321;.</given-names></name><name name-style="western"><surname>Poleszak</surname><given-names>E.</given-names></name></person-group><article-title>Polyvalent mechanical bacterial lysate administration improves the clinical course of grass pollen&#8211;induced allergic rhinitis in children: a randomized controlled trial</article-title><source><italic toggle="yes">The Journal of Allergy and Clinical Immunology: In Practice</italic></source><year>2021</year><volume>9</volume><issue>1</issue><fpage>453</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2020.08.025</pub-id><pub-id pub-id-type="pmid">32858239</pub-id></element-citation></ref><ref id="B16" content-type="article"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ivanov</surname><given-names>D. D.</given-names></name><name name-style="western"><surname>Ivanova</surname><given-names>T. P.</given-names></name><name name-style="western"><surname>Fedorenko</surname><given-names>E. G.</given-names></name><name name-style="western"><surname>Kushnirenko</surname><given-names>S. V.</given-names></name><name name-style="western"><surname>Ivanova</surname><given-names>M. D.</given-names></name></person-group><article-title>Possibilities of modern anti-relapse therapy of urinary tract infections in children: crutil trial 1 year follow-up</article-title><source><italic toggle="yes">Journal of Nephrology &amp; Renal Therapy</italic></source><year>2020</year><pub-id pub-id-type="doi">10.24966/NRT-7313/100024</pub-id></element-citation></ref><ref id="B17" content-type="article"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Triantafillou</surname><given-names>V.</given-names></name><name name-style="western"><surname>Workman</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>N. N.</given-names></name><etal/></person-group><article-title>Broncho-Vaxom&#174; (OM-85 BV) soluble components stimulate sinonasal innate immunity</article-title><source><italic toggle="yes">International Forum of Allergy &amp; Rhinology</italic></source><year>2019</year><volume>9</volume><issue>4</issue><fpage>370</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1002/alr.22276</pub-id><pub-id pub-id-type="other">2-s2.0-85059650531</pub-id><pub-id pub-id-type="pmid">30615298</pub-id><pub-id pub-id-type="pmcid">PMC6438742</pub-id></element-citation></ref><ref id="B18" content-type="article"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Che</surname><given-names>D.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>R.</given-names></name></person-group><article-title>Bacterial lysate treatment in allergic disease: a systematic review and meta-analysis</article-title><source><italic toggle="yes">Pediatric Allergy and Immunology</italic></source><year>2021</year><volume>32</volume><issue>8</issue><fpage>1813</fpage><lpage>1823</lpage><pub-id pub-id-type="doi">10.1111/pai.13572</pub-id><pub-id pub-id-type="pmid">34097747</pub-id><pub-id pub-id-type="pmcid">PMC8597000</pub-id></element-citation></ref><ref id="B19" content-type="article"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rebolledo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Vigil</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carmen</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Bacterial immunotherapy is highly effective in reducing recurrent upper respiratory tract infections in children: a prospective observational study</article-title><source><italic toggle="yes">European Archives of Oto-Rhino-Laryngology</italic></source><year>2023</year><volume>280</volume><fpage>4519</fpage><lpage>4530</lpage><pub-id pub-id-type="doi">10.1007/s00405-023-08035-4</pub-id><pub-id pub-id-type="pmid">37254001</pub-id><pub-id pub-id-type="pmcid">PMC10477114</pub-id></element-citation></ref><ref id="B20" content-type="article"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Boer</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>&#379;&#243;&#322;kiewicz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Strzelec</surname><given-names>K. P.</given-names></name><etal/></person-group><article-title>Bacterial lysate therapy for the prevention of wheezing episodes and asthma exacerbations: a systematic review and meta-analysis</article-title><source><italic toggle="yes">European Respiratory Review</italic></source><year>2020</year><volume>29</volume><issue>158</issue><pub-id pub-id-type="doi">10.1183/16000617.0175-2019</pub-id><pub-id pub-id-type="publisher-id">190175</pub-id><pub-id pub-id-type="pmcid">PMC9488706</pub-id><pub-id pub-id-type="pmid">33246991</pub-id></element-citation></ref><ref id="B21" content-type="article"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banche</surname><given-names>G.</given-names></name><name name-style="western"><surname>Allizond</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mandras</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Improvement of clinical response in allergic rhinitis patients treated with an oral immunostimulating bacterial lysate: <italic toggle="yes">in vivo</italic> immunological effects</article-title><source><italic toggle="yes">International Journal of Immunopathology and Pharmacology</italic></source><year>2007</year><volume>20</volume><issue>1</issue><fpage>129</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1177/039463200702000115</pub-id><pub-id pub-id-type="other">2-s2.0-33947719010</pub-id><pub-id pub-id-type="pmid">17346436</pub-id></element-citation></ref><ref id="B22" content-type="article"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Bacterial lysate for the prevention of chronic rhinosinusitis recurrence in children</article-title><source><italic toggle="yes">The Journal of Laryngology &amp; Otology</italic></source><year>2017</year><volume>131</volume><issue>6</issue><fpage>523</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1017/S0022215117000524</pub-id><pub-id pub-id-type="other">2-s2.0-85015652429</pub-id><pub-id pub-id-type="pmid">28318451</pub-id></element-citation></ref><ref id="B23" content-type="article"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zagar</surname><given-names>S.</given-names></name><name name-style="western"><surname>L&#246;fler-Badzek</surname><given-names>D.</given-names></name></person-group><article-title>Broncho-Vaxom&#174; in children with rhinosinusitis: a double-blind clinical trial</article-title><source><italic toggle="yes">ORL</italic></source><year>1988</year><volume>50</volume><issue>6</issue><fpage>397</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1159/000276020</pub-id><pub-id pub-id-type="other">2-s2.0-0023823824</pub-id><pub-id pub-id-type="pmid">3068610</pub-id></element-citation></ref><ref id="B24" content-type="article"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aziminia</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hadjipavlou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Philippou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pandian</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Malde</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hammadeh</surname><given-names>M. Y.</given-names></name></person-group><article-title>Vaccines for the prevention of recurrent urinary tract infections: a systematic review</article-title><source><italic toggle="yes">BJU International</italic></source><year>2019</year><volume>123</volume><issue>5</issue><fpage>753</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1111/bju.14606</pub-id><pub-id pub-id-type="other">2-s2.0-85058846386</pub-id><pub-id pub-id-type="pmid">30378242</pub-id></element-citation></ref><ref id="B25" content-type="article"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>T. K.</given-names></name><name name-style="western"><surname>Arsov</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schirlau</surname><given-names>K.</given-names></name><etal/></person-group><article-title>T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx</article-title><source><italic toggle="yes">International Journal of Cancer</italic></source><year>2006</year><volume>118</volume><issue>8</issue><fpage>1984</fpage><lpage>1991</lpage><pub-id pub-id-type="doi">10.1002/ijc.21565</pub-id><pub-id pub-id-type="other">2-s2.0-33645215135</pub-id><pub-id pub-id-type="pmid">16284959</pub-id></element-citation></ref><ref id="B26" content-type="article"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kramer</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Masner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>F. A.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>R. M.</given-names></name></person-group><article-title>Bacterial therapy of cancer: promises, limitations, and insights for future directions</article-title><source><italic toggle="yes">Frontiers in Microbiology</italic></source><year>2018</year><volume>9</volume><pub-id pub-id-type="doi">10.3389/fmicb.2018.00016</pub-id><pub-id pub-id-type="other">2-s2.0-85040807960</pub-id><pub-id pub-id-type="publisher-id">16</pub-id><pub-id pub-id-type="pmcid">PMC5810261</pub-id><pub-id pub-id-type="pmid">29472896</pub-id></element-citation></ref><ref id="B27" content-type="incollection"><label>27</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Nauts</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>McLaren</surname><given-names>J. R.</given-names></name></person-group><article-title>Coley toxins&#8212;the first century</article-title><source><italic toggle="yes">Consensus on Hyperthermia for the 1990s</italic></source><year>1990</year><volume>267</volume><publisher-loc>Boston, MA</publisher-loc><publisher-name>Springer</publisher-name><fpage>483</fpage><lpage>500</lpage><series>Advances in Experimental Medicine and Biology</series><pub-id pub-id-type="doi">10.1007/978-1-4684-5766-7_52</pub-id><pub-id pub-id-type="pmid">2088067</pub-id></element-citation></ref><ref id="B28" content-type="article"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chorobik</surname><given-names>P.</given-names></name><name name-style="western"><surname>Czaplicki</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ossysek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bereta</surname><given-names>J.</given-names></name></person-group><article-title>Salmonella and cancer: from pathogens to therapeutics</article-title><source><italic toggle="yes">Acta Biochimica Polonica</italic></source><year>2013</year><volume>60</volume><issue>3</issue><fpage>285</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.18388/abp.2013_1984</pub-id><pub-id pub-id-type="pmid">23828775</pub-id></element-citation></ref><ref id="B29" content-type="article"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexandroff</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>James</surname><given-names>K.</given-names></name></person-group><article-title>BCG immunotherapy of bladder cancer: 20 years on</article-title><source><italic toggle="yes">The Lancet</italic></source><year>1999</year><volume>353</volume><issue>9165</issue><fpage>1689</fpage><lpage>1694</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(98)07422-4</pub-id><pub-id pub-id-type="other">2-s2.0-0033562695</pub-id><pub-id pub-id-type="pmid">10335805</pub-id></element-citation></ref><ref id="B30" content-type="article"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gandhi</surname><given-names>N. M.</given-names></name><name name-style="western"><surname>Morales</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lamm</surname><given-names>D. L.</given-names></name></person-group><article-title>Bacillus Calmette-Gu&#233;rin immunotherapy for genitourinary cancer</article-title><source><italic toggle="yes">BJU International</italic></source><year>2013</year><volume>112</volume><issue>3</issue><fpage>288</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1111/j.1464-410X.2012.11754.x</pub-id><pub-id pub-id-type="other">2-s2.0-84879887890</pub-id><pub-id pub-id-type="pmid">23517232</pub-id></element-citation></ref><ref id="B31" content-type="article"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zarenezhad</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kanaan</surname><given-names>M. H. G.</given-names></name><name name-style="western"><surname>Abdollah</surname><given-names>S. S.</given-names></name><etal/></person-group><article-title>Metallic nanoparticles: their potential role in breast cancer immunotherapy via trained immunity provocation</article-title><source><italic toggle="yes">Biomedicines</italic></source><year>2023</year><volume>11</volume><issue>5</issue><pub-id pub-id-type="doi">10.3390/biomedicines11051245</pub-id><pub-id pub-id-type="publisher-id">1245</pub-id><pub-id pub-id-type="pmcid">PMC10215451</pub-id><pub-id pub-id-type="pmid">37238916</pub-id></element-citation></ref><ref id="B32" content-type="article"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhuri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mukhopadhyay</surname><given-names>S.</given-names></name></person-group><article-title>Bladder preserving approach for muscle invasive bladder cancer&#8212;role of mycobacterium w</article-title><source><italic toggle="yes">Journal of The Indian Medical Association</italic></source><year>2003</year><volume>101</volume><issue>9</issue><fpage>559</fpage><lpage>560</lpage><pub-id pub-id-type="pmid">15168998</pub-id></element-citation></ref><ref id="B33" content-type="article"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sur</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>Dastidar</surname><given-names>A. G.</given-names></name></person-group><article-title>Role of mycobacterium w as adjuvant treatment of lung cancer (non-small cell lung cancer)</article-title><source><italic toggle="yes">Journal of The Indian Medical Association</italic></source><year>2003</year><volume>101</volume><issue>2</issue><fpage>118</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">12841498</pub-id></element-citation></ref><ref id="B34" content-type="article"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brunet</surname><given-names>L. R.</given-names></name><name name-style="western"><surname>Hagemann</surname><given-names>T.</given-names></name></person-group><article-title>William Coley&#8217;s legacy&#8212;the development of modern mycobacteria-based therapies for cancer</article-title><source><italic toggle="yes">Trends in Cancer Research</italic></source><year>2013</year><volume>9</volume><fpage>109</fpage><lpage>117</lpage></element-citation></ref><ref id="B35" content-type="article"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braido</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schenone</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pallestrini</surname><given-names>E.</given-names></name><etal/></person-group><article-title>The relationship between mucosal immunoresponse and clinical outcome in patients with recurrent upper respiratory tract infections treated with a mechanical bacterial lysate</article-title><source><italic toggle="yes">Journal of Biological Regulators and Homeostatic Agents</italic></source><year>2011</year><volume>25</volume><issue>3</issue><fpage>477</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">22023774</pub-id></element-citation></ref><ref id="B36" content-type="article"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esposito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Soto-Martinez</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Feleszko</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>K.-L.</given-names></name><name name-style="western"><surname>Schaad</surname><given-names>U. B.</given-names></name></person-group><article-title>Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence</article-title><source><italic toggle="yes">Current Opinion in Allergy &amp; Clinical Immunology</italic></source><year>2018</year><volume>18</volume><issue>3</issue><fpage>198</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1097/ACI.0000000000000433</pub-id><pub-id pub-id-type="other">2-s2.0-85046705072</pub-id><pub-id pub-id-type="pmid">29561355</pub-id><pub-id pub-id-type="pmcid">PMC6037280</pub-id></element-citation></ref><ref id="B37" content-type="article"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaczynska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Klosinska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Janeczek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zarobkiewicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Emeryk</surname><given-names>A.</given-names></name></person-group><article-title>Promising immunomodulatory effects of bacterial lysates in allergic diseases</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2022</year><volume>13</volume><pub-id pub-id-type="doi">10.3389/fimmu.2022.907149</pub-id><pub-id pub-id-type="publisher-id">907149</pub-id><pub-id pub-id-type="pmcid">PMC9257936</pub-id><pub-id pub-id-type="pmid">35812388</pub-id></element-citation></ref><ref id="B38" content-type="article"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kearney</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Dziekiewicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Feleszko</surname><given-names>W.</given-names></name></person-group><article-title>Immunoregulatory and immunostimulatory responses of bacterial lysates in respiratory infections and asthma</article-title><source><italic toggle="yes">Annals of Allergy, Asthma &amp; Immunology</italic></source><year>2015</year><volume>114</volume><issue>5</issue><fpage>364</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1016/j.anai.2015.02.008</pub-id><pub-id pub-id-type="other">2-s2.0-84929512015</pub-id><pub-id pub-id-type="pmid">25752734</pub-id></element-citation></ref><ref id="B39" content-type="article"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jurkiewicz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zielnik-Jurkiewicz</surname><given-names>B.</given-names></name></person-group><article-title>Bacterial lysates in the prevention of respiratory tract infections</article-title><source><italic toggle="yes">Otolaryngologia Polska</italic></source><year>2018</year><volume>72</volume><issue>5</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.5604/01.3001.0012.7216</pub-id><pub-id pub-id-type="other">2-s2.0-85056803369</pub-id><pub-id pub-id-type="pmid">30460909</pub-id></element-citation></ref><ref id="B40" content-type="article"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>Bacterial lysate add-on therapy in adult and childhood asthma: a systematic review and meta-analysis</article-title><source><italic toggle="yes">Journal of Thoracic Disease</italic></source><year>2023</year><volume>15</volume><issue>6</issue><fpage>3143</fpage><lpage>3157</lpage><pub-id pub-id-type="doi">10.21037/jtd-22-1469</pub-id><pub-id pub-id-type="pmid">37426164</pub-id><pub-id pub-id-type="pmcid">PMC10323573</pub-id></element-citation></ref><ref id="B41" content-type="misc"><label>41</label><element-citation publication-type="other"><collab>European Medicines Agency</collab><article-title>Bacterial lysate medicines for respiratory conditions to be used only for prevention of recurrent infections</article-title><year>2019</year><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/medicines/human/referrals/bacterial-lysates-containing-medicinal-products-indicated-respiratory-conditions" ext-link-type="uri">https://www.ema.europa.eu/en/medicines/human/referrals/bacterial-lysates-containing-medicinal-products-indicated-respiratory-conditions</ext-link></comment></element-citation></ref><ref id="B42" content-type="article"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasquali</surname><given-names>C.</given-names></name><name name-style="western"><surname>Salami</surname><given-names>O.</given-names></name><name name-style="western"><surname>Taneja</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Enhanced mucosal antibody production and protection against respiratory infections following an orally administered bacterial extract</article-title><source><italic toggle="yes">Frontiers in Medicine</italic></source><year>2014</year><volume>1</volume><pub-id pub-id-type="doi">10.3389/fmed.2014.00041</pub-id><pub-id pub-id-type="other">2-s2.0-84992462683</pub-id><pub-id pub-id-type="publisher-id">41</pub-id><pub-id pub-id-type="pmcid">PMC4292070</pub-id><pub-id pub-id-type="pmid">25593914</pub-id></element-citation></ref><ref id="B43" content-type="article"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roth</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pasquali</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stolz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tamm</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ryffel</surname><given-names>B.</given-names></name></person-group><article-title>Broncho Vaxom (OM-85) modulates rhinovirus docking proteins on human airway epithelial cells via Erk1/2 mitogen activated protein kinase and cAMP</article-title><source><italic toggle="yes">PLOS ONE</italic></source><year>2017</year><volume>12</volume><issue>11</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0188010</pub-id><pub-id pub-id-type="other">2-s2.0-85035813115</pub-id><pub-id pub-id-type="publisher-id">e0188010</pub-id><pub-id pub-id-type="pmcid">PMC5705076</pub-id><pub-id pub-id-type="pmid">29182620</pub-id></element-citation></ref><ref id="B44" content-type="article"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guti&#233;rrez-Tarango</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Berber</surname><given-names>A.</given-names></name></person-group><article-title>Safety and efficacy of two courses of OM-85 BV in the prevention of respiratory tract infections in children during 12 months</article-title><source><italic toggle="yes">Chest</italic></source><year>2001</year><volume>119</volume><issue>6</issue><fpage>1742</fpage><lpage>1748</lpage><pub-id pub-id-type="doi">10.1378/chest.119.6.1742</pub-id><pub-id pub-id-type="other">2-s2.0-0034892542</pub-id><pub-id pub-id-type="pmid">11399700</pub-id></element-citation></ref><ref id="B45" content-type="article"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaad</surname><given-names>U. B.</given-names></name><name name-style="western"><surname>M&#252;tterlein</surname><given-names>R.</given-names></name><name name-style="western"><surname>Goffin</surname><given-names>H.</given-names></name></person-group><article-title>Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract: a double-blind, placebo-controlled multicenter study</article-title><source><italic toggle="yes">Chest</italic></source><year>2002</year><volume>122</volume><issue>6</issue><fpage>2042</fpage><lpage>2049</lpage><pub-id pub-id-type="doi">10.1378/chest.122.6.2042</pub-id><pub-id pub-id-type="other">2-s2.0-0036928674</pub-id><pub-id pub-id-type="pmid">12475845</pub-id></element-citation></ref><ref id="B46" content-type="article"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Razi</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Harmanc&#305;</surname><given-names>K.</given-names></name><name name-style="western"><surname>Abac&#305;</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The immunostimulant OM-85 BV prevents wheezing attacks in preschool children</article-title><source><italic toggle="yes">Journal of Allergy and Clinical Immunology</italic></source><year>2010</year><volume>126</volume><issue>4</issue><fpage>763</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2010.07.038</pub-id><pub-id pub-id-type="other">2-s2.0-77957783557</pub-id><pub-id pub-id-type="pmid">20920766</pub-id></element-citation></ref><ref id="B47" content-type="article"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sly</surname><given-names>P. D.</given-names></name><name name-style="western"><surname>Galbraith</surname><given-names>S.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Holt</surname><given-names>B.</given-names></name><name name-style="western"><surname>Troy</surname><given-names>N.</given-names></name><name name-style="western"><surname>Holt</surname><given-names>P. G.</given-names></name></person-group><article-title>Primary prevention of severe lower respiratory illnesses in at-risk infants using the immunomodulator OM-85</article-title><source><italic toggle="yes">Journal of Allergy and Clinical Immunology</italic></source><year>2019</year><volume>144</volume><issue>3</issue><fpage>870</fpage><lpage>872.e11</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2019.05.032</pub-id><pub-id pub-id-type="other">2-s2.0-85067662799</pub-id><pub-id pub-id-type="pmid">31185221</pub-id></element-citation></ref><ref id="B48" content-type="article"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holt</surname><given-names>P. G.</given-names></name><name name-style="western"><surname>Strickland</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Custovic</surname><given-names>A.</given-names></name></person-group><article-title>Targeting maternal immune function during pregnancy for asthma prevention in offspring: harnessing the &#8220;farm effect&#8221;?</article-title><source><italic toggle="yes">Journal of Allergy and Clinical Immunology</italic></source><year>2020</year><volume>146</volume><issue>2</issue><fpage>270</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2020.04.008</pub-id><pub-id pub-id-type="pmid">32333916</pub-id></element-citation></ref><ref id="B49" content-type="article"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez</surname><given-names>F. D.</given-names></name></person-group><article-title>Childhood asthma inception and progression: role of microbial exposures, susceptibility to viruses and early allergic sensitization</article-title><source><italic toggle="yes">Immunology and Allergy Clinics of North America</italic></source><year>2019</year><volume>39</volume><issue>2</issue><fpage>141</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.iac.2018.12.001</pub-id><pub-id pub-id-type="other">2-s2.0-85063741089</pub-id><pub-id pub-id-type="pmid">30954166</pub-id><pub-id pub-id-type="pmcid">PMC6613822</pub-id></element-citation></ref><ref id="B50" content-type="article"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pivniouk</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vercelli</surname><given-names>D.</given-names></name></person-group><article-title>The OM-85 bacterial lysate: a new tool against SARS-CoV-2?</article-title><source><italic toggle="yes">Multidisciplinary Respiratory Medicine</italic></source><year>2023</year><volume>18</volume><pub-id pub-id-type="doi">10.4081/mrm.2023.906</pub-id><pub-id pub-id-type="publisher-id">906</pub-id><pub-id pub-id-type="pmcid">PMC9926922</pub-id><pub-id pub-id-type="pmid">36798954</pub-id></element-citation></ref><ref id="B51" content-type="article"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koatz</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Coe</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Cicer&#225;n</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alter</surname><given-names>A. J.</given-names></name></person-group><article-title>Clinical and immunological benefits of OM-85 bacterial lysate in patients with allergic rhinitis, asthma, and COPD and recurrent respiratory infections</article-title><source><italic toggle="yes">Lung</italic></source><year>2016</year><volume>194</volume><issue>4</issue><fpage>687</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1007/s00408-016-9880-5</pub-id><pub-id pub-id-type="other">2-s2.0-84979052786</pub-id><pub-id pub-id-type="pmid">27117798</pub-id><pub-id pub-id-type="pmcid">PMC7087659</pub-id></element-citation></ref><ref id="B52" content-type="article"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorokman</surname><given-names>T. V.</given-names></name><name name-style="western"><surname>Moldovan</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Popeluk</surname><given-names>N. O.</given-names></name><name name-style="western"><surname>Kolesnik</surname><given-names>D. I.</given-names></name><name name-style="western"><surname>Sokolnyk</surname><given-names>&#1030;. S.</given-names></name></person-group><article-title>Clinical and immunological efficacy of bacterial lysate OM-85 in children with respiratory tract infection</article-title><source><italic toggle="yes">Actual Infectology</italic></source><year>2020</year><volume>8</volume><issue>2</issue><fpage>18</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.22141/2312-413x.8.2.2020.199731</pub-id></element-citation></ref><ref id="B53" content-type="article"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esposito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marchisio</surname><given-names>P.</given-names></name><name name-style="western"><surname>Prada</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2014</year><volume>32</volume><issue>22</issue><fpage>2546</fpage><lpage>2552</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.03.055</pub-id><pub-id pub-id-type="other">2-s2.0-84898546522</pub-id><pub-id pub-id-type="pmid">24681270</pub-id></element-citation></ref><ref id="B54" content-type="article"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lau</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gerhold</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zimmermann</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Oral application of bacterial lysate in infancy decreases the risk of atopic dermatitis in children with 1 atopic parent in a randomized, placebo-controlled trial</article-title><source><italic toggle="yes">Journal of Allergy and Clinical Immunology</italic></source><year>2012</year><volume>129</volume><issue>4</issue><fpage>1040</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2012.02.005</pub-id><pub-id pub-id-type="other">2-s2.0-84859135395</pub-id><pub-id pub-id-type="pmid">22464674</pub-id></element-citation></ref><ref id="B55" content-type="article"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaad</surname><given-names>U. B.</given-names></name></person-group><article-title>OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review</article-title><source><italic toggle="yes">World Journal of Pediatrics</italic></source><year>2010</year><volume>6</volume><issue>1</issue><fpage>5</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1007/s12519-010-0001-x</pub-id><pub-id pub-id-type="other">2-s2.0-76749112026</pub-id><pub-id pub-id-type="pmid">20143206</pub-id></element-citation></ref><ref id="B56" content-type="article"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steurer-Stey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lagler</surname><given-names>L.</given-names></name><name name-style="western"><surname>Straub</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Steurer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bachmann</surname><given-names>L. M.</given-names></name></person-group><article-title>Oral purified bacterial extracts in acute respiratory tract infections in childhood: a systematic quantitative review</article-title><source><italic toggle="yes">European Journal of Pediatrics</italic></source><year>2007</year><volume>166</volume><issue>4</issue><fpage>365</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1007/s00431-006-0248-3</pub-id><pub-id pub-id-type="other">2-s2.0-33847148399</pub-id><pub-id pub-id-type="pmid">17115184</pub-id></element-citation></ref><ref id="B57" content-type="article"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L.</given-names></name></person-group><article-title>Bacterial lysate increases the percentage of natural killer T cells in peripheral blood and alleviates asthma in children</article-title><source><italic toggle="yes">Pharmacology</italic></source><year>2015</year><volume>95</volume><issue>3-4</issue><fpage>139</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1159/000377683</pub-id><pub-id pub-id-type="other">2-s2.0-84926142680</pub-id><pub-id pub-id-type="pmid">25833066</pub-id></element-citation></ref><ref id="B58" content-type="article"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sabor&#237;o</surname><given-names>G. P.</given-names></name><name name-style="western"><surname>Xiu</surname><given-names>Q.</given-names></name></person-group><article-title>Efficacy and safety of OM-85 in patients with chronic bronchitis and/or chronic obstructive pulmonary disease</article-title><source><italic toggle="yes">Lung</italic></source><year>2015</year><volume>193</volume><issue>4</issue><fpage>513</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1007/s00408-015-9737-3</pub-id><pub-id pub-id-type="other">2-s2.0-84937524393</pub-id><pub-id pub-id-type="pmid">26044556</pub-id></element-citation></ref><ref id="B59" content-type="article"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Troiano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Messina</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nante</surname><given-names>N.</given-names></name></person-group><article-title>Bacterial lysates (OM-85 BV): a cost-effective proposal in order to contrast antibiotic resistance</article-title><source><italic toggle="yes">Journal of Preventive Medicine and Hygiene</italic></source><year>2021</year><volume>62</volume><issue>2</issue><fpage>E564</fpage><lpage>e573</lpage><pub-id pub-id-type="doi">10.15167/2421-4248/jpmh2021.62.2.1734</pub-id><pub-id pub-id-type="pmid">34604601</pub-id><pub-id pub-id-type="pmcid">PMC8451348</pub-id></element-citation></ref><ref id="B60" content-type="article"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Broncho-vaxom alleviates persistent allergic rhinitis in patients by improving Th1/Th2 cytokine balance of nasal mucosa</article-title><source><italic toggle="yes">Rhinology</italic></source><year>2019</year><volume>57</volume><issue>6</issue><fpage>451</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.4193/Rhin19.161</pub-id><pub-id pub-id-type="pmid">31403136</pub-id></element-citation></ref><ref id="B61" content-type="article"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fokkens</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Lund</surname><given-names>V. J.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>C.</given-names></name><etal/></person-group><article-title>European position paper on rhinosinusitis and nasal polyps 2020</article-title><source><italic toggle="yes">Rhinology</italic></source><year>2020</year><volume>58</volume><issue>Suppl S29</issue><fpage>1</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.4193/Rhin20.600</pub-id><pub-id pub-id-type="pmid">32077450</pub-id></element-citation></ref><ref id="B62" content-type="article"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bodemer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guillet</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cambazard</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Adjuvant treatment with the bacterial lysate (OM-85) improves management of atopic dermatitis: a randomized study</article-title><source><italic toggle="yes">PLOS ONE</italic></source><year>2017</year><volume>12</volume><issue>3</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0161555</pub-id><pub-id pub-id-type="other">2-s2.0-85016151158</pub-id><pub-id pub-id-type="publisher-id">e0161555</pub-id><pub-id pub-id-type="pmcid">PMC5363804</pub-id><pub-id pub-id-type="pmid">28333952</pub-id></element-citation></ref><ref id="B63" content-type="article"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernstein</surname><given-names>D. I.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>J. A.</given-names></name></person-group><article-title>Allergic rhinitis: mechanisms and treatment</article-title><source><italic toggle="yes">Immunology and Allergy Clinics of North America</italic></source><year>2016</year><volume>36</volume><issue>2</issue><fpage>261</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/j.iac.2015.12.004</pub-id><pub-id pub-id-type="other">2-s2.0-84960156442</pub-id><pub-id pub-id-type="pmid">27083101</pub-id></element-citation></ref><ref id="B64" content-type="article"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braido</surname><given-names>F.</given-names></name><name name-style="western"><surname>Melioli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Candoli</surname><given-names>P.</given-names></name><etal/></person-group><article-title>The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: the results of a double blind, placebo controlled, multicenter clinical trial</article-title><source><italic toggle="yes">Immunology Letters</italic></source><year>2014</year><volume>162</volume><issue>2, Part B</issue><fpage>185</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2014.10.026</pub-id><pub-id pub-id-type="other">2-s2.0-84912562005</pub-id><pub-id pub-id-type="pmid">25445613</pub-id><pub-id pub-id-type="pmcid">PMC7173099</pub-id></element-citation></ref><ref id="B65" content-type="article"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pivniouk</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gimenes-Junior</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Ezeh</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Airway administration of OM-85, a bacterial lysate, blocks experimental asthma by targeting dendritic cells and the epithelium/IL-33/ILC2 axis</article-title><source><italic toggle="yes">Journal of Allergy and Clinical Immunology</italic></source><year>2022</year><volume>149</volume><issue>3</issue><fpage>943</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2021.09.013</pub-id><pub-id pub-id-type="pmid">34560105</pub-id><pub-id pub-id-type="pmcid">PMC8901455</pub-id></element-citation></ref><ref id="B66" content-type="article"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huber</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mossmann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bessler</surname><given-names>W. G.</given-names></name></person-group><article-title>Th1-orientated immunological properties of the bacterial extract OM-85-BV</article-title><source><italic toggle="yes">European Journal of Medical Research</italic></source><year>2005</year><volume>10</volume><issue>5</issue><fpage>209</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">15946922</pub-id></element-citation></ref><ref id="B67" content-type="article"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navarro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cossalter</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chiavaroli</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways</article-title><source><italic toggle="yes">Mucosal Immunology</italic></source><year>2011</year><volume>4</volume><issue>1</issue><fpage>53</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/mi.2010.51</pub-id><pub-id pub-id-type="other">2-s2.0-78650807878</pub-id><pub-id pub-id-type="pmid">20811345</pub-id></element-citation></ref><ref id="B68" content-type="article"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rozy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chorostowska-Wynimko</surname><given-names>J.</given-names></name></person-group><article-title>Bacterial immunostimulants&#8212;mechanism of action and clinical application in respiratory diseases</article-title><source><italic toggle="yes">Advances in Respiratory Medicine</italic></source><year>2008</year><volume>76</volume><issue>5</issue><fpage>353</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.5603/ARM.27879</pub-id><pub-id pub-id-type="pmid">19003766</pub-id></element-citation></ref><ref id="B69" content-type="article"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pivniouk</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pivniouk</surname><given-names>O.</given-names></name><name name-style="western"><surname>DeVries</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The OM-85 bacterial lysate inhibits SARS-CoV-2 infection of epithelial cells by downregulating SARS-CoV-2 receptor expression</article-title><source><italic toggle="yes">Journal of Allergy and Clinical Immunology</italic></source><year>2022</year><volume>149</volume><issue>3</issue><fpage>923</fpage><lpage>933.e6</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2021.11.019</pub-id><pub-id pub-id-type="pmid">34902435</pub-id><pub-id pub-id-type="pmcid">PMC8660661</pub-id></element-citation></ref><ref id="B70" content-type="article"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janeczek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Emeryk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>&#321;.</given-names></name><name name-style="western"><surname>Poleszak</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ordak</surname><given-names>M.</given-names></name></person-group><article-title>Nasal carriage of <italic toggle="yes">Staphylococcus aureus</italic> in children with grass pollen-induced allergic rhinitis and the effect of polyvalent mechanical bacterial lysate immunostimulation on carriage status: a randomized controlled trial</article-title><source><italic toggle="yes">Immunity, Inflammation and Disease</italic></source><year>2022</year><volume>10</volume><issue>3</issue><pub-id pub-id-type="doi">10.1002/iid3.584</pub-id><pub-id pub-id-type="publisher-id">e584</pub-id><pub-id pub-id-type="pmcid">PMC8926494</pub-id><pub-id pub-id-type="pmid">34965026</pub-id></element-citation></ref><ref id="B71" content-type="article"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartkowiak-Emeryk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Emeryk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Roli&#324;ski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wawryk-Gawda</surname><given-names>E.</given-names></name><name name-style="western"><surname>Markut-Miot&#322;a</surname><given-names>E.</given-names></name></person-group><article-title>Impact of polyvalent mechanical bacterial lysate on lymphocyte number and activity in asthmatic children: a randomized controlled trial</article-title><source><italic toggle="yes">Allergy, Asthma &amp; Clinical Immunology</italic></source><year>2021</year><volume>17</volume><issue>1</issue><pub-id pub-id-type="doi">10.1186/s13223-020-00503-4</pub-id><pub-id pub-id-type="publisher-id">10</pub-id><pub-id pub-id-type="pmcid">PMC7816436</pub-id><pub-id pub-id-type="pmid">33472687</pub-id></element-citation></ref><ref id="B72" content-type="article"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hans</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sklyar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kalinichenko</surname><given-names>S.</given-names></name><name name-style="western"><surname>Markovich</surname><given-names>I.</given-names></name></person-group><article-title>The use of bacterial lysates in the complex treatment of patients with chronic decompensated tonsillitis</article-title><source><italic toggle="yes">Annals of Mechnikov&#8217;s Institute</italic></source><year>2017</year><volume>Institute</volume><issue>4</issue><fpage>46</fpage><lpage>52</lpage></element-citation></ref><ref id="B73" content-type="article"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braido</surname><given-names>F.</given-names></name><name name-style="western"><surname>Melioli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cazzola</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced immunological approach in COPD exacerbation)</article-title><source><italic toggle="yes">Pulmonary Pharmacology &amp; Therapeutics</italic></source><year>2015</year><volume>33</volume><fpage>75</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.pupt.2015.03.006</pub-id><pub-id pub-id-type="other">2-s2.0-84938541217</pub-id><pub-id pub-id-type="pmid">25951945</pub-id></element-citation></ref><ref id="B74" content-type="article"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jareoncharsri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bunnag</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tunsuriyawong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Assanasane</surname><given-names>P.</given-names></name><name name-style="western"><surname>Voraprayoon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pinkaew</surname><given-names>B.</given-names></name></person-group><article-title>An open-label, prospective study of an oral polyvalent bacterial lysate (Luivac) in the treatment of recurrent respiratory tract infections in Thai patients</article-title><source><italic toggle="yes">Asian Pacific Journal of Allergy and Immunology</italic></source><year>2003</year><volume>21</volume><issue>4</issue><fpage>223</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">15198340</pub-id></element-citation></ref><ref id="B75" content-type="article"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grevers</surname><given-names>G.</given-names></name><name name-style="western"><surname>Palacios</surname><given-names>O. A.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Abel</surname><given-names>S.</given-names></name><name name-style="western"><surname>van Aubel</surname><given-names>A.</given-names></name></person-group><article-title>Treatment of recurrent respiratory tract infections with a polyvalent bacterial lysate: results of an open, prospective, multinational study</article-title><source><italic toggle="yes">Advances in Therapy</italic></source><year>2000</year><volume>17</volume><issue>2</issue><fpage>103</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1007/BF02854843</pub-id><pub-id pub-id-type="other">2-s2.0-0033919524</pub-id><pub-id pub-id-type="pmid">11010054</pub-id></element-citation></ref><ref id="B76" content-type="article"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kowalska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Emeryk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Janeczek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pawluk</surname><given-names>I. C.</given-names></name></person-group><article-title>Effect of nasal polivalent bacterial lysate on the clinical course of seasonal allergic rhinitis in children-preliminary study</article-title><source><italic toggle="yes">European Respiratory Journal</italic></source><year>2020</year><volume>56</volume><pub-id pub-id-type="doi">10.1183/13993003.congress-2020.1208</pub-id><pub-id pub-id-type="publisher-id">1208</pub-id></element-citation></ref><ref id="B77" content-type="article"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>J.-Y.</given-names></name></person-group><article-title>Risk factor associated with recurrence after OM-89 (Uro-Vaxom&#174;) treatment for female recurrent cystitis</article-title><source><italic toggle="yes">Urogenital Tract Infection</italic></source><year>2019</year><volume>14</volume><issue>2</issue><fpage>42</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.14777/uti.2019.14.2.42</pub-id></element-citation></ref><ref id="B78" content-type="article"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bauer</surname><given-names>H. W.</given-names></name><name name-style="western"><surname>Alloussi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Egger</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bl&#252;mlein</surname><given-names>H.-M.</given-names></name><name name-style="western"><surname>Cozma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schulman</surname><given-names>C. C.</given-names></name></person-group><article-title>A long-term, multicenter, double-blind study of an <italic toggle="yes">Escherichia coli</italic> extract (OM-89) in female patients with recurrent urinary tract infections</article-title><source><italic toggle="yes">European Urology</italic></source><year>2005</year><volume>47</volume><issue>4</issue><fpage>542</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2004.12.009</pub-id><pub-id pub-id-type="other">2-s2.0-14844350297</pub-id><pub-id pub-id-type="pmid">15774256</pub-id></element-citation></ref><ref id="B79" content-type="article"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baertschi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Balmer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Eduah</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liechi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lurie</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schams</surname><given-names>H.</given-names></name></person-group><article-title>Bacterial extract for the prevention of recurrent urinary tract infections in pregnant women: a pilot study</article-title><source><italic toggle="yes">International Journal of Immunotherapy</italic></source><year>2003</year><volume>19</volume><issue>1</issue><fpage>25</fpage><lpage>31</lpage></element-citation></ref><ref id="B80" content-type="article"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magasi</surname><given-names>P.</given-names></name><name name-style="western"><surname>P&#225;novics</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ill&#233;s</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nagy</surname><given-names>M.</given-names></name></person-group><article-title>Uro-Vaxom^&#174; and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial</article-title><source><italic toggle="yes">European Urology</italic></source><year>1994</year><volume>26</volume><issue>2</issue><fpage>137</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1159/000475363</pub-id><pub-id pub-id-type="other">2-s2.0-0028168490</pub-id><pub-id pub-id-type="pmid">7957468</pub-id></element-citation></ref><ref id="B81" content-type="article"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rugendorff</surname><given-names>E. W.</given-names></name></person-group><article-title>Immunological therapy of recurrent urinary tract infections with immunoactive E. coll fractions in women</article-title><source><italic toggle="yes">International Urogynecology Journal</italic></source><year>1992</year><volume>3</volume><issue>3</issue><fpage>179</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1007/BF00454997</pub-id><pub-id pub-id-type="other">2-s2.0-0041428322</pub-id></element-citation></ref><ref id="B82" content-type="article"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hachen</surname><given-names>H. J.</given-names></name></person-group><article-title>Oral immunotherapy in paraplegic patients with chronic urinary tract infections: a double-blind, placebo-controlled trial</article-title><source><italic toggle="yes">Journal of Urology</italic></source><year>1990</year><volume>143</volume><issue>4</issue><fpage>759</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1016/S0022-5347(17)40084-X</pub-id><pub-id pub-id-type="pmid">2179584</pub-id></element-citation></ref><ref id="B83" content-type="article"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tammen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>C.</given-names></name></person-group><article-title>Treatment of recurrent urinary tract infections with Uro-Vaxom</article-title><source><italic toggle="yes">Urologe</italic></source><year>1988</year><volume>28</volume><fpage>294</fpage><lpage>296</lpage></element-citation></ref><ref id="B84" content-type="article"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Foley</surname><given-names>S.</given-names></name></person-group><article-title>First experience in the UK of treating women with recurrent urinary tract infections with the bacterial vaccine Uromune&#174;</article-title><source><italic toggle="yes">BJU International</italic></source><year>2018</year><volume>121</volume><issue>2</issue><fpage>289</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1111/bju.14067</pub-id><pub-id pub-id-type="other">2-s2.0-85034949556</pub-id><pub-id pub-id-type="pmid">29171130</pub-id></element-citation></ref><ref id="B85" content-type="article"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lorenzo-G&#243;mez</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Padilla-Fern&#225;ndez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Garc&#237;a-Cenador</surname><given-names>M. B.</given-names></name><etal/></person-group><article-title>Comparison of sublingual therapeutic vaccine with antibiotics for the prophylaxis of recurrent urinary tract infections</article-title><source><italic toggle="yes">Frontiers in Cellular and Infection Microbiology</italic></source><year>2015</year><volume>5</volume><pub-id pub-id-type="doi">10.3389/fcimb.2015.00050</pub-id><pub-id pub-id-type="other">2-s2.0-85006208122</pub-id><pub-id pub-id-type="publisher-id">50</pub-id><pub-id pub-id-type="pmcid">PMC4452880</pub-id><pub-id pub-id-type="pmid">26090341</pub-id></element-citation></ref><ref id="B86" content-type="article"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lorenzo-G&#243;mez</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Padilla-Fern&#225;ndez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Garc&#237;a-Criado</surname><given-names>F. J.</given-names></name><etal/></person-group><article-title>Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics</article-title><source><italic toggle="yes">International Urogynecology Journal</italic></source><year>2013</year><volume>24</volume><issue>1</issue><fpage>127</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1007/s00192-012-1853-5</pub-id><pub-id pub-id-type="other">2-s2.0-84872282337</pub-id><pub-id pub-id-type="pmid">22806485</pub-id><pub-id pub-id-type="pmcid">PMC3536982</pub-id></element-citation></ref><ref id="B87" content-type="article"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hopkins</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Elkahwaji</surname><given-names>J.</given-names></name><name name-style="western"><surname>Beierle</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Leverson</surname><given-names>G. E.</given-names></name><name name-style="western"><surname>Uehling</surname><given-names>D. T.</given-names></name></person-group><article-title>Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial</article-title><source><italic toggle="yes">Journal of Urology</italic></source><year>2007</year><volume>177</volume><issue>4</issue><fpage>1349</fpage><lpage>1353</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2006.11.093</pub-id><pub-id pub-id-type="other">2-s2.0-33947251205</pub-id><pub-id pub-id-type="pmid">17382730</pub-id></element-citation></ref><ref id="B88" content-type="article"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uehling</surname><given-names>D. T.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Elkahwaji</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Leverson</surname><given-names>G. E.</given-names></name></person-group><article-title>Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections</article-title><source><italic toggle="yes">Journal of Urology</italic></source><year>2003</year><volume>170</volume><issue>3</issue><fpage>867</fpage><lpage>869</lpage><pub-id pub-id-type="doi">10.1097/01.ju.0000075094.54767.6e</pub-id><pub-id pub-id-type="other">2-s2.0-0041736550</pub-id><pub-id pub-id-type="pmid">12913718</pub-id></element-citation></ref><ref id="B89" content-type="article"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uehling</surname><given-names>D. T.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Balish</surname><given-names>E.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Heisey</surname><given-names>D. M.</given-names></name></person-group><article-title>Vaginal mucosal immunization for recurrent urinary tract infection: phase II clinical trial</article-title><source><italic toggle="yes">Journal of Urology</italic></source><year>1997</year><volume>157</volume><issue>6</issue><fpage>2049</fpage><lpage>2052</lpage><pub-id pub-id-type="doi">10.1016/S0022-5347(01)64671-8</pub-id><pub-id pub-id-type="other">2-s2.0-0031003792</pub-id><pub-id pub-id-type="pmid">9146577</pub-id></element-citation></ref><ref id="B90" content-type="article"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huttner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hatz</surname><given-names>C.</given-names></name><name name-style="western"><surname>van den Dobbelsteen</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic <italic toggle="yes">Escherichia coli</italic> in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial</article-title><source><italic toggle="yes">The Lancet Infectious Diseases</italic></source><year>2017</year><volume>17</volume><issue>5</issue><fpage>528</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30108-1</pub-id><pub-id pub-id-type="other">2-s2.0-85013648004</pub-id><pub-id pub-id-type="pmid">28238601</pub-id></element-citation></ref><ref id="B91" content-type="article"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossi</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Feleszko</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Immunomodulation therapy&#8212;clinical relevance of bacterial lysates OM-85</article-title><source><italic toggle="yes">European Respiratory &amp; Pulmonary Diseases</italic></source><year>2019</year><volume>5</volume><issue>1</issue><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.17925/ERPD.2019.5.1.17</pub-id></element-citation></ref><ref id="B92" content-type="article"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dang</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Pasquali</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ludigs</surname><given-names>K.</given-names></name><name name-style="western"><surname>Guarda</surname><given-names>G.</given-names></name></person-group><article-title>OM-85 is an immunomodulator of interferon-<italic toggle="yes">&#946;</italic> production and inflammasome activity</article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2017</year><volume>7</volume><pub-id pub-id-type="doi">10.1038/srep43844</pub-id><pub-id pub-id-type="other">2-s2.0-85014738526</pub-id><pub-id pub-id-type="publisher-id">43844</pub-id><pub-id pub-id-type="pmcid">PMC5338315</pub-id><pub-id pub-id-type="pmid">28262817</pub-id></element-citation></ref><ref id="B93" content-type="article"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>OM85-BV induced the productions of IL-1<italic toggle="yes">&#946;</italic>, IL-6, and TNF-<italic toggle="yes">&#945;</italic> via TLR4- and TLR2-mediated ERK1/2/NF-<italic toggle="yes">&#954;</italic>B pathway in RAW264.7 cells</article-title><source><italic toggle="yes">Journal of Interferon &amp; Cytokine Research</italic></source><year>2014</year><volume>34</volume><issue>7</issue><fpage>526</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1089/jir.2013.0077</pub-id><pub-id pub-id-type="other">2-s2.0-84903795150</pub-id><pub-id pub-id-type="pmid">24605772</pub-id><pub-id pub-id-type="pmcid">PMC4080859</pub-id></element-citation></ref><ref id="B94" content-type="article"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strickland</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Judd</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Larcombe</surname><given-names>A. N.</given-names></name><name name-style="western"><surname>Sly</surname><given-names>P. D.</given-names></name><name name-style="western"><surname>Holt</surname><given-names>P. G.</given-names></name></person-group><article-title>Boosting airway T-regulatory cells by gastrointestinal stimulation as a strategy for asthma control</article-title><source><italic toggle="yes">Mucosal Immunology</italic></source><year>2011</year><volume>4</volume><issue>1</issue><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1038/mi.2010.43</pub-id><pub-id pub-id-type="other">2-s2.0-78650813165</pub-id><pub-id pub-id-type="pmid">20668438</pub-id></element-citation></ref><ref id="B95" content-type="article"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parola</surname><given-names>C.</given-names></name><name name-style="western"><surname>Salogni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vaira</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Selective activation of human dendritic cells by OM-85 through a NF-kB and MAPK dependent pathway</article-title><source><italic toggle="yes">PLOS ONE</italic></source><year>2013</year><volume>8</volume><issue>12</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0082867</pub-id><pub-id pub-id-type="other">2-s2.0-84893609201</pub-id><pub-id pub-id-type="publisher-id">e82867</pub-id><pub-id pub-id-type="pmcid">PMC3875422</pub-id><pub-id pub-id-type="pmid">24386121</pub-id></element-citation></ref><ref id="B96" content-type="article"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cardinale</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lombardi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bagnasco</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bellocchi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Menzella</surname><given-names>F.</given-names></name></person-group><article-title>Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85</article-title><source><italic toggle="yes">Expert Review of Respiratory Medicine</italic></source><year>2020</year><volume>14</volume><issue>10</issue><fpage>1019</fpage><lpage>1026</lpage><pub-id pub-id-type="doi">10.1080/17476348.2020.1793673</pub-id><pub-id pub-id-type="pmid">32635771</pub-id></element-citation></ref><ref id="B97" content-type="article"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuvim</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>C. G.</given-names></name><name name-style="western"><surname>Dickey</surname><given-names>B. F.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>B. E.</given-names></name><name name-style="western"><surname>Tailleux</surname><given-names>L.</given-names></name></person-group><article-title>Augmented lung inflammation protects against influenza A pneumonia</article-title><source><italic toggle="yes">PLOS ONE</italic></source><year>2009</year><volume>4</volume><issue>1</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0004176</pub-id><pub-id pub-id-type="other">2-s2.0-58449136268</pub-id><pub-id pub-id-type="publisher-id">e4176</pub-id><pub-id pub-id-type="pmcid">PMC2613561</pub-id><pub-id pub-id-type="pmid">19137067</pub-id></element-citation></ref><ref id="B98" content-type="article"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>C. G.</given-names></name><etal/></person-group><article-title>Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi</article-title><source><italic toggle="yes">American Journal of Respiratory Cell and Molecular Biology</italic></source><year>2010</year><volume>42</volume><issue>1</issue><fpage>40</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2008-0260OC</pub-id><pub-id pub-id-type="other">2-s2.0-73949118392</pub-id><pub-id pub-id-type="pmid">19329554</pub-id><pub-id pub-id-type="pmcid">PMC2809220</pub-id></element-citation></ref><ref id="B99" content-type="article"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tazza</surname><given-names>R.</given-names></name></person-group><article-title>Efficacy and safety of a new immunostimulating bacterial lysate in the prophylaxis of acute lower respiratory tract infections. A randomised, open, controlled clinical trial</article-title><source><italic toggle="yes">Arzneimittelforschung</italic></source><year>2004</year><volume>54</volume><issue>1</issue><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1055/s-0031-1296936</pub-id><pub-id pub-id-type="pmid">14979609</pub-id></element-citation></ref><ref id="B100" content-type="article"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avdeev</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Nuralieva</surname><given-names>G. S.</given-names></name><name name-style="western"><surname>Gainitdinova</surname><given-names>V. V.</given-names></name><name name-style="western"><surname>Baimakanova</surname><given-names>G. E.</given-names></name><name name-style="western"><surname>So</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Merzhoeva</surname><given-names>Z. M.</given-names></name></person-group><article-title>Clinical efficacy of mechanical bacterial lysate in the prevention of infectious exacerbations of chronic obstructive pulmonary disease</article-title><source><italic toggle="yes">Terapevticheskii Arkhiv</italic></source><year>2020</year><volume>92</volume><issue>4</issue><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.26442/00403660.2020.04.000590</pub-id><pub-id pub-id-type="pmid">32598699</pub-id></element-citation></ref><ref id="B101" content-type="article"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riedl-Seifert</surname><given-names>R.</given-names></name><name name-style="western"><surname>van Aubel</surname><given-names>A.</given-names></name><name name-style="western"><surname>K&#228;mmereit</surname><given-names>A.</given-names></name><name name-style="western"><surname>Elsasser</surname><given-names>U.</given-names></name></person-group><article-title>Recurrent infections during childhood&#8212;are they still a &#8220;crux medicorum&#8221;? Results of a placebo-controlled double-blind study with an oral bacterial lysate in children prone to infections</article-title><source><italic toggle="yes">Journal of Pharmacology and Experimental Therapeutics</italic></source><year>1993</year><volume>3</volume><fpage>108</fpage><lpage>117</lpage></element-citation></ref><ref id="B102" content-type="misc"><label>102</label><element-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Ruah</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Binder</surname><given-names>M.</given-names></name><name name-style="western"><surname>van Aubel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Elsasser</surname><given-names>U.</given-names></name><name name-style="western"><surname>Kammereit</surname><given-names>A.</given-names></name></person-group><article-title>Paspat oral in portugal-prevention and therapy of respiratory tract infections in infection-prone children</article-title><year>1996</year><comment>A Double-Blind, Placebo-Controlled, Multicenter Study, Study No</comment></element-citation></ref><ref id="B103" content-type="article"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Blick</surname><given-names>C.</given-names></name><name name-style="western"><surname>Foley</surname><given-names>S.</given-names></name></person-group><article-title>Avoiding antibiotics in the management of recurrent UTIs in women: what are our options?</article-title><source><italic toggle="yes">Journal of Clinical Urology</italic></source><year>2020</year><volume>13</volume><issue>1</issue><fpage>76</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1177/2051415819854912</pub-id><pub-id pub-id-type="other">2-s2.0-85067840944</pub-id></element-citation></ref><ref id="B104" content-type="article"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meredith</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chiavaroli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>H. G.</given-names></name></person-group><article-title>Immunotherapy for recurrent urinary tract infections: effects of an <italic toggle="yes">Escherichia coli</italic> extract</article-title><source><italic toggle="yes">Current Urology</italic></source><year>2009</year><volume>3</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1159/000189674</pub-id><pub-id pub-id-type="other">2-s2.0-77953385445</pub-id></element-citation></ref><ref id="B105" content-type="article"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagenlehner</surname><given-names>F. M. E.</given-names></name><name name-style="western"><surname>Ballarini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pilatz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Weidner</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lehr</surname><given-names>L.</given-names></name><name name-style="western"><surname>Naber</surname><given-names>K. G.</given-names></name></person-group><article-title>A randomized, double-blind, parallel-group, multicenter clinical study of <italic toggle="yes">Escherichia coli</italic>-lyophilized lysate for the prophylaxis of recurrent uncomplicated urinary tract infections</article-title><source><italic toggle="yes">Urologia Internationalis</italic></source><year>2015</year><volume>95</volume><issue>2</issue><fpage>167</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1159/000371894</pub-id><pub-id pub-id-type="other">2-s2.0-84941995825</pub-id><pub-id pub-id-type="pmid">25721866</pub-id></element-citation></ref><ref id="B106" content-type="article"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kiencke</surname><given-names>P.</given-names></name><name name-style="western"><surname>Viehmann</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rychlik</surname><given-names>R.</given-names></name></person-group><article-title>Cost-effectiveness analysis, prevention of atopic dermatitis by oral application of bacterial lysate in newborns/small children</article-title><source><italic toggle="yes">The European Journal of Health Economics</italic></source><year>2013</year><volume>14</volume><issue>6</issue><fpage>995</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1007/s10198-012-0448-x</pub-id><pub-id pub-id-type="other">2-s2.0-84888433522</pub-id><pub-id pub-id-type="pmid">23242758</pub-id></element-citation></ref><ref id="B107" content-type="article"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ro&#223;berg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Keller</surname><given-names>T.</given-names></name><name name-style="western"><surname>Icke</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Orally applied bacterial lysate in infants at risk for atopy does not prevent atopic dermatitis, allergic rhinitis, asthma or allergic sensitization at school age: follow-up of a randomized trial</article-title><source><italic toggle="yes">Allergy</italic></source><year>2020</year><volume>75</volume><issue>8</issue><fpage>2020</fpage><lpage>2025</lpage><pub-id pub-id-type="doi">10.1111/all.14247</pub-id><pub-id pub-id-type="pmid">32087032</pub-id></element-citation></ref><ref id="B108" content-type="article"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Czinn</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>H. S.</given-names></name><name name-style="western"><surname>Speck</surname><given-names>W. T.</given-names></name></person-group><article-title>Diagnosis of gastritis caused by <italic toggle="yes">Helicobacter pylori</italic> in children by means of an ELISA</article-title><source><italic toggle="yes">Clinical Infectious Diseases</italic></source><year>1991</year><volume>13</volume><issue>Supplement_8</issue><fpage>S700</fpage><lpage>S703</lpage><pub-id pub-id-type="doi">10.1093/clinids/13.supplement_8.s700</pub-id><pub-id pub-id-type="other">2-s2.0-0025819612</pub-id><pub-id pub-id-type="pmid">1925312</pub-id></element-citation></ref><ref id="B109" content-type="article"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nystr&#246;m</surname><given-names>J.</given-names></name><name name-style="western"><surname>Raghavan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Svennerholm</surname><given-names>A.-M.</given-names></name></person-group><article-title>Mucosal immune responses are related to reduction of bacterial colonization in the stomach after therapeutic <italic toggle="yes">Helicobacter pylori</italic> immunization in mice</article-title><source><italic toggle="yes">Microbes and Infection</italic></source><year>2006</year><volume>8</volume><issue>2</issue><fpage>442</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2005.07.010</pub-id><pub-id pub-id-type="other">2-s2.0-32244438803</pub-id><pub-id pub-id-type="pmid">16243563</pub-id></element-citation></ref><ref id="B110" content-type="article"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neto</surname><given-names>K. A. T.</given-names></name><name name-style="western"><surname>Castilho</surname><given-names>L. N.</given-names></name><name name-style="western"><surname>Reis</surname><given-names>L. O.</given-names></name></person-group><article-title>Vacuna oral (OM-89) en la profilaxis de infecci&#243;n urinaria recurrente: una revisi&#243;n sistem&#225;tica realista con metaan&#225;lisis</article-title><source><italic toggle="yes">Actas Urol&#243;gicas Espa&#241;olas</italic></source><year>2016</year><volume>40</volume><issue>4</issue><fpage>203</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/j.acuro.2015.04.008</pub-id><pub-id pub-id-type="other">2-s2.0-84951037370</pub-id><pub-id pub-id-type="pmid">26601727</pub-id></element-citation></ref><ref id="B111" content-type="article"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahumada-Cota</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Hernandez-Chi&#241;as</surname><given-names>U.</given-names></name><name name-style="western"><surname>Mili&#225;n-Suazo</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Effect and analysis of bacterial lysates for the treatment of recurrent urinary tract infections in adults</article-title><source><italic toggle="yes">Pathogens</italic></source><year>2020</year><volume>9</volume><issue>2</issue><pub-id pub-id-type="doi">10.3390/pathogens9020102</pub-id><pub-id pub-id-type="publisher-id">102</pub-id><pub-id pub-id-type="pmcid">PMC7168004</pub-id><pub-id pub-id-type="pmid">32041185</pub-id></element-citation></ref><ref id="B112" content-type="article"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hern&#225;ndez-Chi&#241;as</surname><given-names>U.</given-names></name><name name-style="western"><surname>Ch&#225;vez-Berrocal</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Ahumada-Cota</surname><given-names>R. E.</given-names></name><etal/></person-group><article-title>Prospective study in children with complicated urinary tract infection treated with autologous bacterial lysates</article-title><source><italic toggle="yes">Microorganisms</italic></source><year>2021</year><volume>9</volume><issue>9</issue><pub-id pub-id-type="doi">10.3390/microorganisms9091811</pub-id><pub-id pub-id-type="publisher-id">1811</pub-id><pub-id pub-id-type="pmcid">PMC8470462</pub-id><pub-id pub-id-type="pmid">34576707</pub-id></element-citation></ref><ref id="B113" content-type="article"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Migliore</surname><given-names>G. S.</given-names></name><name name-style="western"><surname>Campana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Barberi</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Mechanical bacterial lysate enhances antimicrobial barrier mechanisms in human airway epithelial cells</article-title><source><italic toggle="yes">Journal of Leukocyte Biology</italic></source><year>2023</year><volume>113</volume><issue>5</issue><fpage>535</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1093/jleuko/qiad003</pub-id><pub-id pub-id-type="pmid">36807710</pub-id></element-citation></ref><ref id="B114" content-type="article"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group><article-title>
<italic toggle="yes">Mycobacterium tuberculosis</italic> infection up-regulates MFN2 expression to promote NLRP3 inflammasome formation</article-title><source><italic toggle="yes">Journal of Biological Chemistry</italic></source><year>2020</year><volume>295</volume><issue>51</issue><fpage>17684</fpage><lpage>17697</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA120.014077</pub-id><pub-id pub-id-type="pmid">33454007</pub-id><pub-id pub-id-type="pmcid">PMC7762945</pub-id></element-citation></ref><ref id="B115" content-type="article"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirsch</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Rojas</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Toossi</surname><given-names>Z.</given-names></name></person-group><article-title>
<italic toggle="yes">Mycobacterium tuberculosis</italic> Induces expansion of Foxp3 positive CD4 T-cells with a regulatory profile in tuberculin non-sensitized healthy subjects: implications for effective immunization against TB</article-title><source><italic toggle="yes">Journal of Clinical &amp; Cellular Immunology</italic></source><year>2016</year><volume>7</volume><issue>3</issue><pub-id pub-id-type="doi">10.4172/2155-9899</pub-id><pub-id pub-id-type="publisher-id">1000428</pub-id><pub-id pub-id-type="pmcid">PMC4948752</pub-id><pub-id pub-id-type="pmid">27441095</pub-id></element-citation></ref><ref id="B116" content-type="article"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crespo</surname><given-names>F. A.</given-names></name><name name-style="western"><surname>Klaes</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Switala</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>DeWitte</surname><given-names>S. N.</given-names></name></person-group><article-title>Do leprosy and tuberculosis generate a systemic inflammatory shift? Setting the ground for a new dialogue between experimental immunology and bioarchaeology</article-title><source><italic toggle="yes">American Journal of Physical Anthropology</italic></source><year>2017</year><volume>162</volume><issue>1</issue><fpage>143</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1002/ajpa.23104</pub-id><pub-id pub-id-type="other">2-s2.0-84994891104</pub-id><pub-id pub-id-type="pmid">27704524</pub-id></element-citation></ref><ref id="B117" content-type="article"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Camussone</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Veaute</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Pujato</surname><given-names>N.</given-names></name><name name-style="western"><surname>Morein</surname><given-names>B.</given-names></name><name name-style="western"><surname>Marcipar</surname><given-names>I. S.</given-names></name><name name-style="western"><surname>Calvinho</surname><given-names>L. F.</given-names></name></person-group><article-title>Immune response of heifers against a <italic toggle="yes">Staphylococcus aureus</italic> CP5 whole cell and lysate vaccine formulated with ISCOM Matrix adjuvant</article-title><source><italic toggle="yes">Research in Veterinary Science</italic></source><year>2014</year><volume>96</volume><issue>1</issue><fpage>86</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.rvsc.2013.10.004</pub-id><pub-id pub-id-type="other">2-s2.0-84892532337</pub-id><pub-id pub-id-type="pmid">24210331</pub-id></element-citation></ref><ref id="B118" content-type="article"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Camussone</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Veaute</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Porporatto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Morein</surname><given-names>B.</given-names></name><name name-style="western"><surname>Marcipar</surname><given-names>I. S.</given-names></name><name name-style="western"><surname>Calvinho</surname><given-names>L. F.</given-names></name></person-group><article-title>Immune response of heifers against a <italic toggle="yes">Staphylococcus aureus</italic> CP5 whole cell vaccine formulated with ISCOMATRIX&#8482; adjuvant</article-title><source><italic toggle="yes">Journal of Dairy Research</italic></source><year>2013</year><volume>80</volume><issue>1</issue><fpage>72</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1017/S0022029912000593</pub-id><pub-id pub-id-type="other">2-s2.0-84872482827</pub-id><pub-id pub-id-type="pmid">23171590</pub-id></element-citation></ref><ref id="B119" content-type="article"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Molina</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mastroianni</surname><given-names>J.</given-names></name><name name-style="western"><surname>Suarez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Soni</surname><given-names>B.</given-names></name><name name-style="western"><surname>Forsberg</surname><given-names>E.</given-names></name><name name-style="western"><surname>Finley</surname><given-names>K.</given-names></name></person-group><article-title>Treatment with bacterial biologics promotes healthy aging and traumatic brain injury responses in adult drosophila, modeling the gut&#8211;brain axis and inflammation responses</article-title><source><italic toggle="yes">Cells</italic></source><year>2021</year><volume>10</volume><issue>4</issue><pub-id pub-id-type="doi">10.3390/cells10040900</pub-id><pub-id pub-id-type="publisher-id">900</pub-id><pub-id pub-id-type="pmcid">PMC8070821</pub-id><pub-id pub-id-type="pmid">33919883</pub-id></element-citation></ref><ref id="B120" content-type="article"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galluzzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vacchelli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Eggermont</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Trial Watch: experimental toll-like receptor agonists for cancer therapy</article-title><source><italic toggle="yes">OncoImmunology</italic></source><year>2012</year><volume>1</volume><issue>5</issue><fpage>699</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.4161/onci.20696</pub-id><pub-id pub-id-type="pmid">22934262</pub-id><pub-id pub-id-type="pmcid">PMC3429574</pub-id></element-citation></ref><ref id="B121" content-type="article"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vacchelli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Galluzzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Eggermont</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy</article-title><source><italic toggle="yes">OncoImmunology</italic></source><year>2012</year><volume>1</volume><issue>6</issue><fpage>894</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.4161/onci.20931</pub-id><pub-id pub-id-type="other">2-s2.0-84877262630</pub-id><pub-id pub-id-type="pmid">23162757</pub-id><pub-id pub-id-type="pmcid">PMC3489745</pub-id></element-citation></ref><ref id="B122" content-type="article"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gabrilovich</surname><given-names>D. I.</given-names></name><name name-style="western"><surname>Ostrand-Rosenberg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bronte</surname><given-names>V.</given-names></name></person-group><article-title>Coordinated regulation of myeloid cells by tumours</article-title><source><italic toggle="yes">Nature Reviews Immunology</italic></source><year>2012</year><volume>12</volume><issue>4</issue><fpage>253</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1038/nri3175</pub-id><pub-id pub-id-type="other">2-s2.0-84858785703</pub-id><pub-id pub-id-type="pmcid">PMC3587148</pub-id><pub-id pub-id-type="pmid">22437938</pub-id></element-citation></ref><ref id="B123" content-type="article"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palucka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Banchereau</surname><given-names>J.</given-names></name></person-group><article-title>Cancer immunotherapy via dendritic cells</article-title><source><italic toggle="yes">Nature Reviews Cancer</italic></source><year>2012</year><volume>12</volume><issue>4</issue><fpage>265</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1038/nrc3258</pub-id><pub-id pub-id-type="other">2-s2.0-84858780815</pub-id><pub-id pub-id-type="pmid">22437871</pub-id><pub-id pub-id-type="pmcid">PMC3433802</pub-id></element-citation></ref><ref id="B124" content-type="article"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prescott</surname><given-names>S.</given-names></name><name name-style="western"><surname>James</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hargreave</surname><given-names>T. B.</given-names></name><name name-style="western"><surname>Chisholm</surname><given-names>G. D.</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>J. F.</given-names></name></person-group><article-title>Intravesical evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall</article-title><source><italic toggle="yes">Journal of Urology</italic></source><year>1992</year><volume>147</volume><issue>6</issue><fpage>1636</fpage><lpage>1642</lpage><pub-id pub-id-type="doi">10.1016/S0022-5347(17)37668-1</pub-id><pub-id pub-id-type="other">2-s2.0-0026717957</pub-id><pub-id pub-id-type="pmid">1593713</pub-id></element-citation></ref><ref id="B125" content-type="article"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ratliff</surname><given-names>T. L.</given-names></name><name name-style="western"><surname>Ritchey</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J. J. J.</given-names></name><name name-style="western"><surname>Andriole</surname><given-names>G. L.</given-names></name><name name-style="western"><surname>Catalona</surname><given-names>W. J.</given-names></name></person-group><article-title>T-cell subsets required for intravesical BCG immunotherapy for bladder cancer</article-title><source><italic toggle="yes">Journal of Urology</italic></source><year>1993</year><volume>150</volume><issue>3</issue><fpage>1018</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1016/S0022-5347(17)35678-1</pub-id><pub-id pub-id-type="other">2-s2.0-0027179385</pub-id><pub-id pub-id-type="pmid">8102183</pub-id></element-citation></ref><ref id="B126" content-type="article"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahmanyar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vakil</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Al-Awsi</surname><given-names>G. R. L.</given-names></name><etal/></person-group><article-title>Anticancer traits of chimeric antigen receptors (CARs)-natural killer (NK) cells as novel approaches for melanoma treatment</article-title><source><italic toggle="yes">BMC Cancer</italic></source><year>2022</year><volume>22</volume><pub-id pub-id-type="doi">10.1186/s12885-022-10320-0</pub-id><pub-id pub-id-type="publisher-id">1220</pub-id><pub-id pub-id-type="pmcid">PMC9701052</pub-id><pub-id pub-id-type="pmid">36434591</pub-id></element-citation></ref><ref id="B127" content-type="article"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biswas</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>A.</given-names></name></person-group><article-title>Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm</article-title><source><italic toggle="yes">Nature Immunology</italic></source><year>2010</year><volume>11</volume><issue>10</issue><fpage>889</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1038/ni.1937</pub-id><pub-id pub-id-type="other">2-s2.0-77956976681</pub-id><pub-id pub-id-type="pmid">20856220</pub-id></element-citation></ref><ref id="B128" content-type="article"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagemann</surname><given-names>T.</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sica</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>C. E.</given-names></name></person-group><article-title>Regulation of macrophage function in tumors: the multifaceted role of NF-<italic toggle="yes">&#954;</italic>B</article-title><source><italic toggle="yes">Blood</italic></source><year>2009</year><volume>113</volume><issue>14</issue><fpage>3139</fpage><lpage>3146</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-12-172825</pub-id><pub-id pub-id-type="other">2-s2.0-63149160727</pub-id><pub-id pub-id-type="pmid">19171876</pub-id><pub-id pub-id-type="pmcid">PMC2869029</pub-id></element-citation></ref><ref id="B129" content-type="article"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stenvinkel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ketteler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R. J.</given-names></name><etal/></person-group><article-title>IL-10, IL-6, and TNF-<italic toggle="yes">&#945;</italic>: central factors in the altered cytokine network of uremia&#8212;the good, the bad, and the ugly</article-title><source><italic toggle="yes">Kidney International</italic></source><year>2005</year><volume>67</volume><issue>4</issue><fpage>1216</fpage><lpage>1233</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2005.00200.x</pub-id><pub-id pub-id-type="other">2-s2.0-16244367738</pub-id><pub-id pub-id-type="pmid">15780075</pub-id></element-citation></ref><ref id="B130" content-type="article"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Alexandroff</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>R. W.</given-names></name><etal/></person-group><article-title>Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette&#8212;Gu&#233;rin (BCG) immunotherapy</article-title><source><italic toggle="yes">Clinical and Experimental Immunology</italic></source><year>1995</year><volume>99</volume><issue>3</issue><fpage>369</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.1995.tb05560.x</pub-id><pub-id pub-id-type="pmid">7882559</pub-id><pub-id pub-id-type="pmcid">PMC1534215</pub-id></element-citation></ref><ref id="B131" content-type="article"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ludwig</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Tumor necrosis factor-related apoptosis-inducing ligand</article-title><source><italic toggle="yes">Cancer Research</italic></source><year>2004</year><volume>64</volume><issue>10</issue><fpage>3386</fpage><lpage>3390</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-0374</pub-id><pub-id pub-id-type="other">2-s2.0-2442710545</pub-id><pub-id pub-id-type="pmid">15150089</pub-id></element-citation></ref><ref id="B132" content-type="article"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wolchok</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Humphrey</surname><given-names>R. W.</given-names></name><name name-style="western"><surname>Hodi</surname><given-names>F. S.</given-names></name></person-group><article-title>CCR 20th anniversary commentary: immune-related response criteria&#8211;capturing clinical activity in immuno-oncology</article-title><source><italic toggle="yes">Clinical Cancer Research</italic></source><year>2015</year><volume>21</volume><issue>22</issue><fpage>4989</fpage><lpage>4991</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-3128</pub-id><pub-id pub-id-type="other">2-s2.0-84957583827</pub-id><pub-id pub-id-type="pmid">26567357</pub-id></element-citation></ref><ref id="B133" content-type="article"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolchok</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Hoos</surname><given-names>A.</given-names></name><name name-style="western"><surname>O&#8217;Day</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria</article-title><source><italic toggle="yes">Clinical Cancer Research</italic></source><year>2009</year><volume>15</volume><issue>23</issue><fpage>7412</fpage><lpage>7420</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-1624</pub-id><pub-id pub-id-type="other">2-s2.0-73149092567</pub-id><pub-id pub-id-type="pmid">19934295</pub-id></element-citation></ref><ref id="B134" content-type="article"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunn</surname><given-names>G. P.</given-names></name><name name-style="western"><surname>Old</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>R. D.</given-names></name></person-group><article-title>The immunobiology of cancer immunosurveillance and immunoediting</article-title><source><italic toggle="yes">Immunity</italic></source><year>2004</year><volume>21</volume><issue>2</issue><fpage>137</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2004.07.017</pub-id><pub-id pub-id-type="other">2-s2.0-4143141823</pub-id><pub-id pub-id-type="pmid">15308095</pub-id></element-citation></ref><ref id="B135" content-type="article"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orange</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reuter</surname><given-names>U.</given-names></name><name name-style="western"><surname>Hobohm</surname><given-names>U.</given-names></name></person-group><article-title>Coley&#8217;s lessons remembered: augmenting mistletoe therapy</article-title><source><italic toggle="yes">Integrative Cancer Therapies</italic></source><year>2016</year><volume>15</volume><issue>4</issue><fpage>502</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1177/1534735416649916</pub-id><pub-id pub-id-type="other">2-s2.0-84995745487</pub-id><pub-id pub-id-type="pmid">27207233</pub-id><pub-id pub-id-type="pmcid">PMC5739169</pub-id></element-citation></ref><ref id="B136" content-type="article"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rius-Rocabert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Llinares Pinel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pozuelo</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nistal-Villan</surname><given-names>E.</given-names></name></person-group><article-title>Oncolytic bacteria: past, present and future</article-title><source><italic toggle="yes">FEMS Microbiology Letters</italic></source><year>2019</year><volume>366</volume><issue>12</issue><pub-id pub-id-type="doi">10.1093/femsle/fnz136</pub-id><pub-id pub-id-type="other">2-s2.0-85069800265</pub-id><pub-id pub-id-type="publisher-id">nz136</pub-id><pub-id pub-id-type="pmid">31226708</pub-id></element-citation></ref><ref id="B137" content-type="article"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oth</surname><given-names>T.</given-names></name><name name-style="western"><surname>Van Elssen</surname><given-names>C. H. M. J.</given-names></name><name name-style="western"><surname>Schnijderberg</surname><given-names>M. C. A.</given-names></name><etal/></person-group><article-title>Potency of both human Th1 and NK helper cell activation is determined by IL-12p70-producing PAMP-matured DCs</article-title><source><italic toggle="yes">Journal of Interferon &amp; Cytokine Research</italic></source><year>2015</year><volume>35</volume><issue>9</issue><fpage>748</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1089/jir.2015.0022</pub-id><pub-id pub-id-type="other">2-s2.0-84941066964</pub-id><pub-id pub-id-type="pmid">26134473</pub-id></element-citation></ref><ref id="B138" content-type="article"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaczanowska</surname><given-names>S.</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Davila</surname><given-names>E.</given-names></name></person-group><article-title>TLR agonists: our best <italic toggle="yes">frenemy</italic> in cancer immunotherapy</article-title><source><italic toggle="yes">Journal of Leukocyte Biology</italic></source><year>2013</year><volume>93</volume><issue>6</issue><fpage>847</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1189/jlb.1012501</pub-id><pub-id pub-id-type="other">2-s2.0-84878414390</pub-id><pub-id pub-id-type="pmid">23475577</pub-id><pub-id pub-id-type="pmcid">PMC3656332</pub-id></element-citation></ref><ref id="B139" content-type="article"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heldwein</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Andresen</surname><given-names>T. K.</given-names></name><etal/></person-group><article-title>TLR2 and TLR4 serve distinct roles in the host immune response against <italic toggle="yes">Mycobacterium bovis</italic> BCG</article-title><source><italic toggle="yes">Journal of Leukocyte Biology</italic></source><year>2003</year><volume>74</volume><issue>2</issue><fpage>277</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1189/jlb.0103026</pub-id><pub-id pub-id-type="other">2-s2.0-0041349291</pub-id><pub-id pub-id-type="pmid">12885945</pub-id></element-citation></ref><ref id="B140" content-type="article"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uehori</surname><given-names>J.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Simultaneous blocking of human toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by <italic toggle="yes">Mycobacterium bovis</italic> bacillus Calmette-Gu&#233;rin peptidoglycan</article-title><source><italic toggle="yes">Infection and Immunity</italic></source><year>2003</year><volume>71</volume><issue>8</issue><fpage>4238</fpage><lpage>4249</lpage><pub-id pub-id-type="doi">10.1128/IAI.71.8.4238-4249.2003</pub-id><pub-id pub-id-type="other">2-s2.0-0043267978</pub-id><pub-id pub-id-type="pmid">12874299</pub-id><pub-id pub-id-type="pmcid">PMC165983</pub-id></element-citation></ref><ref id="B141" content-type="article"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hemmi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kaisho</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Small anti-viral compounds activate immune cells via the TLR7 MyD88&#8211;dependent signaling pathway</article-title><source><italic toggle="yes">Nature Immunology</italic></source><year>2002</year><volume>3</volume><issue>2</issue><fpage>196</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1038/ni758</pub-id><pub-id pub-id-type="other">2-s2.0-0036008014</pub-id><pub-id pub-id-type="pmid">11812998</pub-id></element-citation></ref><ref id="B142" content-type="article"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akazawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Masuda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Saeki</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice</article-title><source><italic toggle="yes">Cancer Research</italic></source><year>2004</year><volume>64</volume><issue>2</issue><fpage>757</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-1518</pub-id><pub-id pub-id-type="other">2-s2.0-9144255378</pub-id><pub-id pub-id-type="pmid">14744795</pub-id></element-citation></ref><ref id="B143" content-type="article"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagemann</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>T.</given-names></name><name name-style="western"><surname>McNeish</surname><given-names>I.</given-names></name><etal/></person-group><article-title>&#8220;Re-educating&#8221; tumor-associated macrophages by targeting NF-<italic toggle="yes">&#954;</italic>B</article-title><source><italic toggle="yes">The Journal of Experimental Medicine</italic></source><year>2008</year><volume>205</volume><issue>6</issue><fpage>1261</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.1084/jem.20080108</pub-id><pub-id pub-id-type="other">2-s2.0-45149134605</pub-id><pub-id pub-id-type="pmid">18490490</pub-id><pub-id pub-id-type="pmcid">PMC2413024</pub-id></element-citation></ref><ref id="B144" content-type="article"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>W.-W.</given-names></name><etal/></person-group><article-title>Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis</article-title><source><italic toggle="yes">Nature</italic></source><year>2009</year><volume>457</volume><fpage>102</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1038/nature07623</pub-id><pub-id pub-id-type="other">2-s2.0-58149269348</pub-id><pub-id pub-id-type="pmid">19122641</pub-id><pub-id pub-id-type="pmcid">PMC2746432</pub-id></element-citation></ref><ref id="B145" content-type="article"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruprecht</surname><given-names>C.&#8196;R.</given-names></name><name name-style="western"><surname>Lanzavecchia</surname><given-names>A.</given-names></name></person-group><article-title>Toll-like receptor stimulation as a third signal required for activation of human naive B cells</article-title><source><italic toggle="yes">European Journal of Immunology</italic></source><year>2006</year><volume>36</volume><issue>4</issue><fpage>810</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1002/eji.200535744</pub-id><pub-id pub-id-type="other">2-s2.0-33645956556</pub-id><pub-id pub-id-type="pmid">16541472</pub-id></element-citation></ref><ref id="B146" content-type="article"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palm</surname><given-names>N. W.</given-names></name><name name-style="western"><surname>Medzhitov</surname><given-names>R.</given-names></name></person-group><article-title>Pattern recognition receptors and control of adaptive immunity</article-title><source><italic toggle="yes">Immunological Reviews</italic></source><year>2009</year><volume>227</volume><issue>1</issue><fpage>221</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2008.00731.x</pub-id><pub-id pub-id-type="other">2-s2.0-58049220365</pub-id><pub-id pub-id-type="pmid">19120487</pub-id></element-citation></ref><ref id="B147" content-type="article"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wherry</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Kurachi</surname><given-names>M.</given-names></name></person-group><article-title>Molecular and cellular insights into T cell exhaustion</article-title><source><italic toggle="yes">Nature Reviews Immunology</italic></source><year>2015</year><volume>15</volume><issue>8</issue><fpage>486</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1038/nri3862</pub-id><pub-id pub-id-type="other">2-s2.0-84937837169</pub-id><pub-id pub-id-type="pmcid">PMC4889009</pub-id><pub-id pub-id-type="pmid">26205583</pub-id></element-citation></ref><ref id="B148" content-type="article"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>I. E.</given-names></name><name name-style="western"><surname>Blank</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kline</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kacha</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Gajewski</surname><given-names>T. F.</given-names></name></person-group><article-title>Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection</article-title><source><italic toggle="yes">The Journal of Immunology</italic></source><year>2006</year><volume>177</volume><issue>7</issue><fpage>4521</fpage><lpage>4529</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.177.7.4521</pub-id><pub-id pub-id-type="other">2-s2.0-33749135271</pub-id><pub-id pub-id-type="pmid">16982889</pub-id></element-citation></ref><ref id="B149" content-type="article"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crespo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Welling</surname><given-names>T. H.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>W.</given-names></name></person-group><article-title>T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment</article-title><source><italic toggle="yes">Current Opinion in Immunology</italic></source><year>2013</year><volume>25</volume><issue>2</issue><fpage>214</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2012.12.003</pub-id><pub-id pub-id-type="other">2-s2.0-84877059916</pub-id><pub-id pub-id-type="pmid">23298609</pub-id><pub-id pub-id-type="pmcid">PMC3636159</pub-id></element-citation></ref><ref id="B150" content-type="article"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maletzki</surname><given-names>C.</given-names></name><name name-style="western"><surname>Linnebacher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Savai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hobohm</surname><given-names>U.</given-names></name></person-group><article-title>Mistletoe lectin has a shiga toxin-like structure and should be combined with other Toll-like receptor ligands in cancer therapy</article-title><source><italic toggle="yes">Cancer Immunology, Immunotherapy</italic></source><year>2013</year><volume>62</volume><issue>8</issue><fpage>1283</fpage><lpage>1292</lpage><pub-id pub-id-type="doi">10.1007/s00262-013-1455-1</pub-id><pub-id pub-id-type="other">2-s2.0-84880917245</pub-id><pub-id pub-id-type="pmid">23832140</pub-id><pub-id pub-id-type="pmcid">PMC11028761</pub-id></element-citation></ref><ref id="B151" content-type="article"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shelley</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Kynaston</surname><given-names>H.</given-names></name></person-group><article-title>Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses</article-title><source><italic toggle="yes">Cancer Treatment Reviews</italic></source><year>2010</year><volume>36</volume><issue>3</issue><fpage>195</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2009.12.005</pub-id><pub-id pub-id-type="other">2-s2.0-77951207009</pub-id><pub-id pub-id-type="pmid">20079574</pub-id></element-citation></ref><ref id="B152" content-type="article"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>V. C.</given-names></name></person-group><article-title>Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma</article-title><source><italic toggle="yes">The Journal of Dermatologic Surgery and Oncology</italic></source><year>1993</year><volume>19</volume><issue>11</issue><fpage>985</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1111/j.1524-4725.1993.tb00989.x</pub-id><pub-id pub-id-type="other">2-s2.0-0027788002</pub-id><pub-id pub-id-type="pmid">8245304</pub-id></element-citation></ref><ref id="B153" content-type="article"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grange</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Krone</surname><given-names>B.</given-names></name><name name-style="western"><surname>Stanford</surname><given-names>J. L.</given-names></name></person-group><article-title>Immunotherapy for malignant melanoma&#8212;tracing Ariadne&#8217;s thread through the labyrinth</article-title><source><italic toggle="yes">European Journal of Cancer</italic></source><year>2009</year><volume>45</volume><issue>13</issue><fpage>2266</fpage><lpage>2273</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2009.05.002</pub-id><pub-id pub-id-type="other">2-s2.0-68749095218</pub-id><pub-id pub-id-type="pmid">19497734</pub-id></element-citation></ref><ref id="B154" content-type="article"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rook</surname><given-names>G. A. W.</given-names></name><name name-style="western"><surname>Dalgleish</surname><given-names>A.</given-names></name></person-group><article-title>Infection, immunoregulation, and cancer</article-title><source><italic toggle="yes">Immunological Reviews</italic></source><year>2011</year><volume>240</volume><issue>1</issue><fpage>141</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2010.00987.x</pub-id><pub-id pub-id-type="other">2-s2.0-79951879290</pub-id><pub-id pub-id-type="pmid">21349092</pub-id></element-citation></ref><ref id="B155" content-type="article"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Brien</surname><given-names>M. E. R.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kaukel</surname><given-names>E.</given-names></name><etal/></person-group><article-title>SRL172 (killed <italic toggle="yes">Mycobacterium vaccae</italic>) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results</article-title><source><italic toggle="yes">Annals of Oncology</italic></source><year>2004</year><volume>15</volume><issue>6</issue><fpage>906</fpage><lpage>914</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdh220</pub-id><pub-id pub-id-type="other">2-s2.0-3442886281</pub-id><pub-id pub-id-type="pmid">15151947</pub-id></element-citation></ref><ref id="B156" content-type="article"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanford</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Stanford</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>M. E. R.</given-names></name><name name-style="western"><surname>Grange</surname><given-names>J. M.</given-names></name></person-group><article-title>Successful immunotherapy with <italic toggle="yes">Mycobacterium vaccae</italic> in the treatment of adenocarcinoma of the lung</article-title><source><italic toggle="yes">European Journal of Cancer</italic></source><year>2008</year><volume>44</volume><issue>2</issue><fpage>224</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2007.08.021</pub-id><pub-id pub-id-type="other">2-s2.0-38149032470</pub-id><pub-id pub-id-type="pmid">17928219</pub-id></element-citation></ref><ref id="B157" content-type="article"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stebbing</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dalgleish</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gifford-Moore</surname><given-names>A.</given-names></name><etal/></person-group><article-title>An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma</article-title><source><italic toggle="yes">Annals of Oncology</italic></source><year>2012</year><volume>23</volume><issue>5</issue><fpage>1314</fpage><lpage>1319</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdr363</pub-id><pub-id pub-id-type="other">2-s2.0-84860491259</pub-id><pub-id pub-id-type="pmid">21930686</pub-id></element-citation></ref><ref id="B158" content-type="article"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srivatsan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Bozeman</surname><given-names>E. N.</given-names></name><etal/></person-group><article-title>Allogeneic tumor cell vaccines: the promise and limitations in clinical trials</article-title><source><italic toggle="yes">Human Vaccines &amp; Immunotherapeutics</italic></source><year>2014</year><volume>10</volume><issue>1</issue><fpage>52</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.4161/hv.26568</pub-id><pub-id pub-id-type="other">2-s2.0-84896708665</pub-id><pub-id pub-id-type="pmid">24064957</pub-id><pub-id pub-id-type="pmcid">PMC4181031</pub-id></element-citation></ref><ref id="B159" content-type="article"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahimmanesh</surname><given-names>I.</given-names></name><name name-style="western"><surname>Esmaili</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ghafouri</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hejazi</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Khanahmad</surname><given-names>H.</given-names></name></person-group><article-title>Enhanced in vivo anti-tumor efficacy of whole tumor lysate in combination with whole tumor cell-specific polyclonal antibody</article-title><source><italic toggle="yes">Research in Pharmaceutical Sciences</italic></source><year>2023</year><volume>18</volume><issue>2</issue><pub-id pub-id-type="doi">10.4103/1735-5362.367793</pub-id><pub-id pub-id-type="publisher-id">138</pub-id><pub-id pub-id-type="pmcid">PMC9976059</pub-id><pub-id pub-id-type="pmid">36873278</pub-id></element-citation></ref><ref id="B160" content-type="article"><label>160</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schnurr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Galambos</surname><given-names>P.</given-names></name><name name-style="western"><surname>Scholz</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines</article-title><source><italic toggle="yes">Cancer Research</italic></source><year>2001</year><volume>61</volume><issue>17</issue><fpage>6445</fpage><lpage>6450</lpage><pub-id pub-id-type="pmid">11522639</pub-id></element-citation></ref><ref id="B161" content-type="article"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kra&#347;ko</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>&#381;ilionyt&#279;</surname><given-names>K.</given-names></name><name name-style="western"><surname>Darinskas</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Bacterial ghosts as adjuvants in syngeneic tumour cell lysate-based anticancer vaccination in a murine lung carcinoma model</article-title><source><italic toggle="yes">Oncology Reports</italic></source><year>2017</year><volume>37</volume><issue>1</issue><fpage>171</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.3892/or.2016.5252</pub-id><pub-id pub-id-type="other">2-s2.0-85006427903</pub-id><pub-id pub-id-type="pmid">27878261</pub-id></element-citation></ref><ref id="B162" content-type="article"><label>162</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuang</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L.</given-names></name></person-group><article-title>Tumor-educated tolerogenic dendritic cells induce CD3<italic toggle="yes">&#949;</italic> down-regulation and apoptosis of T cells through oxygen-dependent pathways</article-title><source><italic toggle="yes">The Journal of Immunology</italic></source><year>2008</year><volume>181</volume><issue>5</issue><fpage>3089</fpage><lpage>3098</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.5.3089</pub-id><pub-id pub-id-type="pmid">18713979</pub-id></element-citation></ref><ref id="B163" content-type="article"><label>163</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Tumor cell lysate induces the immunosuppression and apoptosis of mouse immunocytes</article-title><source><italic toggle="yes">Molecular Medicine Reports</italic></source><year>2014</year><volume>10</volume><issue>6</issue><fpage>2827</fpage><lpage>2834</lpage><pub-id pub-id-type="doi">10.3892/mmr.2014.2606</pub-id><pub-id pub-id-type="other">2-s2.0-84914118520</pub-id><pub-id pub-id-type="pmid">25310154</pub-id><pub-id pub-id-type="pmcid">PMC4227419</pub-id></element-citation></ref><ref id="B164" content-type="article"><label>164</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schijns</surname><given-names>V.</given-names></name><name name-style="western"><surname>Tartour</surname><given-names>E.</given-names></name><name name-style="western"><surname>Michalek</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stathopoulos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dobrovolskien&#279;</surname><given-names>N. T.</given-names></name><name name-style="western"><surname>Strioga</surname><given-names>M. M.</given-names></name></person-group><article-title>Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines</article-title><source><italic toggle="yes">Cytotherapy</italic></source><year>2014</year><volume>16</volume><issue>4</issue><fpage>427</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1016/j.jcyt.2013.09.008</pub-id><pub-id pub-id-type="other">2-s2.0-84895818551</pub-id><pub-id pub-id-type="pmid">24280238</pub-id></element-citation></ref><ref id="B165" content-type="article"><label>165</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krysko</surname><given-names>D. V.</given-names></name><name name-style="western"><surname>Garg</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Kaczmarek</surname><given-names>A.</given-names></name><name name-style="western"><surname>Krysko</surname><given-names>O.</given-names></name><name name-style="western"><surname>Agostinis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vandenabeele</surname><given-names>P.</given-names></name></person-group><article-title>Immunogenic cell death and DAMPs in cancer therapy</article-title><source><italic toggle="yes">Nature Reviews Cancer</italic></source><year>2012</year><volume>12</volume><issue>12</issue><fpage>860</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1038/nrc3380</pub-id><pub-id pub-id-type="other">2-s2.0-84870239310</pub-id><pub-id pub-id-type="pmid">23151605</pub-id></element-citation></ref><ref id="B166" content-type="article"><label>166</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>F. E.</given-names></name><name name-style="western"><surname>Gleisner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Falc&#243;n-Beas</surname><given-names>F.</given-names></name><name name-style="western"><surname>Osorio</surname><given-names>F.</given-names></name><name name-style="western"><surname>L&#243;pez</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Salazar-Onfray</surname><given-names>F.</given-names></name></person-group><article-title>Tumor cell lysates as immunogenic sources for cancer vaccine design</article-title><source><italic toggle="yes">Human Vaccines &amp; Immunotherapeutics</italic></source><year>2014</year><volume>10</volume><issue>11</issue><fpage>3261</fpage><lpage>3269</lpage><pub-id pub-id-type="doi">10.4161/21645515.2014.982996</pub-id><pub-id pub-id-type="other">2-s2.0-84921908804</pub-id><pub-id pub-id-type="pmid">25625929</pub-id><pub-id pub-id-type="pmcid">PMC4514089</pub-id></element-citation></ref><ref id="B167" content-type="article"><label>167</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsan</surname><given-names>M.-F.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>B.</given-names></name></person-group><article-title>Endogenous ligands of Toll-like receptors</article-title><source><italic toggle="yes">Journal of Leukocyte Biology</italic></source><year>2004</year><volume>76</volume><issue>3</issue><fpage>514</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1189/jlb.0304127</pub-id><pub-id pub-id-type="other">2-s2.0-4344627821</pub-id><pub-id pub-id-type="pmid">15178705</pub-id></element-citation></ref><ref id="B168" content-type="article"><label>168</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vacchelli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Eggermont</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saut&#232;s-Fridman</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Trial watch: toll-like receptor agonists for cancer therapy</article-title><source><italic toggle="yes">Oncoimmunology</italic></source><year>2013</year><volume>2</volume><issue>8</issue><pub-id pub-id-type="doi">10.4161/onci.25238</pub-id><pub-id pub-id-type="other">2-s2.0-84885696781</pub-id><pub-id pub-id-type="publisher-id">e25238</pub-id><pub-id pub-id-type="pmcid">PMC3782517</pub-id><pub-id pub-id-type="pmid">24083080</pub-id></element-citation></ref><ref id="B169" content-type="article"><label>169</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwasaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Medzhitov</surname><given-names>R.</given-names></name></person-group><article-title>Toll-like receptor control of the adaptive immune responses</article-title><source><italic toggle="yes">Nature Immunology</italic></source><year>2004</year><volume>5</volume><issue>10</issue><fpage>987</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1038/ni1112</pub-id><pub-id pub-id-type="other">2-s2.0-5444262511</pub-id><pub-id pub-id-type="pmid">15454922</pub-id></element-citation></ref><ref id="B170" content-type="article"><label>170</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medzhitov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Preston-Hurlburt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Janeway</surname><given-names>C. A.</given-names><suffix>Jr.</suffix></name></person-group><article-title>A human homologue of the drosophila toll protein signals activation of adaptive immunity</article-title><source><italic toggle="yes">Nature</italic></source><year>1997</year><volume>388</volume><issue>6640</issue><fpage>394</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1038/41131</pub-id><pub-id pub-id-type="other">2-s2.0-0030831210</pub-id><pub-id pub-id-type="pmid">9237759</pub-id></element-citation></ref><ref id="B171" content-type="article"><label>171</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Apetoh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ghiringhelli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tesniere</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Toll-like receptor 4&#8211;dependent contribution of the immune system to anticancer chemotherapy and radiotherapy</article-title><source><italic toggle="yes">Nature Medicine</italic></source><year>2007</year><volume>13</volume><issue>9</issue><fpage>1050</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.1038/nm1622</pub-id><pub-id pub-id-type="other">2-s2.0-34948820602</pub-id><pub-id pub-id-type="pmid">17704786</pub-id></element-citation></ref><ref id="B172" content-type="article"><label>172</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaisho</surname><given-names>T.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name></person-group><article-title>Toll-like receptor function and signaling</article-title><source><italic toggle="yes">Journal of Allergy and Clinical Immunology</italic></source><year>2006</year><volume>117</volume><issue>5</issue><fpage>979</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2006.02.023</pub-id><pub-id pub-id-type="other">2-s2.0-33646147362</pub-id><pub-id pub-id-type="pmid">16675322</pub-id></element-citation></ref><ref id="B173" content-type="article"><label>173</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandron</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ari&#232;s</surname><given-names>M.-F.</given-names></name><name name-style="western"><surname>Brehm</surname><given-names>R. D.</given-names></name><etal/></person-group><article-title>Human dendritic cells conditioned with <italic toggle="yes">Staphylococcus aureus</italic> enterotoxin B promote TH2 cell polarization</article-title><source><italic toggle="yes">Journal of Allergy and Clinical Immunology</italic></source><year>2006</year><volume>117</volume><issue>5</issue><fpage>1141</fpage><lpage>1147</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2005.12.1360</pub-id><pub-id pub-id-type="other">2-s2.0-33646163669</pub-id><pub-id pub-id-type="pmid">16675344</pub-id></element-citation></ref><ref id="B174" content-type="article"><label>174</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tittarelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>F. E.</given-names></name><name name-style="western"><surname>Pereda</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Toll-like receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients</article-title><source><italic toggle="yes">Cancer Immunology, Immunotherapy</italic></source><year>2012</year><volume>61</volume><issue>11</issue><fpage>2067</fpage><lpage>2077</lpage><pub-id pub-id-type="doi">10.1007/s00262-012-1268-7</pub-id><pub-id pub-id-type="other">2-s2.0-84870978203</pub-id><pub-id pub-id-type="pmid">22552381</pub-id><pub-id pub-id-type="pmcid">PMC11029707</pub-id></element-citation></ref><ref id="B175" content-type="article"><label>175</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osorio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Reis e Sousa</surname><given-names>C.</given-names></name></person-group><article-title>Myeloid C-type lectin receptors in pathogen recognition and host defense</article-title><source><italic toggle="yes">Immunity</italic></source><year>2011</year><volume>34</volume><issue>5</issue><fpage>651</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.05.001</pub-id><pub-id pub-id-type="other">2-s2.0-79956292569</pub-id><pub-id pub-id-type="pmid">21616435</pub-id></element-citation></ref><ref id="B176" content-type="article"><label>176</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zitvogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kepp</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name></person-group><article-title>Decoding cell death signals in inflammation and immunity</article-title><source><italic toggle="yes">Cell</italic></source><year>2010</year><volume>140</volume><issue>6</issue><fpage>798</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.02.015</pub-id><pub-id pub-id-type="other">2-s2.0-77950366886</pub-id><pub-id pub-id-type="pmid">20303871</pub-id></element-citation></ref><ref id="B177" content-type="article"><label>177</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Callmann</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Kusmierz</surname><given-names>C. D.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Horiuchi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mirkin</surname><given-names>C. A.</given-names></name></person-group><article-title>Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2020</year><volume>117</volume><issue>30</issue><fpage>17543</fpage><lpage>17550</lpage><pub-id pub-id-type="doi">10.1073/pnas.2005794117</pub-id><pub-id pub-id-type="pmid">32669433</pub-id><pub-id pub-id-type="pmcid">PMC7395518</pub-id></element-citation></ref><ref id="B178" content-type="article"><label>178</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatfield</surname><given-names>P.</given-names></name><name name-style="western"><surname>Merrick</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>West</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy</article-title><source><italic toggle="yes">Journal of Immunotherapy</italic></source><year>2008</year><volume>31</volume><issue>7</issue><fpage>620</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1097/CJI.0b013e31818213df</pub-id><pub-id pub-id-type="other">2-s2.0-55149118703</pub-id><pub-id pub-id-type="pmid">18600182</pub-id><pub-id pub-id-type="pmcid">PMC3901408</pub-id></element-citation></ref><ref id="B179" content-type="article"><label>179</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohamed</surname><given-names>S. I. A.</given-names></name><name name-style="western"><surname>Jantan</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nafiah</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Seyed</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K. M.</given-names></name></person-group><article-title>Dendritic cells pulsed with generated tumor cell lysate from <italic toggle="yes">Phyllanthus amarus</italic> Schum. &amp; Thonn. induces anti-tumor immune response</article-title><source><italic toggle="yes">BMC Complementary and Alternative Medicine</italic></source><year>2018</year><volume>18</volume><issue>1</issue><pub-id pub-id-type="doi">10.1186/s12906-018-2296-4</pub-id><pub-id pub-id-type="other">2-s2.0-85051691513</pub-id><pub-id pub-id-type="publisher-id">232</pub-id><pub-id pub-id-type="pmcid">PMC6080389</pub-id><pub-id pub-id-type="pmid">30081891</pub-id></element-citation></ref><ref id="B180" content-type="article"><label>180</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moyer</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Maine</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mul&#233;</surname><given-names>J. J.</given-names></name></person-group><article-title>Early vaccination with tumor-lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects</article-title><source><italic toggle="yes">Biology of Blood and Marrow Transplantation</italic></source><year>2006</year><volume>12</volume><issue>10</issue><fpage>1010</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2006.06.009</pub-id><pub-id pub-id-type="other">2-s2.0-33846836896</pub-id><pub-id pub-id-type="pmid">17084367</pub-id></element-citation></ref><ref id="B181" content-type="article"><label>181</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadeghi Najafabadi</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Bolhassani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aghasadeghi</surname><given-names>M. R.</given-names></name></person-group><article-title>Tumor cell-based vaccine: an effective strategy for eradication of cancer cells</article-title><source><italic toggle="yes">Immunotherapy</italic></source><year>2022</year><volume>14</volume><issue>8</issue><fpage>639</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.2217/imt-2022-0036</pub-id><pub-id pub-id-type="pmid">35481358</pub-id></element-citation></ref><ref id="B182" content-type="article"><label>182</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yasuda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kamigaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells</article-title><source><italic toggle="yes">Oncology Reports</italic></source><year>2006</year><volume>16</volume><issue>6</issue><fpage>1317</fpage><lpage>1324</lpage><pub-id pub-id-type="pmid">17089056</pub-id></element-citation></ref><ref id="B183" content-type="article"><label>183</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#246;ltl</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ramoner</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zelle-Rieser</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide</article-title><source><italic toggle="yes">Cancer Immunology, Immunotherapy</italic></source><year>2005</year><volume>54</volume><issue>7</issue><fpage>663</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1007/s00262-004-0629-2</pub-id><pub-id pub-id-type="other">2-s2.0-21244505782</pub-id><pub-id pub-id-type="pmid">15918076</pub-id><pub-id pub-id-type="pmcid">PMC11032994</pub-id></element-citation></ref><ref id="B184" content-type="article"><label>184</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmer</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Midgley</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Mirza</surname><given-names>N.</given-names></name><etal/></person-group><article-title>A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma</article-title><source><italic toggle="yes">Hepatology</italic></source><year>2009</year><volume>49</volume><issue>1</issue><fpage>124</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1002/hep.22626</pub-id><pub-id pub-id-type="other">2-s2.0-58949092553</pub-id><pub-id pub-id-type="pmid">18980227</pub-id></element-citation></ref><ref id="B185" content-type="article"><label>185</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandha</surname><given-names>H. S.</given-names></name><name name-style="western"><surname>John</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Hutchinson</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study</article-title><source><italic toggle="yes">BJU International</italic></source><year>2004</year><volume>94</volume><issue>3</issue><fpage>412</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1111/j.1464-410X.2004.04922.x</pub-id><pub-id pub-id-type="other">2-s2.0-4344637057</pub-id><pub-id pub-id-type="pmid">15291878</pub-id></element-citation></ref><ref id="B186" content-type="article"><label>186</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morii</surname><given-names>K.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>R.</given-names></name></person-group><article-title>The generation of anti-tumoral cells using dendritic cells from the peripheral blood of patients with malignant brain tumors</article-title><source><italic toggle="yes">Cancer Immunology, Immunotherapy</italic></source><year>2001</year><volume>50</volume><issue>6</issue><fpage>321</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1007/s002620100201</pub-id><pub-id pub-id-type="other">2-s2.0-0034887334</pub-id><pub-id pub-id-type="pmid">11570586</pub-id><pub-id pub-id-type="pmcid">PMC11036844</pub-id></element-citation></ref><ref id="B187" content-type="article"><label>187</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguilera</surname><given-names>R.</given-names></name><name name-style="western"><surname>Saffie</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tittarelli</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells</article-title><source><italic toggle="yes">Clinical Cancer Research</italic></source><year>2011</year><volume>17</volume><issue>8</issue><fpage>2474</fpage><lpage>2483</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-2384</pub-id><pub-id pub-id-type="other">2-s2.0-79954610784</pub-id><pub-id pub-id-type="pmid">21292818</pub-id></element-citation></ref><ref id="B188" content-type="article"><label>188</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#243;pez</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Pereda</surname><given-names>C.</given-names></name><name name-style="western"><surname>Segal</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Prolonged survival of dendritic cell&#8211;vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor <italic toggle="yes">&#946;</italic>-expressing T cells</article-title><source><italic toggle="yes">Journal of Clinical Oncology</italic></source><year>2009</year><volume>27</volume><issue>6</issue><fpage>945</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.18.0794</pub-id><pub-id pub-id-type="other">2-s2.0-60849084473</pub-id><pub-id pub-id-type="pmid">19139436</pub-id></element-citation></ref><ref id="B189" content-type="article"><label>189</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mantia-Smaldone</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>C. S.</given-names></name></person-group><article-title>A review of dendritic cell therapy for cancer: progress and challenges</article-title><source><italic toggle="yes">BioDrugs</italic></source><year>2013</year><volume>27</volume><issue>5</issue><fpage>453</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1007/s40259-013-0030-9</pub-id><pub-id pub-id-type="other">2-s2.0-84881507207</pub-id><pub-id pub-id-type="pmid">23592406</pub-id></element-citation></ref><ref id="B190" content-type="article"><label>190</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mantia-Smaldone</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Corr</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>C. S.</given-names></name></person-group><article-title>Immunotherapy in ovarian cancer</article-title><source><italic toggle="yes">Human Vaccines &amp; Immunotherapeutics</italic></source><year>2012</year><volume>8</volume><issue>9</issue><fpage>1179</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.4161/hv.20738</pub-id><pub-id pub-id-type="other">2-s2.0-84867009579</pub-id><pub-id pub-id-type="pmid">22906947</pub-id><pub-id pub-id-type="pmcid">PMC3579897</pub-id></element-citation></ref><ref id="B191" content-type="article"><label>191</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watchmaker</surname><given-names>P. B.</given-names></name><name name-style="western"><surname>Berk</surname><given-names>E.</given-names></name><name name-style="western"><surname>Muthuswamy</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells</article-title><source><italic toggle="yes">The Journal of Immunology</italic></source><year>2010</year><volume>184</volume><issue>2</issue><fpage>591</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0902062</pub-id><pub-id pub-id-type="other">2-s2.0-76249100089</pub-id><pub-id pub-id-type="pmid">20018619</pub-id><pub-id pub-id-type="pmcid">PMC2922038</pub-id></element-citation></ref><ref id="B192" content-type="article"><label>192</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Sustained release of tumor cell lysate and CpG from an injectable, cytotoxic hydrogel for melanoma immunotherapy</article-title><source><italic toggle="yes">Nanoscale Advances</italic></source><year>2023</year><volume>5</volume><issue>7</issue><fpage>2071</fpage><lpage>2084</lpage><pub-id pub-id-type="doi">10.1039/D2NA00911K</pub-id><pub-id pub-id-type="pmid">36998647</pub-id><pub-id pub-id-type="pmcid">PMC10044724</pub-id></element-citation></ref><ref id="B193" content-type="incollection"><label>193</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Chiang</surname><given-names>C. L. L.</given-names></name><name name-style="western"><surname>Kandalaft</surname><given-names>L. E.</given-names></name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>Buonaguro</surname><given-names>L.</given-names></name><name name-style="western"><surname>Van Der Burg</surname><given-names>S.</given-names></name></person-group><article-title>Tumor lysates cancer vaccine</article-title><source><italic toggle="yes">Cancer Vaccines as Immunotherapy of Cancer</italic></source><year>2022</year><publisher-name>Academic Press</publisher-name><fpage>21</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-823901-8.00001-7</pub-id></element-citation></ref><ref id="B194" content-type="thesis"><label>194</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Shields</surname><given-names>N. J.</given-names></name></person-group><source><italic toggle="yes">Tumour lysate-based immunotherapy for colorectal cancer</italic></source><year>2022</year><publisher-name>University of Otago</publisher-name><comment>Doctoral Thesis</comment></element-citation></ref><ref id="B195" content-type="article"><label>195</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiang</surname><given-names>C. L.-L.</given-names></name><name name-style="western"><surname>Kandalaft</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Tanyi</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside</article-title><source><italic toggle="yes">Clinical Cancer Research</italic></source><year>2013</year><volume>19</volume><issue>17</issue><fpage>4801</fpage><lpage>4815</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-1185</pub-id><pub-id pub-id-type="other">2-s2.0-84883466843</pub-id><pub-id pub-id-type="pmid">23838316</pub-id><pub-id pub-id-type="pmcid">PMC4049094</pub-id></element-citation></ref><ref id="B196" content-type="article"><label>196</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogino</surname><given-names>H.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Nejo</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas</article-title><source><italic toggle="yes">Journal of Clinical Investigation</italic></source><year>2022</year><volume>132</volume><issue>3</issue><pub-id pub-id-type="doi">10.1172/JCI151239</pub-id><pub-id pub-id-type="publisher-id">e151239</pub-id><pub-id pub-id-type="pmcid">PMC8803342</pub-id><pub-id pub-id-type="pmid">34882581</pub-id></element-citation></ref><ref id="B197" content-type="article"><label>197</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanyi</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Bobisse</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ophir</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer</article-title><source><italic toggle="yes">Science Translational Medicine</italic></source><year>2018</year><volume>10</volume><issue>436</issue><pub-id pub-id-type="doi">10.1126/scitranslmed.aao5931</pub-id><pub-id pub-id-type="other">2-s2.0-85045325399</pub-id><pub-id pub-id-type="publisher-id">eaao5931</pub-id><pub-id pub-id-type="pmid">29643231</pub-id></element-citation></ref><ref id="B198" content-type="article"><label>198</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neller</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>L&#243;pez</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>C. W.</given-names></name></person-group><article-title>Antigens for cancer immunotherapy</article-title><source><italic toggle="yes">Seminars in Immunology</italic></source><year>2008</year><volume>20</volume><issue>5</issue><fpage>286</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2008.09.006</pub-id><pub-id pub-id-type="other">2-s2.0-55749115774</pub-id><pub-id pub-id-type="pmid">18951039</pub-id></element-citation></ref><ref id="B199" content-type="article"><label>199</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gleisner</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Pereda</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tittarelli</surname><given-names>A.</given-names></name><etal/></person-group><article-title>A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth</article-title><source><italic toggle="yes">Journal for ImmunoTherapy of Cancer</italic></source><year>2020</year><volume>8</volume><issue>2</issue><pub-id pub-id-type="doi">10.1136/jitc-2020-000999</pub-id><pub-id pub-id-type="publisher-id">e000999</pub-id><pub-id pub-id-type="pmcid">PMC7373330</pub-id><pub-id pub-id-type="pmid">32690772</pub-id></element-citation></ref><ref id="B200" content-type="article"><label>200</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.-L.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>S.</given-names></name><name name-style="western"><surname>He</surname><given-names>H.-P.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>L.-L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.-G.</given-names></name></person-group><article-title>A hybrid glioma tumor cell lysate immunotherapy vaccine demonstrates good clinical efficacy in the rat model</article-title><source><italic toggle="yes">OncoTargets and Therapy</italic></source><year>2020</year><volume>13</volume><fpage>8109</fpage><lpage>8124</lpage><pub-id pub-id-type="doi">10.2147/OTT.S259516</pub-id><pub-id pub-id-type="pmid">32884294</pub-id><pub-id pub-id-type="pmcid">PMC7438187</pub-id></element-citation></ref><ref id="B201" content-type="article"><label>201</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sosman</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Sondak</surname><given-names>V. K.</given-names></name></person-group><article-title>Melacine&#174;: an allogeneic melanoma tumor cell lysate vaccine</article-title><source><italic toggle="yes">Expert Review of Vaccines</italic></source><year>2003</year><volume>2</volume><issue>3</issue><fpage>353</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1586/14760584.2.3.353</pub-id><pub-id pub-id-type="other">2-s2.0-0037496082</pub-id><pub-id pub-id-type="pmid">12903801</pub-id></element-citation></ref><ref id="B202" content-type="article"><label>202</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mpande</surname><given-names>C. A. M.</given-names></name><name name-style="western"><surname>Rozot</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mosito</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Immune profiling of <italic toggle="yes">Mycobacterium tuberculosis</italic>-specific T cells in recent and remote infection</article-title><source><italic toggle="yes">EBioMedicine</italic></source><year>2021</year><volume>64</volume><pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103233</pub-id><pub-id pub-id-type="publisher-id">103233</pub-id><pub-id pub-id-type="pmcid">PMC7902886</pub-id><pub-id pub-id-type="pmid">33610126</pub-id></element-citation></ref><ref id="B203" content-type="article"><label>203</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Igarashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sasada</surname><given-names>T.</given-names></name></person-group><article-title>Cancer vaccines: toward the next breakthrough in cancer immunotherapy</article-title><source><italic toggle="yes">Journal of Immunology Research</italic></source><year>2020</year><volume>2020</volume><fpage>13</fpage><pub-id pub-id-type="doi">10.1155/2020/5825401</pub-id><pub-id pub-id-type="publisher-id">5825401</pub-id><pub-id pub-id-type="pmcid">PMC7685825</pub-id><pub-id pub-id-type="pmid">33282961</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>Mechanisms of action of the most studied bacterial lysate OM-85. In humans, pathogen-associated molecular patterns (PAMPs) of OM-85 stimulate the Toll-like receptors of the immune cells and activate monocytes, macrophages, dendritic cells (DCs), and natural killer cells, activating the immune system to fight infections. OM-85 also stimulates the production of secretory immunoglobulin A (sIgA) (1a). In sinonasal immunity, OM-85 activates bitter taste receptors (T2R), resulting in increases in ciliary beat frequency (CBF) (indicating improved lung functions), and other local immune defenses such as the release of nitric oxide (NO) and secretion of antimicrobial compounds lead to the killing of pathogens. Moreover, OM-85 also activates polyclonal B cells, increasing IgG levels in serum and IgA and IgG levels in bronchoalveolar lavage. IgA neutralizes viruses and controls secondary bacterial infections (1b). An effect on the expansion of type 1 helper T (Th1) cells, regulatory T cells (Treg), and CD8+ T cells has also been observed with the administration of OM-85. Th1 cells produce inflammatory cytokines, which send signals to immune cells to destroy pathogens, whereas the cytotoxic activity of CD8+ T cells also does the same. Treg cells downregulate the Th2 cells and restore Th/Th1 balance, improving overall mucosal immunity (1c). In a mice study, OM-85 increased the production of IL-6 and TNF-<italic toggle="yes">&#945;</italic> in bronchoalveolar lavage fluid, contributing to reduced viral load (2a). Also, nonspecific maturation of B cells and DCs by OM-85 leads to increased surface expression of antigen-presenting molecules (MHC II, CD86, and CD40) and helps to neutralize pathogens, and a decrease in inducible T-cell costimulator ligand (ICOSL) provides protection against allergic responses (2b). <italic toggle="yes">In vitro</italic>, data showed that OM-85 could activate T2R (downstream processes are like in human studies) and NF-kB and MAPK in monocyte-derived DCs from COPD patients, resulting in the upregulation of chemokines (CXCL8, CXCL6, CCL3, CCL20, and CCL22), and B-cell-activating cytokines (IL-6, BAFF, and IL-10) may impact in fighting against pathogens (3a). OM-85 also increased the expression of virus-interacting proteins such as C1q-R and <italic toggle="yes">&#946;</italic>-defensin, essential for antigen presentation and phagocytosis, and significantly reduced rhinovirus-induced expression of intracellular adhesion molecule (ICAM)-1, resulting reduced viral load (3b).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JIR2024-4312908.001.jpg"/></fig><fig position="float" id="fig2" orientation="portrait"><label>Figure 2</label><caption><p>Mode of actions of bacterial lysate-based cancer immunotherapy. Pathogen recognition receptors (PRR) in immune cells such as natural killer cells, macrophages, T cells, and dendritic cells (DCs) interact with the pathogen-associated molecular pattern (PAMPs), activating the immune cells (1). This activation creates a cytokine milieu (IL-1, IL-6, IL-12, and TNF-<italic toggle="yes">&#945;</italic>), ultimately leading to type 1 immunity. Activating type 1 immunity helps to restore the ability of tumor-specific type 1 helper T cells (Th1) and cytotoxic T cells, which then recognize cancer antigens and destroy cancer cells (2). In addition, PAMP-activated DCs gained the ability to present antigens to CD4+ T cells and CD8+ T cells. This nonspecific immune activation could also play a role in destroying cancer cells (3) (PFN, perforin; GzmB, granzyme B).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JIR2024-4312908.002.jpg"/></fig><table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1</label><caption><p>Commercially available immunotherapeutic bacterial lysates or extract-based preparations effectively manage infectious diseases.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Bacterial lysates</th><th align="left" rowspan="1" colspan="1">Study type</th><th align="left" rowspan="1" colspan="1">Immune response and therapeutic significance</th><th align="left" rowspan="1" colspan="1">Host</th><th align="left" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="13" colspan="1">OM&#8722;85 (<italic toggle="yes">H. influenzae</italic>, <italic toggle="yes">Diplococcus pneumoniae</italic>, <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">K. ozaenae</italic>, <italic toggle="yes">S. aureus</italic>, <italic toggle="yes">S. pyogenes</italic>, <italic toggle="yes">Streptococcus viridans</italic>, and <italic toggle="yes">Neisseria catarrhalis</italic>)</td><td align="left" rowspan="1" colspan="1">Clinical trial of 108 children: standard therapy (57) and standard therapy&#8201;+&#8201;OM-85 (51)</td><td align="left" rowspan="1" colspan="1">(a) Normalized the phagocytic level; concentration of CD3+, CD4+, and CD21+ lymphocytes; and restore the IgA and IgM levels (b) Reduced the period of acute intoxication and the likelihood of bacterial complications in respiratory tract infections (RTIs)</td><td align="left" rowspan="1" colspan="1">Children (1&#8211;3 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B52" ref-type="bibr">52</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Meta-analysis (13 RCTs)</td><td align="left" rowspan="1" colspan="1">Significantly reduced the mean number of chronic obstructive pulmonary disease (COPD) exacerbations (<italic toggle="yes">p</italic>&#8201; &lt; 0.01; WMD&#8201;=&#8201;&#8722;0.86; 95% confidence interval CI (&#8722;1.38, &#8722;0.34)) and the days of antibiotic treatment (<italic toggle="yes">p</italic>&#8201; &lt; 0.01; WMD&#8201;=&#8201;&#8722;9.49; 95% CI (&#8722;11.93, &#8722;7.05))</td><td align="left" rowspan="1" colspan="1">Adults (20&#8211;82 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B59" ref-type="bibr">59</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Double-blind, randomized control trial (RCT) (<italic toggle="yes">N</italic>&#8201;=&#8201;60)</td><td align="left" rowspan="1" colspan="1">(a) Increased IFN-<italic toggle="yes">&#947;</italic>, decreased IL-4 and IL-13 in nasal lavage, and decreased eosinophils in nasal swabs (b) In acute allergic rhinitis (AR), decreased total nasal symptom (<italic toggle="yes">p</italic>&#8201; &lt; 0.05), itching (<italic toggle="yes">p</italic>&#8201; &lt; 0.05), nasal rhinorrhea (<italic toggle="yes">p</italic>&#8201; &lt; 0.05), and sneezing (<italic toggle="yes">p</italic>&#8201; &lt; 0.05) scores</td><td align="left" rowspan="1" colspan="1">Adults (mean age 31.34 years: OM-85 group 33.34&#8201;&#177;&#8201;3.21 years and placebo group 29.33&#8201;&#177;&#8201;4.13 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B60" ref-type="bibr">60</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Meta-analysis (53 studies)</td><td align="left" rowspan="1" colspan="1">Reduced the frequency of RTIs (MD&#8201;=&#8201;&#8722;2.33, 95% CI (&#8722;2.75, &#8722;1.90), <italic toggle="yes">p</italic>&#8201; &lt; 0.001)</td><td align="left" rowspan="1" colspan="1">Children (1&#8211;16 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B13" ref-type="bibr">13</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">RCT</td><td align="left" rowspan="1" colspan="1">Reduced the frequency of rhinosinusitis episodes</td><td align="left" rowspan="1" colspan="1">Children (4&#8211;12 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B22" ref-type="bibr">22</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Clinical study</td><td align="left" rowspan="1" colspan="1">A 20% reduction in the occurrence of repeated events of atopic dermatitis (AD)</td><td align="left" rowspan="1" colspan="1">Children (0.5&#8211;7 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B62" ref-type="bibr">62</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Open-label, prospective, sequential study (<italic toggle="yes">N</italic>&#8201;=&#8201;84)</td><td align="left" rowspan="1" colspan="1">(a) Increased serum and salivary secretory Ig (b) Reduce of the number RTIs, exacerbations of AR, asthma, or COPD</td><td align="left" rowspan="1" colspan="1">Children and adults (16&#8211;65 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B51" ref-type="bibr">51</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Clinical trial (<italic toggle="yes">N</italic>&#8201;=&#8201;60)</td><td align="left" rowspan="1" colspan="1">(a) Numbers of peripheral blood NKT cells and CD4+ NKT cells were higher, and IFN-<italic toggle="yes">&#947;</italic>, IL-4, and IL-10 levels were increased (b) Prevented recurrent RTIs and reduced asthma attack severity</td><td align="left" rowspan="1" colspan="1">Children (5&#8211;14 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B57" ref-type="bibr">57</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Randomized, double-blind, placebo-controlled clinical trial (<italic toggle="yes">N</italic>&#8201;=&#8201;428)</td><td align="left" rowspan="1" colspan="1">Reduced chronic bronchitis and COPD significantly</td><td align="left" rowspan="1" colspan="1">Adults (40&#8211;75 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B58" ref-type="bibr">58</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Prospective, randomized, single-blind study (<italic toggle="yes">N</italic>&#8201;=&#8201;33)</td><td align="left" rowspan="1" colspan="1">Decreased respiratory morbidity (<italic toggle="yes">p</italic>&#8201; &lt; 0.05)</td><td align="left" rowspan="1" colspan="1">Children (3&#8211;5 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B53" ref-type="bibr">53</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Randomized placebo-controlled trial (<italic toggle="yes">N</italic>&#8201;=&#8201;606)</td><td align="left" rowspan="1" colspan="1">Treatment with OM-85 has no impact on AD prevalence after 3 years of follow-up; however, reduced AD occurrence in infants with a single atopic family history</td><td align="left" rowspan="1" colspan="1">Newborns (4&#8211;5 weeks)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B54" ref-type="bibr">54</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Double-blind, placebo-controlled RCT (<italic toggle="yes">N</italic>&#8201;=&#8201;80)</td><td align="left" rowspan="1" colspan="1">Nasal colonization of <italic toggle="yes">S. aureus</italic> has not been affected by the sublingual treatment in children with seasonal AR</td><td align="left" rowspan="1" colspan="1">Children (5&#8211;17 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B70" ref-type="bibr">70</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Double-blind, placebo-controlled, multicenter RCT (<italic toggle="yes">N</italic>&#8201;=&#8201;49)</td><td align="left" rowspan="1" colspan="1">Have a preventative impact on episodes of asthma exacerbation connected to infections as well as those unrelated to them</td><td align="left" rowspan="1" colspan="1">Children</td><td align="left" rowspan="1" colspan="1">[<xref rid="B71" ref-type="bibr">71</xref>]</td></tr><tr><td align="left" rowspan="6" colspan="1">Ismigen (a PMBL of <italic toggle="yes">S. aureus</italic>, <italic toggle="yes">S. pyogenes</italic>, <italic toggle="yes">S. viridans</italic>, <italic toggle="yes">S. pneumoniae</italic> (six different serotypes: TY I/EQII, TY2/EQ22, TY3/EQ 14, TY5/EQ 15, TY8/EQ23, and TY47/EQ24), <italic toggle="yes">K. pneumoniae</italic>, K. ozaenae, <italic toggle="yes">H. influenzae</italic> serotype B, and <italic toggle="yes">Moraxella catharralis</italic>)</td><td align="left" rowspan="1" colspan="1">Double-blind RCT (<italic toggle="yes">N</italic>&#8201;=&#8201;70)</td><td align="left" rowspan="1" colspan="1">(a) Reduced eosinophils in nasal swabs (b) Decreased overall nasal symptom score (<italic toggle="yes">p</italic>=0.01) and nasal visual analog scale (<italic toggle="yes">p</italic>&#8201; &lt; 0.001); increased peak nasal inspiratory flow (<italic toggle="yes">p</italic>=0.04)</td><td align="left" rowspan="1" colspan="1">Children (5&#8211;17 years, mean age: 9.23 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B15" ref-type="bibr">15</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Clinical trial (<italic toggle="yes">N</italic>&#8201;=&#8201;31)</td><td align="left" rowspan="1" colspan="1">In patients with chronic decompensated tonsillitis, selectively antagonistic activity against the most common respiratory pathogens (<italic toggle="yes">S. aureus</italic>, <italic toggle="yes">S. pyogenes</italic>, <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">H. influenzae</italic>, and <italic toggle="yes">M. catarrhalis</italic>)</td><td align="left" rowspan="1" colspan="1">&#8212;</td><td align="left" rowspan="1" colspan="1">[<xref rid="B72" ref-type="bibr">72</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">A phase IV, randomized, controlled, double-blind, multicenter AIACE (Advanced Immunological Approach in COPD Exacerbation) trial (<italic toggle="yes">N</italic>&#8201;=&#8201;49)</td><td align="left" rowspan="1" colspan="1">Have no impact on the reduction in exacerbations of COPD</td><td align="left" rowspan="1" colspan="1">Children</td><td align="left" rowspan="1" colspan="1">[<xref rid="B73" ref-type="bibr">73</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Meta-analysis (15 RCTs, <italic toggle="yes">N</italic>&#8201;=&#8201;2,557) (this study is for all PMBL)</td><td align="left" rowspan="1" colspan="1">Reduced the recurrence of RTIs (relative risk: &#8722;0.513, 95% CI (&#8722;0.722 &#8722; &#8722;0.303), <italic toggle="yes">p</italic>=0.001)</td><td align="left" rowspan="1" colspan="1">Children and adults</td><td align="left" rowspan="1" colspan="1">[<xref rid="B8" ref-type="bibr">8</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Double-blind RCT (<italic toggle="yes">N</italic>&#8201;=&#8201;41)</td><td align="left" rowspan="1" colspan="1">(a) Increased serum IL-4 (b) Reduced (61.5%) symptoms severity of AR</td><td align="left" rowspan="1" colspan="1">Children and adults (5&#8211;78 years, mean age 28.9 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B21" ref-type="bibr">21</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Double-blind, randomized, placebo-controlled trial (<italic toggle="yes">N</italic>&#8201;=&#8201;178)</td><td align="left" rowspan="1" colspan="1">Reduced frequency (215 vs. 248) and length (10.6 vs. 15.8 days) of exacerbations and decreased antibiotic usage (&#8722;270 doses) and hospitalization time (275 vs. 590 days) in patients with moderate to severe COPD</td><td align="left" rowspan="1" colspan="1">&#8212;</td><td align="left" rowspan="1" colspan="1">[<xref rid="B14" ref-type="bibr">14</xref>]</td></tr><tr><td colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Lantigen B (a PCBL of <italic toggle="yes">S. aureus</italic>, <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">S. pneumoniae</italic>, <italic toggle="yes">S. pyogenes</italic>, <italic toggle="yes">M. catarrhalis</italic>, and <italic toggle="yes">H. influenzae</italic>)</td><td align="left" rowspan="1" colspan="1">Double-blind, placebo-controlled, multicenter clinical study (<italic toggle="yes">N</italic>&#8201;=&#8201;160)</td><td align="left" rowspan="1" colspan="1">Reduced episodes of recurrent RTIs (95% CI (1.01, 1.86))</td><td align="left" rowspan="1" colspan="1">Adults (18&#8211;65 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B64" ref-type="bibr">64</xref>]</td></tr><tr><td colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="2" colspan="1">LW 50020 (Luivac) (<italic toggle="yes">S. aureus</italic>, <italic toggle="yes">S. mitis</italic>, <italic toggle="yes">S. pyogenes</italic>, <italic toggle="yes">S. pneumoniae</italic>, <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">M. catarrhalis</italic>, and <italic toggle="yes">H. influenzae</italic>)</td><td align="left" rowspan="1" colspan="1">Open-label, non-comparative study (<italic toggle="yes">N</italic>&#8201;=&#8201;33)</td><td align="left" rowspan="1" colspan="1">Prevented RTIs</td><td align="left" rowspan="1" colspan="1">Adults (mean age: 34.0&#8201;&#177;&#8201;14.7 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B74" ref-type="bibr">74</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Multicenter, open study (<italic toggle="yes">N</italic>&#8201;=&#8201;4965)</td><td align="left" rowspan="1" colspan="1">Decreased the frequency, severity, and duration of RTIs and their socioeconomic costs</td><td align="left" rowspan="1" colspan="1">Children and adults (3&#8211;86 years; mean, 19 years; median, 11 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B75" ref-type="bibr">75</xref>]</td></tr><tr><td colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Polyvaccinum mite (a PCBL consists of <italic toggle="yes">S. aureus</italic>, <italic toggle="yes">S. epidermidis</italic>, <italic toggle="yes">S. salivarius</italic>, <italic toggle="yes">S. pneumoniae</italic>, <italic toggle="yes">S. pyogenes</italic>, <italic toggle="yes">E. coli</italic>, <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">H. influenzae</italic>, <italic toggle="yes">C. pseudodiphtheriticum</italic>, and <italic toggle="yes">M. catarrhalis</italic>)</td><td align="left" rowspan="1" colspan="1">Double-blind RCT (<italic toggle="yes">N</italic>&#8201;=&#8201;40)</td><td align="left" rowspan="1" colspan="1">Increased peak nasal inspiratory flow (<italic toggle="yes">p</italic>=0.01) and decreased visual analog scale for nasal symptoms (<italic toggle="yes">p</italic>=0.03)</td><td align="left" rowspan="1" colspan="1">Children (mean age, 8.7 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B76" ref-type="bibr">76</xref>]</td></tr><tr><td colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="7" colspan="1">OM-89 (Uro-Vaxom) (bacterial extracts from 18 uropathogenic <italic toggle="yes">E. coli</italic> strains)</td><td align="left" rowspan="1" colspan="1">Retrospective review of medical records (<italic toggle="yes">N</italic>&#8201;=&#8201;52)</td><td align="left" rowspan="1" colspan="1">Effective treatment for the management of recurrent cystitis in female</td><td align="left" rowspan="1" colspan="1">Adult women (54.4&#8201;&#177;&#8201;12.6 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B77" ref-type="bibr">77</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Multinational, randomized double-blinded placebo-controlled trial (<italic toggle="yes">N</italic>&#8201;=&#8201;453)</td><td align="left" rowspan="1" colspan="1">Decreased mean rate of urinary tract infections (UTIs) (<italic toggle="yes">p</italic>&#8201; &lt; 0.003)</td><td align="left" rowspan="1" colspan="1">Adult women (18&#8211;65 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B78" ref-type="bibr">78</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Open-label, multicentre pilot study (<italic toggle="yes">N</italic>&#8201;=&#8201;62)</td><td align="left" rowspan="1" colspan="1">Reduced incidence UTIs (<italic toggle="yes">p&#8201;=</italic>&#8201;0.001)</td><td align="left" rowspan="1" colspan="1">Women of 16&#8211;28 weeks of pregnancy (age not found)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B79" ref-type="bibr">79</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Randomized multicenter double-blind trial (<italic toggle="yes">N</italic>&#8201;=&#8201;112)</td><td align="left" rowspan="1" colspan="1">Decreased the number of recurrences (<italic toggle="yes">p</italic>&#8201; &lt; 0.001) of UTIs</td><td align="left" rowspan="1" colspan="1">Adult (details not found)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B80" ref-type="bibr">80</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Clinical study (<italic toggle="yes">N</italic>&#8201;=&#8201;74)</td><td align="left" rowspan="1" colspan="1">Decreased the incidence of reinfection in patients with lower UTIs</td><td align="left" rowspan="1" colspan="1">Adult women (18&#8211;77 years, means 37.47 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B81" ref-type="bibr">81</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Double-blind cross-over study (<italic toggle="yes">N</italic>&#8201;=&#8201;70)</td><td align="left" rowspan="1" colspan="1">Reduced UTIs recurrence rate</td><td align="left" rowspan="1" colspan="1">Female (13&#8211;80 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B82" ref-type="bibr">82</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Clinical study (<italic toggle="yes">N</italic>&#8201;=&#8201;521) (women, 365; and men, 86)</td><td align="left" rowspan="1" colspan="1">Reduced number of recurrences of UTI (<italic toggle="yes">p</italic>&#8201; &lt; 0.001)</td><td align="left" rowspan="1" colspan="1">Adults (51.8&#8201;&#177;&#8201;0.9 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B83" ref-type="bibr">83</xref>]</td></tr><tr><td colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">Uromune (an inactivated bacterial cell suspension of selected strains of <italic toggle="yes">E. coli</italic>, <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">P. vulgaris</italic>, and <italic toggle="yes">E. faecalis</italic>)</td><td align="left" rowspan="1" colspan="1">Prospective study (<italic toggle="yes">N</italic>&#8201;=&#8201;77)</td><td align="left" rowspan="1" colspan="1">Reduced recurrent UTIs</td><td align="left" rowspan="1" colspan="1">Adult women (18&#8211;87 years, mean age 56 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B84" ref-type="bibr">84</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Retrospective cohort study evaluating the medical records (<italic toggle="yes">N</italic>&#8201;=&#8201;669)</td><td align="left" rowspan="1" colspan="1">Reduced the incidence of recurrent UTIs and antibiotic consumption</td><td align="left" rowspan="1" colspan="1">Female (age not known)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B85" ref-type="bibr">85</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Multicentred observational study (<italic toggle="yes">N</italic>&#8201;=&#8201;319)</td><td align="left" rowspan="1" colspan="1">Reduced recurrent UTIs</td><td align="left" rowspan="1" colspan="1">Adult women (18&#8211;87 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B86" ref-type="bibr">86</xref>]</td></tr><tr><td colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">Urovac (a mixture of heat-killed 10 uropathogenic strains, including 6 <italic toggle="yes">E. coli</italic> strains and 1 strain each of <italic toggle="yes">P. mirabilis</italic>, <italic toggle="yes">P. morganii</italic>, <italic toggle="yes">E. faecalis</italic>, and <italic toggle="yes">K. pneumoniae</italic> in equal proportions)</td><td align="left" rowspan="1" colspan="1">Randomized, double-blind, placebo-controlled clinical trial (<italic toggle="yes">N</italic>&#8201;=&#8201;75)</td><td align="left" rowspan="1" colspan="1">Reduced recurrence of UTIs</td><td align="left" rowspan="1" colspan="1">Adult women (19&#8211;70 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B87" ref-type="bibr">87</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Double-blind, placebo-controlled, phase 2 clinical trial (<italic toggle="yes">N</italic>&#8201;=&#8201;54)</td><td align="left" rowspan="1" colspan="1">Helped to remain infection-free</td><td align="left" rowspan="1" colspan="1">Adult women (18&#8722;74 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B88" ref-type="bibr">88</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Randomized, double-blind, placebo-controlled clinical trial (<italic toggle="yes">N</italic>&#8201;=&#8201;91)</td><td align="left" rowspan="1" colspan="1">Delayed the interval in reinfection of recurrent UTIs</td><td align="left" rowspan="1" colspan="1">Adult women (18&#8211;82 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B89" ref-type="bibr">89</xref>]</td></tr><tr><td colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Urivac (lysates of <italic toggle="yes">P. acnes</italic>, <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">P. aeruginosa</italic>, <italic toggle="yes">E. faecalis</italic>, <italic toggle="yes">E. coli</italic>, <italic toggle="yes">P. mirabilis</italic>)</td><td align="left" rowspan="1" colspan="1">Prospective, open, multicenter, parallel-group randomized CRUTIL study (<italic toggle="yes">N</italic>&#8201;=&#8201;83)</td><td align="left" rowspan="1" colspan="1">87% (19) relapse-free patients who had received the vaccine</td><td align="left" rowspan="1" colspan="1">Children (3&#8211;15 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B16" ref-type="bibr">16</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">ExPEC4V (had four bioconjugates with the O-antigens of the four extraintestinal pathogenic <italic toggle="yes">E coli</italic> serotypes: O1A, O2, O6A, and O25B.)</td><td align="left" rowspan="1" colspan="1">Randomized, placebo-controlled single-blind (<italic toggle="yes">N</italic>&#8201;=&#8201;196)</td><td align="left" rowspan="1" colspan="1">Reduced UTIs</td><td align="left" rowspan="1" colspan="1">Adult women (18&#8211;70 years)</td><td align="left" rowspan="1" colspan="1">[<xref rid="B90" ref-type="bibr">90</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>
<italic toggle="yes">Note</italic>: AR, allergic rhinitis; CI, confidence interval; COPD, chronic obstructive pulmonary disease; Ig, Immunoglobulin; MD, mean difference; N, subject numbers (sample size); PMBL, polymicrobial bacterial lysate; RCT, randomized control trial; RTIs, respiratory tract infections; UTIs, urinary tract infections; WMD, weighted mean difference.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>